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Abstract

Staphylococcus aureus is a highly successful pathogen capable of producing a
wealth of virulence factors in the human host. Of note, ten extracellular proteases are
produced alongside these virulence factors and play a multifaceted role during infection.
They not only cleave host proteins to promote bacterial invasion, immune evasion and
survival, but also control disease progression by modulating the stability of self-derived
pathogenic determinants. The importance of the secreted proteases modulating virulence
factor stability is evidenced by our groups previous finding that a protease-null strain has
a substantially increased infectious capacity in a murine model of sepsis; resulting from
the unchecked accumulation of virulence factors. However, as the pathogenic potential
was only determined for a strain genetically lacking all 10 secreted proteases, the
importance of the individual proteases has yet to be determined. As such, we constructed
and assessed the pathogenic potential of a combinatorial protease mutant library that
revealed the enhanced killing observed for the complete protease-null strain during sepsis
appears to be driven by the absence of only Aureolysin and Staphopain A. Further, using
a proteomics approach, we identified a number of secreted factors increased in
abundance in both the aur/scpA and protease-null mutant, but not in the parent, including
LukA, Sbi, and PSMa4. Using our murine model of sepsis, we created an aur/scpA/lukA
mutant and found that, although it still exhibited hypervirulence, the progression of
vii

infection was substantially delayed in comparison to the aur/scpA mutant. Thus, it
appears that LukA is necessary, but not sufficient, for the hypervirulence observed, and
that other secreted virulence factors seemingly also contribute to this phenotype. Further
to this, given the complex regulatory roles of the secreted proteases, tight regulation of
their production is obviously required. Whilst this process has been well studied, a major
oversight has been the consideration of proteases as a single entity, rather than 10
enzymes produced from 4 different promoters. As such, we next fully characterized the
regulation of each protease gene by known major regulators, discovering vast differences
in the way each protease operon is controlled. Additionally, we deepened our
understanding of protease regulation using a global screen to identify novel loci
controlling protease activity, identifying 7 new elements that strongly altered protease
activity, including XdrA, Rbf and Rex. We find that each of the novel regulators, other than
ArgR2, appears to influence protease expression though the well studied primary network
of protease regulation. Using the data generated from our study, we were able to generate
of a comprehensive protease regulatory map that further emphasizes the complexity of
their regulation. Lastly, in effort to continue to understand the network controlling virulence
factor production, we further characterized XdrA and its effects on S. aureus gene
expression. Using an unbiased global analysis, we find that XdrA has a broad impact on
the transcriptome, influencing the expression of several important virulence determinants,
and factors involved in gene regulation. When assessing the role of XdrA in virulence, we
find that an xdrA mutant has an increased ability to survive in whole human blood,
mediated in part by increased survival within neutrophils. Furthermore, the increased
survival within neutrophils appears to result from an upregulation in expression of sodM,

viii

recA, and sae, all of which assist bacterial cells in combating the effects of oxidative
stress. In addition to these changes, we find that the xdrA mutant has a decreased
abundance of cytolytic toxins, likely resulting from changes in agr and sae activity. We
suggest that the broad impact of XdrA on the expression of genes involved in immune
evasion, DNA damage, and oxidative stress tolerance, collectively result in a survival
advantage, allowing for the increased ability to causes disease in vivo, when xdrA is
disrupted. Collectively, this study sheds light onto the role of secreted proteases in the
infectious process, generates a comprehensive regulatory map of their regulation, and
presents characterization of a novel protease regulator and its unique influence on the
pathogenic potential of S. aureus.
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Chapter 1: Introduction

Introduction

Staphylococcus aureus
Staphylococcus aureus is a Gram-positive, opportunistic human pathogen known
for causing both hospital and community acquired infections. It was first identified from
pus isolated from a surgical abscess by Alexander Ogston in 1880 (1). S. aureus is
commonly found on the skin of infected individuals, but is most frequently carried in the
anterior nares of the nasal passages (2). Further to this, it is thought that about one-third
of the population within the United States are carriers of S. aureus (3). This organism is
a member of the Firmicutes, a phylum characterized by the presence of low G+C
genomes, but is unable to produce endospores. Its genome is approximately 2.8Mb with
a G+C content of 33% and contains a variety of mobile genetic elements, which includes
bacteriophages, transposons, pathogenicity islands and chromosomal cassettes (4, 5). A
distinct characteristic of this bacterium is the production of staphyloxanthin, a membranebound golden carotenoid pigment. This pigment functions as an antioxidant, promoting
bacterial survival in the presence of the host innate immune system (6, 7). Other notable
features of S. aureus are that it’s a facultative anaerobe, able to completely lyse red
bloods cells by producing numerous cytolytic toxins, promote the clotting of plasma or
1

blood by producing coagulases, as well as catalyze the breakdown of hydrogen peroxide
through the use of catalase (8-11).

Disease causation of S. aureus
Although S. aureus is generally a commensal organism, asymptomatically
colonizing about 30% of the population, it can also cause disease (12). Carriage of this
bacterium increases the risk for developing an infection as well as transmitting it among
individuals. Generally, it is spread through human-to-human contact, but can also occur
through adjunctive reservoirs such as domestic animals, livestock and fomites (13).
Although the main ecological niche of S. aureus is the anterior nares it can also colonize
a variety of other sites such as the groin, axillae and gastrointestinal tract (12). The point
at which colonization becomes a problem for healthy individuals is when there is break in
the skin or mucous membranes allowing access to the blood stream as well as any tissue
of the body (14). S. aureus is capable of causing a variety of diseases that range from
minor skin and soft tissue infections to the more severe diseases, such as osteomyelitis,
sepsis, endocarditis, and toxic shock syndrome (5, 15, 16). This disease potential results
from the large number of virulence factors that assist in colonization and persistence,
immune evasion and dissemination (17).

Community-associated methicillin resistant S. aureus (CA-MRSA)
In the past, S. aureus infections were mostly isolated to the hospital environment,
where people with pre-existing conditions, or from those in contact with individuals from
a hospital setting, were the primary population (13). Not long after the introduction of
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methicillin in the 1961, hospital-associated methicillin resistant Staphylococcus aureus
strains (HA-MRSA) emerged in the United Kingdom. This where S. aureus infections
largely remained on a global scale until the last few decades, when we began to observe
them in the community as well. The first case of infections cause by communityassociated-MRSA were reported in the 1980s amongst drug users in Detroit (18).
Following this, in the early 1990s an increasing number of patients that were otherwise
healthy were reported as having CA-MRSA infections as well (19). While these cases
were most frequently skin and soft-tissue infections, there were instances of more severe
diseases, like sepsis and necrotizing pneumonia. To begin defining what was classified
as a CA-MRSA infection, the CDC determined that it was an infection identified in a
patient within 48h of hospitalization who lacked a specific set of risk factors including,
residing in a long-term care facility, undergoing dialysis or surgery, or who had recent
hospitalizations (13). In addition to this, work began using molecular characteristics to
distinguish between HA and CA strains. This included, multilocus sequence type (MLST
or ST) or staphylococcal protein A (spa) type, staphylococcal chromosomal cassette mec
(SCCmec) type, pulsed filed gel electrophoresis (PFGE) profile, and the presence of PVL
genes (13, 18, 19).

In the United States in the early 2000s, it was established that the most prominent
CA-MRSA strain was the USA300 clone (19). This clone was identified in outbreaks in
Pennsylvania with football plays (20), in prisons located in several states, including Texas,
California, Georgia, and Mississippi (21), and also with athletes in Colorado, California,
and Indiana (20). Following this, the USA300 clone came to dominate throughout the US
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as the primary CA-MRSA strain causing infection. Given the prevalence of USA300
strains, several studies focused on elucidating the cause for its success. It was found that
USA300 has an increased ability to evade the immune system through increased
expression of alpha-toxin and the PSMs (22). Further, presence of the arginine catabolic
mobile element (ACME), which is only found within USA300 strains, was also suggested
as contributing to its enhanced virulence. Within this element are two main clusters of
genes, including the arc genes and opp genes (23). The arc genes encode the arginine
deaminase pathway, which of interest because this pathways contributes to virulence in
Streptococcus pyogenes (12). Indeed, recent studies have shown that the arc genes in
S. aureus contribute to survival within acidic environments, which could translate to better
survival on human skin (24). Further, an additional gene within the ACME element, speG,
encodes a spermine/spermidine acetyltransferase that enables polyamine resistance
(24). Polyamines are produced by the host, particularly on the skin, thus, S. aureus would
be challenged with them during colonization and infection. Given the polyamine
resistance of USA300, it is presented with an additional survival advantage during skin
and soft tissue infections (24), and during person-to-person transmission via contact.

S. aureus virulence factors
The wealth of virulence factors produced by S. aureus within the human host
contributes significantly to its success in causing a wide range of infections. Such
extensive virulence mechanisms are not observed in other human pathogens, thus
making S. aureus an ideal model for the study of disease causation by an infectious
organism (25). These virulence determinants include adhesins, lipases, proteases,
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hemolysins, toxins and nucleases (17, 26). Collectively these factors allow the pathogen
to evade the immune system, adhere to and colonize host tissues, acquire nutrients, and
to disseminate to new host tissues (25-28). These factors can be divided into two broad
groups, which are adhesins and exoproteins. Adhesins mediate S. aureus colonization
by promoting attachment of bacteria to host tissues, and, in addition, are capable of
interfering with the host immune system to promote infection (29, 30). A fundamental
group of adhesins is the microbial surface component recognizing adhesive matrix
molecules (MSCRAMMs) (31). These proteins are covalently linked to peptidoglycan via
a sortase mediated pathway and are capable of attaching to extracellular matrix (ECM)
components or plasma, via fibronectin, fibrinogen and collagens (29, 31). Classic
members of this group are staphylococcal protein A (SpA), clumping factor (Clf) A and B
proteins, fibronectin-binding proteins A and B (FnbpA and FnbpB) and the collagenbinding proteins (32, 33). Specifically, protein A functions to promote immune evasion by
binding the Fc region of IgG to prevent opsonization (34), whereas fibronectin-binding
protein A assists in immune evasion by promoting the uptake of bacteria by nonprofessional phagocytes, to prevent uptake by professional phagocytes (35). Lastly, it has
been suggested that clumping factor A, similar to FnbpA, interferes with phagocytosis by
promoting S. aureus uptake into host cells (36).

Exoproteins, which are secreted from essentially all S. aureus strains, function to
acquire nutrients by breaking down host tissues and more importantly by acting upon the
immune system to engender immune evasion (28). Numerous cytolytic toxins, also
termed pore-forming toxins, are also secreted, including the leukocidins LukDE and
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LukAB, Panton-Valentine leukocidin (PVL, made up of LukS and LukF), alpha-hemolysin,
and gamma-hemolysin (HlgA, HlgB, HlgC), and serve to damage and lyse host cells (37).
Specifically, alpha-hemolysin binds the ADAM10 receptor, which is found on several
different host cells, including macrophages, monocytes, erythrocytes, epithelial cells,
fibroblasts, and lymphocytes (38) (but not neutrophils), and forms heptameric pores,
ultimately leading to destruction of the host cell (38). While the remaining toxins
mentioned above are structurally similar to Hla, they are bi-component toxins that require
both components for cell lysis (11, 38). These toxins are known to lyse multiple cell types
as well, including monocytes, neutrophils, and macrophages (38). In addition to promoting
host cell lysis, in sub-lytic concentrations, Hla, PVL, and Hlg are also able to induce a proinflammatory response by activating the NIrp3 inflammasome, which results in the release
of cytokines (38).

Another group of pore-forming toxins are the phenol-soluble modulins (PSMs),
which are small amphipathic, alpha-helical peptides, that are secreted without a signal
peptide via the PSM export system (39). These peptides are classified by their length as
either a-type, including PSMa1-4 and delta-toxin, which are 20-25 amino acids in length,
or b-type, including PSM b1-2, which are 43-45 amino acids in length (38). These peptides
lyse several different cell types, including osteoblasts, epithelial cells, monocytes,
erythrocytes, and neutrophils in a receptor independent manner; and can also induce an
inflammatory response (39). Interestingly, a-type PSMs are more cytolytic than the btype, possibly because the a-type have either a neutral or positive charge, while the btype have a negative charge.
6

In addition to the lytic toxins, S. aureus also secretes a variety of exotoxins,
including exfoliative toxins, staphylococcal enterotoxins and toxic shock syndrome toxin1 (TSST-1) (32). The exfoliative toxins are highly specific enzymes that selectively cleave
human desmoglein-1, which results in the skin separation and erythema observed in
staphylococcal scalded skin syndrome (40). The staphylococcal enterotoxins are unique
in that they remain stable under typical protein denaturing conditions, such as high
temperatures or the low acidity of the stomach, and as such are able to elicit food
poisoning without the presence of the producing organism (38). TSST-1 is the causative
agent of toxic shock syndrome, which triggers the production of massive amounts of proinflammatory cytokines (cytokine storm), often resulting in total organ failure (28, 29).
Each of the infections caused by these toxins are considered toxinoses, given that only
the toxins are required for infection (41).

The regulation of virulence factor production
The diverse roles of virulence determinants necessitates coordinated expression
in response to different grow phases and environmental cues. The production of these
elements is regulated by a complex network of factors, including transcriptional
regulators, two-component systems, sigma factors, and regulatory RNAs (42).
Collectively these regulators help S. aureus rapidly adapt to and survive in hostile
environments, and facilitate disease causation. Nutrient availability, pH, temperature and
oxygen tension are all examples of environmental signals that have been shown to
influence virulence factor production (43). Together these regulators form complex
network to control the precise expression of genes, such that individual factors can be
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controlled by several different regulators ensuring expression only occurs under favorable
conditions.

In S. aureus, arguably one of the most important global regulators of virulence
factor production is agr (accessory gene regulator) (44), a two-component, quorum
sensing system. The function of the agr system is growth phase dependent and allows
for S. aureus to transition from adherent to invasive phenotypes by its repression of cell
surface adhesins and promotion of secreted factors in post-exponential phase (45). The
agr locus contains two divergent promoters P2 and P3, where the P2 promoter controls
the transcription of the quorum sensing system genes agrB, agrD, agrC and agrA, and
the P3 promoter controls transcription of RNAIII, which function as the effector molecule
of this system, and also encodes the delta-hemolysin (16, 46). The agrA and agrC genes
encode a two-component system, where ArgC is the sensor histidine kinase and AgrA is
the associated response regulator (47). Sensed by the two-component system is the
autoinducing peptide (AIP), which is produced from the precursor AgrD that is processed
into its mature form upon secretion through a transmembrane endopeptidase encoded by
agrB. During post-exponential phase, AIP accumulation is sensed by AgrC, leading to its
auto-phosphorylation, followed in turn by transfer of that phosphate to AgrA (46).
Activated AgrA then upregulates transcription from the P2 and P3 promoters. In addition
to producing more Agr proteins, RNAIII and delta-hemolysin expression is also
upregulated. RNAIII is a regulatory RNA that acts through direct binding, or through its
control of the regulator rot (repressor of toxins) (47). RNAIII can directly bind transcripts
either promoting translation, as has been shown with hla (48), or preventing translation,
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as it has been shown with coa, spa, and rot (49-51). Rot directly represses the production
of multiple virulence factors, thus upon inhibition by RNAIII, the production of these
virulence factors is consequently upregulated (49).

Another important global regulator of S. aureus gene expression is SarA
(staphylococcal accessory regulator). SarA it is produced from the sar locus, which
contains three promoters resulting in the production of three separate transcripts, each
containing the sarA open reading frame (52). It has been established that SarA promotes
the production of cell-wall-associated proteins and represses the production of secreted
proteases through direct action as well as by its influence on the agr system (53). This
regulation of the Agr system occurs via direct binding of SarA to the P2 and P3 promoters,
which results in an increasing abundance of RNAII and RNAIII (54).

An additional important regulatory system is the SaeRS two-component system,
which is encoded by the sae locus. The sae locus is made up of four genes (saeP, saeQ,
saeR, and saeS) controlled by two promoters, where the P1 promoter drives the
production of all four genes and the P3 promoter only drives the production of saeR and
saeS (55). SaeS is a sensor histidine kinase that senses environmental signals, whilst
SaeR is the response regulator that is phosphorylated by SaeS, following its
autophosphorylation. SaeQ is a membrane protein and SaeP is a lipoprotein, however
how these proteins interact with SaeRS is not yet fully understood yet. What we do know
is that SaePQ is not required for Sae activation, however these two proteins do form a
ternary complex with SaeS to induce its phosphatase activity. The Sae system has been
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found to be activated by a variety of environmental signals, including human neutrophil
peptides, calprotectin, hydrogen peroxide, and beta-lactam antibiotics (55). With regards
to the Sae regulon, this system promotes the expression of several major virulence
factors with roles in adhesion, cytotoxicity, and immune modulation (56). Although the
Sae system has not currently been found to influence gene expression via other major
regulators, its expression is influenced by several such factors, including Rot, and CodY
(57-59).

Another major regulator of virulence in S. aureus is CodY, which links the
nutritional status of the cell to gene expression by directly interacting with branched-chain
amino acids and GTP (60). The DNA binding affinity of CodY decreases as the levels of
branched-chain amino acids and GTP declines, resulting in the de-repression of target
genes (61). In addition to regulating genes that control metabolic pathways, CodY also
represses the expression of several virulence factors through direct binding, and also by
repressing the agr and sae system (59, 60, 62, 63). As such, when nutrients become
limited during the transition between exponential and post-exponential growth, CodY
repression diminishes, promoting the upregulation of agr and sae, engendering an
increase in expression of several important virulence factors (64).

A further key component of the S. aureus global regulatory system is MgrA
(multiple gene regulator). MgrA has been shown to influence the expression of genes
involved in biofilm formation, virulence, autolysis, and antibiotic resistance (65). MgrA
exerts control of gene expression by direct binding, and likely by influencing the
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production of other transcriptional regulators, such as SarR and SarS (66, 67). The mgrA
locus is under the control of two promoters, which result in the production of two different
mRNA transcripts (65). Importantly, Agr promotes the expression of mgrA by the binding
of RNAIII to regions within the mgrA mRNA UTR transcribed from the P2 promoter. In
addition, mgrA expression is also enhanced by the two-component system, ArlRS (67,
68).

Proteases
Proteases are hydrolytic enzymes that catabolize the peptide bonds linking amino
acids together in a polypeptide chain (69). These enzymes are found within all living
organisms where they function in complex processes involved in the normal physiology
of the cell (69). Depending on their specific role, they can be located in the cytoplasm,
membrane, or extracellularly. Generally, intracellular proteases are involved in
metabolism regulation and extracellular proteases support uptake of small peptides by
hydrolyzing large proteins (70). Proteases can be classified based upon the reaction they
catalyze, catalytic site characteristics and by evolutionary relationships (69). Regarding
the reaction they catalyze, proteases are either endopeptidases or exopeptidases.
Endopeptidases hydrolyze peptide bonds found in the inner region of the polypeptides
and exopeptidases are preferential to the peptide bonds near the carboxy or amino end
of polypeptides (69, 70). These enzymes are also functionally characterized by their
activity class, which is based upon the residues that are located within their catalytic
pocket (e.g. serine-, cysteine-, threonine proteases). Activity classes can also be based
on the requirement of a metal for stabilization (e.g. metalloproteases) (69).
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Bacterial proteases
Several important bacterial proteases are ATP-dependent, and, of these, the Clp
proteases are perhaps the most well characterized. Clp proteases were first discovered
in Escherichia coli where their production was found to be induced upon heat stress,
resulting in the degradation of misfolded and damaged proteins (71). These proteases
are made up of two domains, an ATPase domain (ClpX) and a proteolytic domain (ClpP).
Beyond their role in cleaving damaged proteins, they have also been shown to play a role
in controlling the abundance of regulatory proteins (71). Further, in several pathogens,
these proteases are found to be important for virulence (71).

An additional ATP-dependent protease, with similar roles to the Clp enzymes, is
the Lon protease. In contrast to Clp, Lon proteases are composed of identical subunits
containing an ATPase and protease domain (72). The first Lon protease was described
in Escherichia coli and was found to identify and remove misfolded proteins in the
cytoplasm (73, 74). In addition to this, these proteases have been characterized in several
other bacteria with roles in multiple important cellular functions such as DNA replication
and repair, virulence factor production, motility, persistence, competence, heat-shock
response, and encapsulation (75).

FtsH is an additional ATP-dependent protease, however unlike the Clp and Lon
proteases, it is membrane bound with its catalytic domain located within the cytoplasm
(76). Although FtsH has the capacity to remove abnormal cytoplasmic proteins, its
involvement in the quality control of membrane proteins is believed to be its primary
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function. For example, in Escherichia coli, Ftsh degrades the SecY component of the
SecYEG translocase (77). Further, FtsH also regulates the abundance of UDP-3-O-(R-3hydroxymyristoyl)-N-acetylglucosamine deacetylase, a committed enzyme in lipid A
biosynthesis, which is an essential component of membrane synthesis. Thus, FtsH is
required for cell viability in E. coli. In contrast, in Bacillus subtilis it is not essential for
viability and is believed to play a role in the stress response, sporulation, and protein
secretion. Beyond this, FtsH also has described roles in the heat shock response and
limiting viral infection (76),

An additional protease involved in protein quality control is DegP. In contrast to the
previously discussed proteases, DegP is ATP-independent, and belongs to the high
temperature requirement A (HTRA) family of Serine proteases (78). Although these
enzymes mainly function in protein quality control, DegP has also been described to
function as a chaperone. In addition, HTRAs have also been shown to be important for
virulence in a several bacteria, including but not limited to, Streptococcus mutans,
Helicobacter pylori, and Bordetella pertussis (79-81).

SrtA, known as sortase A, is a protease with a highly unique role within bacterial
cells. SrtA is a membrane associated transpeptidase responsible for the anchoring of
surface proteins with sorting signals consisting of an LPXTG motif, to the cell wall in
Gram-positive bacteria (82). For anchoring to occur, cleavage by SrtA occurs between
the threonine and glycine of the sorting motif (83), and a peptide bond is formed between
the carboxyl-group of the protein and the amine-group of the cell-wall precursor Lipid II

13

(83-85). During peptidoglycan synthesis, the lipid II-linked protein is incorporated into the
cell wall. While srtA was first identified in S. aureus, numerous other sortases have since
been identified in other Gram-positive bacteria. As a number of the proteins anchored to
the bacterial cell wall of staphylococci, enterococci, and streptococci are important
virulence factors, SrtA plays an important role in bacterial pathogenesis (86).

S. aureus proteases
S. aureus contains several important intracellular and membrane bound
proteases, and of them, the most well characterized are the Clp proteases. In S. aureus
there are two ClpATPases, ClpX and ClpC, which can both associate with ClpP (87).
Strains containing disruptions in either clpP or clpX have been found to be attenuated
when assessed in a murine abscess model (88). Further, with ClpC, it was shown to be
important for long term survival and intracellular replication (89). In a more recent study,
it was shown that ClpXP and ClpCP do in fact play different roles within the S. aureus cell
(90). Specifically, cell size and growth at low temperatures is influenced by ClpXP activity,
while ClpCP activity is important for normal growth at optimal conditions, as well as at
high temperatures. Further it was also established that the ClpC targeting of damaged
proteins to ClpP is superior to that of ClpX.

Beyond this, the Abi-domain protein MroQ, which is also a transmembrane/M79
protease-family protein, was recently characterized as playing an important role in
virulence in S. aureus (91). Originally, Abi-domain proteins in bacteria were noted for their
ability to disrupt bacterial infection by bacteriophages, through slowing cellular activity
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(92). Regarding the recent study by our group on MroQ, it was shown that this protein
has a significant role in influencing virulence factor expression, possibly through its
interaction with the histidine kinase of the Agr quorum sensing system, AgrC (91). With
an mroQ mutant, it displayed several changes in virulence factor production, which
appeared to be a result of a decrease in transcription for the agr operon. Further, changes
in transcriptional regulators that would explain the decrease in agr were not observed,
therefore suggesting that MroQ could be interacting directly with the Agr system.
Importantly, the ability of MroQ to regulate agr is dependent upon its proteolytic activity.

Another intracellular protease that is important for virulence is the leucine
aminopeptidase (LAP), PepZ. Leucine aminopeptidases cleave amino acids from the Nterminus of proteins and have a cleavage preference for leucine residues (93). In a study
by our group it was shown that a pepZ mutant is attenuated during infection when using
murine models for localized and systemic infection. Further, the survival of the pepZ
mutant was decreased when challenged with human macrophages. While PepZ
substrates have yet to be identified, it was suggested that PepZ targets proteins
contributing to virulence given that it does not appear to play a role in nutrition. In addition,
while pepZ is classified as a LAP, our group also established that the enzyme’s specificity
range is broad given that leucine is not its primary target, and that it has the capacity to
hydrolyze a cysteine-glycine dipeptide under certain specific biochemical conditions (94).

In direct contrast to the activity of PepZ, S. aureus also produces the protease
CtpA, which cleaves amino acids from the C-terminus of proteins (95). When studied in

15

Gram-negative bacteria carboxy terminal peptidases (CTP) have previously been shown
to have a role in virulence (96-101). When the importance of the lone CtpA enzyme was
explored in S. aureus it was determined that the survival a ctpA mutant displayed a
decrease in survival in whole human blood, in addition to a decrease in survival following
phagocytosis by human macrophages. Further, when the role of CtpA was assessed in
vivo using a murine model of sepsis, a decrease in mortality and dissemination was
observed with the ctpA mutant. Most recently, the first substrate of CtpA was identified to
be SosA, a cell division inhibitor (102). Under DNA-damaging conditions, SosA stalls cell
division allowing for the expression SOS response genes, once replication again
becomes favorable, SosA is cleaved by CtpA allowing for cell division to resume.

S. aureus secreted proteases
S. aureus possesses 10 major secreted proteolytic enzymes, which are
transcribed from four different loci within the chromosome (103, 104). These include a
metalloprotease (aur, aureolysin), a serine protease (sspA, V8), two cysteine proteases
(scpA (staphopain A) and sspB (staphopain B)), and six serine-like proteases
(splABCDEF) (104, 105). With respect to genomic context, SspB is encoded in an operon
downstream of SspA, whilst the serine-protease like proteins are also encoded together
within an operon (104, 105).

Aureolysin was first characterized in 1973 by Arvidson et al. (106) and found to be
a member of the thermolysin family (107). Its catalytic activity requires the presence of
zinc, and for structure stability, it requires the presence of calcium (107). While aur is
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strongly conserved in S. aureus strains, there are two allelic variants of the aur gene
(108), with the type II variant proving to be twice as active as type I (109). Aureolysin is
secreted as a zymogen which undergoes auto-proteolysis to become active (110). With
regards to enzyme specificity, it has a preference for hydrophobic P1’ residues and
alanine, which is similar to that of thermolysin. In addition to activating itself, aureolysin is
at the beginning of the protease activation cascade that is responsible for the activation
of V8 and staphopain B. Like aureolysin, V8 is produced as a zymogen and becomes
active following secretion via the action of aureolysin (111). In contrast to its activating
enzyme, V8 has a strict substrate specificity, only cleaving after glutamic acid residues
(112). Concluding the activation cascade, the V8 protease is responsible for the activation
of staphopain B (113). Like aureolysin and V8, staphopain B is produced as a zymogen
that requires activation following secretion (111). With regards to its specificity, it is similar
to aureolysin in that it was determined to be rather broad, but not as broad as staphopain
A. Specifically, at the P2 position the enzyme has a preference for hydrophobic residues.
In addition, at the P1 position, a small uncharged amino acid is preferred (113).

Staphopain A and the Spls stand apart from the other proteases in that their
activation is sits outside of the main protease activation pathway. Staphopain A, was
purified in 1988 (114) and following the characterization of Staphopain B in 2001, they
were found to be structurally similar (113). As with the other proteases, staphopain A is
produced as a zymogen, and similar to aureolysin it undergoes auto-activation. Like
aureolysin and staphopain B, the specificity of staphopain A is very broad (114).
Specifically, at the P2 position it has a strong preference for hydrophobic residues, which
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is a characteristic of papain family cysteine protease. With regards to the Spls, their
identification began when antigens were found against these proteins in endocarditis
patients (115). Following their analysis in a study by Reed et al. in 2001 (105) it was found
that the spl operon encoded 6 enzymes. The amino acid sequences for these proteins
share 44 to 95% sequence homology to each other, and they also share 33 to 36%
sequence homology to V8, therefore dictating them as serine-protease-like proteins. The
Spl enzymes also share high sequence homology with the exfoliative toxins, and have a
similarly strict substrate specificity (116-120). Unlike the other secreted proteases, these
proteins are synthesized without propetides and therefore are active immediately upon
secretion (105).

The functions of these enzymes has been studied by ourselves and others, and
includes their ability to hydrolyze a variety of host proteins, as well as self-derived toxins.
With regards to targeting the host, the secreted proteases have been demonstrated to
cleave host proteins to promote tissue invasion, immune system evasion and the
dissemination of infection (121-123). For example, Staphopain A (ScpA) has been shown
to cleave the CXC chemokine receptor (CXCR2), which blocks neutrophil recruitment
(124). Similarly, Staphopain B blocks phagocytosis by neutrophils and monocytes via
cleavage of CD31 (125). Additionally, SplA has been shown to contribute to bacterial
invasion and dissemination in a rabbit model of pneumonia through its cleavage of mucin
16 (126). In the context of the self-degradome, these enzymes can cleave multiple
virulence determinants to promote bacterial invasion, immune evasion, and survival. For
example, Aureolysin was shown to control the stability of both phenol soluble modulins
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and alpha-toxin (127, 128), as well as the adhesin clumping factor B (ClfB) (129), whereas
Staphopain A has been shown to control the abundance of biofilm components (130). In
addition, V8 was shown to cleave the adhesion proteins, surface protein A (SpA) and
fibrinogen-binding proteins (FnBPs) (131, 132).

Several investigations have been performed to determine the function of the above
enzymes, however their specific role in the disease process was unclear during early
work due to contradictory evidence. For example, an sspA mutant was used in three
different animals models of infection and displayed attenuation of virulence in each case
(103). Additionally, attenuation in virulence was observed for mutations in sspABC and
sspBC in a murine skin abscess model (104). In contrast, an sspA mutant displayed
increased virulence using a tissue abscess model (133). Conversely, using a murine
model of septic arthritis, mutations for sspABC, sspB, and aur, did not display any
virulence defect (134). Similarly, it was shown that deletion of splABCDEF resulted in no
significant virulence defect using a murine peritonitis infection model (105). Other studies
with an spl operon mutant, this time using a rabbit model of pneumonia, demonstrated
that there was no attenuation in overall virulence for the mutant strain, however severe
infection was only induced in one lung, whereas the wild-type affected both lungs equally
(126). Additionally, using a guinea pig model of vascular permeability, it was shown that
both of the Staphopains promote permeability, and as such can contribute to septic shock
(135). Finally, using a murine skin abscess model it was shown that mutations in aur and
scpAB resulted in no virulence defect (104).
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In order to categorically assess the role of S. aureus secreted proteases in
virulence, a study by our group focused on analyzing a strain genetically lacking all 10
enzymes (136). In this study, the most notable observation was that, when assessing the
infectious capacity of the protease-null strain in a murine model of sepsis, there was a
significant increase in mortality for mice infected with this strain in comparison to the wildtype. This hypervirulence was contrary to a number of other observations from this study,
where secreted proteases were shown to be required for resisting phagocytosis, survival
in whole human blood, growing in the presence of antimicrobial peptides, as well as for
growth in peptide rich media, and serum. To explain these conflicting phenotypes, a
proteomic analysis was performed revealing that the enhanced virulence observed was
mediated by increased abundance of surface and secreted virulence factors in the mutant
strain. Thus, it would appear that in the absence of secreted protease, the stability and
abundance of virulence factors is no longer controlled, allowing for their unregulated
accumulation, and consequently one observes more aggressive and deadly infections.
Similarly, but in contrast, those conditions where the protease-null strain demonstrated
ablated growth and/or survival compared to the parental strain are likely the result of
protease action directly on the host, or host substrates. In support of these findings, these
observations were also reported in a companion study by Zielinska et al (137). As such,
it is suggested that in addition to cleaving host proteins to facilitate host invasion and
immune subversion, the secreted proteases of S. aureus also appear to influence disease
progression by controlling the stability of self-derived virulence determinants.
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S. aureus protease regulation
With respect to the regulation of the secreted proteases, they are maximally
produced during post-exponential growth along with a variety of other secreted virulence
factors(104). The complex roles of the proteases require that they be tightly regulated by
a network of regulatory factors. Evidence of this is in the sheer number of factors that
have been identified to influence proteases production, including SarS, SarR, CodY, Rot,
MgrA, SaeR, SarA, ArlRS, SarX, SarZ, SarV (60, 138-149). Of these, SarS, SarR, CodY,
Rot, MgrA, SaeR and SarA are considered the major regulators and have been shown to
directly influence protease transcription (60, 138-143). Regardless of the major impact
these regulators have on protease expression in general, their specific effects on all of
the four protease promoters has only been described for SarA and Rot (104, 105).
Specifically, for SarA, it is well established that represses the transcription of aur, ssp,
and scp but not spl (104, 105). In addition, Rot was shown to repress transcription from
all four promoter promoters (139). With MgrA, it has been shown to promote the
production of aur, ssp, and sp (67, 141), whilst CodY has been identified as a repressor
of ssp transcription (60). Finally, SarS has been shown to repress aur and ssp (141),
while in contrast, SarR was identified as an activator of aur and ssp (138).

Project aims
The aim of this project is to further characterize the role and regulation of secreted
proteases in S. aureus. The first aim is to follow up on our group’s earlier finding that
proteases modulate virulence factor stability to influence disease progression. Given that
in this previous study we only assessed the pathogenic potential of a strain genetically
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lacking all 10 secreted proteases, herein we will assess the individual importance of these
proteases by constructing and assessing a combinatorial protease mutant library using
the same murine model. After narrowing in on the proteases that are potentially
modulating factors with profound impacts on disease progression, we will then identify
the secreted factors increased in the specific strains using a proteomics approach.
Following this, we would then determine the importance of these secreted factors for the
hypervirulence phenotype.

The second aim is to explore the regulation of the four protease loci by known and
novel factors. Given that the effects of the major protease regulators on each of the
protease loci has not been completely described, we will begin by quantifying the
transcript abundance for each protease loci, in mutants for these regulators. Following
this, will we explore the remaining S. aureus transcriptional regulators for novel roles in
protease regulation by screening regulator mutants via zymography. We will then
characterize the loci specific effects of these novel regulators as well as assess their
effects on the major protease regulators. With this data will generate a comprehensive
map of protease regulation. Finally, the third aim will be to characterize the importance of
one of the novel protease regulators in influencing S. aureus gene expression.
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Chapter 2: Dissecting the Contribution of Secreted Proteases to
Hypervirulence in Staphylococcus aureus

Abstract

One of the mechanisms used by Staphylococcus aureus to control the progression
of infection is the coordinated production of extracellular proteases, which selectively
modulate virulence determinant stability. This is evidenced by our previous finding that a
protease-null (PN) strain has a substantially increased infectious capacity in a murine
model of sepsis; resulting from the unchecked accumulation of virulence factors. Herein,
we assessed the individual roles of these proteases by constructing and assessing the
pathogenic potential of a combinatorial protease mutant library. When adding back a
single protease to the PN strain, hypervirulence was still observed, and in some cases,
was increased beyond that of the PN strain. When adding back two enzymes, a variable
impact on hypervirulence was observed, with some strains exhibiting hypervirulence,
whilst others phenocopied the wild-type. The common thread for hypervirulent strains was
that each lacked both Aureolysin and Staphopain A. Upon assessment we found that the
combined loss of these two enzymes alone was necessary and sufficient to generate the
hypervirulent phenotype. Using a proteomic approach, a number of important secreted
factors were found to be overrepresented in both the aur/scpA and PN mutants, but not
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the parent, including LukA, Sbi, and PSMa4. When assessing the virulence of an
aur/scpA/lukA mutant, the progression of infection was substantially delayed, however
hypervirulence was ultimately still observed; suggesting the hypervirulent phenotype is
engendered by multiple secreted factors. Collectively, our novel findings shed light on the
influence of extracellular proteases, and the manner in which the infectious process is
regulated in S. aureus.

Introduction

Staphylococcus aureus is a Gram-positive pathogen capable of causing an array
of serious infections (13). Contributing to the pathogenic complexity of S. aureus is the
coordinated production of a collection of virulence factors, including include toxins,
proteases, hemolysins, nucleases, adhesins, and lipases, which allow the bacteria to
evade the immune system, adhere to and colonize host tissues, and acquire nutrients
(26-28). With regards to proteases, S. aureus produces 10 major extracellular proteases
which are transcribed from four different loci within the chromosome (103, 104). These
include a metalloprotease (aur, aureolysin), a serine protease (sspA, V8), two cysteine
proteases (scpA (staphopain A) and sspB (staphopain B)), and six serine-like proteases
(splABCDEF) (104, 105).

In the context of secreted proteases and virulence, several contradictory studies
have been performed to determine their function during S. aureus infection. For example,
an sspA mutant was used in three different animals models of infection and displayed
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attenuation of virulence in each case (103). Additionally, attenuation in virulence was
observed for mutations in sspABC and sspBC in a murine skin abscess model (104). In
contrast, an sspA mutant displayed increased virulence using a tissue abscess model
(133). Conversely, using a murine model of septic arthritis, mutations for sspABC, sspB,
and aur, did not display any virulence defect (134). Similarly, it was shown that deletion
of splABCDEF resulted in no significant virulence defect using a murine peritonitis
infection model (105). Other studies with an spl operon mutant, this time using a rabbit
model of pneumonia, demonstrated that there was no attenuation in overall virulence for
the mutant strain, however severe infection was only induced in one lung whereas the
wild-type affected both lungs equally (126). Additionally, using a guinea pig model of
vascular permeability, it was shown that ScpA and SspB promote permeability, and as
such can contribute to septic shock (135). Finally, using a murine skin abscess model it
was shown that mutations in aur and scpAB resulted in no virulence defect (104).

In order to categorically assess the role of S. aureus secreted proteases in
virulence, a study by our group focused on analyzing a strain genetically lacking all 10
enzymes (136). In the study, the most notable observation was that, when assessing the
infectious capacity of the protease-null strain in a murine model of sepsis, there was a
significant increase in mortality for mice infected with this strain in comparison to the wildtype. This hypervirulence was contrary to a number of our other observations from this
study, where secreted proteases were shown to be required for resisting phagocytosis,
survival in whole human blood, growing in the presence of antimicrobial peptides, as well
as for growth in peptide rich media, and serum. To explain these conflicting phenotypes,
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a proteomic analysis was performed revealing that the enhanced virulence observed was
mediated by increased abundance of surface and secreted virulence factors in the mutant
strain. Thus, it would appear that in the absence of secreted protease, the stability and
abundance of virulence factors is no longer controlled, allowing for their unregulated
accumulation, and consequently one observes more aggressive and deadly infections.
Similarly, but in contrast, those conditions where the protease-null strain demonstrated
ablated growth and/or survival compared to the parental strain are likely the result of
protease action directly on the host, or host substrates. In support of our findings, these
observations were also reported in a companion study by Zielinska et al (137). As such,
we suggest that in addition to cleaving host proteins to facilitate host invasion and immune
subversion, the secreted proteases of S. aureus also appear to influence disease
progression by controlling the stability of self-derived virulence determinants.

To explore further the pathogenesis related findings from our study, herein we
characterize the individual roles of secreted proteases with regards to the observed
hypervirulence. To do this, we constructed and assessed a combinatorial protease mutant
library that revealed the enhanced killing observed for the complete protease-null strain
during sepsis appears to be driven by the absence of only Aureolysin and Staphopain A.
Further, using a proteomics approach, we identified a number of secreted factors
increased in abundance across both the aur/scpA and protease-null mutant, but not in
the parent, including LukA, Sbi, and PSMa4. Using our murine model of sepsis, we
created an aur/scpA/lukA mutant and found that, although it still exhibited hypervirulence,
the progression of infection was substantially delayed in comparison to the aur/scpA
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mutant. Thus, it appears that LukA is necessary, but not sufficient, for the hypervirulence
observed, and that other secreted virulence factors seemingly also contribute to this
phenotype.

Materials and Methods

Media and growth conditions
All bacterial strains and plasmids used are listed in Table 1. All overnight cultures
were grown at 37°C with shaking at 250 rpm in 5 mL of either lysogeny broth (LB) or
tryptic soy broth (TSB). When required, the following concentrations of antibiotics were
added: For E. coli: 100 μg ml-1 ampicillin; for S. aureus: 5 μg ml-1 tetracycline, 5 μg ml-1
erythromycin, 25 μg ml-1 lincomycin, 50 μg ml-1 kanamycin, 50 μg ml-1 neomycin, 1000 μg
ml-1 spectinomycin, and 2.5 μg ml-1 chloramphenicol. When experiments required
synchronous cultures of S. aureus, overnight cultures were diluted 1:100 into 5 mL of
fresh TSB and grown for 3 hours, at which point they were standardized to an optical
density (OD600) of 0.05 in 100 mL of TSB.
Table 1: Strains and plasmids used in this study.
Strain or plasmid

Descriptiona

Reference
or source

Cloning strain

(150)

E. coli
DH5α
S. aureus
RN4220

Restriction-deficient strain

Lab stock

AH1263

s

USA300 LAC CA-MRSA Erm

(151)

AH1919

USA300 LAC Daur/DsspAB/DscpA/spl::Erm (protease-null)

(152)

NE163

USA300 JE2 aur::Tn::Erm

(153)

NE1506

USA300 JE2 sspA::Tn::Erm

(153)

NE934

USA300 JE2 sspB::Tn::Erm

(153)
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Table 1 (Continued)
NE1278

USA300 JE2 scpA::Tn::Erm

(153)

KB600

RN6390 spl::Erm

(105)

BDG2485

USA300 LAC aur::Tn::Erm

This study

BDG2487

USA300 LAC sspA::Tn::Erm

This study

BDG2488

USA300 LAC sspB::Tn::Erm

This study

BDG2486

USA300 LAC scpA::Tn::Erm

This study

DM2288

USA300 LAC spl::Erm

This study

DM2294

USA300 LAC aur::Tn::Spc

This study

BB2481

USA300 LAC aur::Kan

This study

DM2298

USA300 LAC sspA::Tn::Spc

This study

BDG2745

USA300 LAC sspB::Kan

This study

DM2293

USA300 LAC sspB::Tn::Kan

This study

DM2297

USA300 LAC sspB::Tn::Tet

This study

DM2296

USA300 LAC scpA::Tn::Tet

This study

BDG2748

USA300 LAC scpA::Tn::CM

This study

BDG2391

USA300 LAC aur::Tn::Spc/sspA::Tn::Erm/sspB::Tn::Kan/scpA::Tn::Tet

This study

BDG2649

USA300 LAC aur::Kan/sspA::Tn::Spc/sspB::Tn::Tet/spl::Erm

This study

BDG2648

USA300 LAC aur::Kan/sspA::Tn::Spc/scpA::Tn::Tet/spl::Erm

This study

BDG2392

USA300 LAC aur::Tn::Spc/sspB::Tn::Kan/scpA::Tn::Tet/spl::Erm

This study

BDG2750

USA300 LAC sspA:Tn::Spc/sspB::Tn::Tet/scpA::Tn::CM/spl::Erm

This study

BDG2640

USA300 LAC aur::Kan/sspA::Tn::Erm/sspB::Tn::Tet

This study

BDG2643

USA300 LAC aur::Kan/sspA::Tn::Erm/scpA::Tn::Tet

This study

BDG2639

USA300 LAC aur::Kan/sspA::Tn::Spc/spl::Erm

This study

BDG2642

USA300 LAC aur::Kan/sspB::Tn::Erm/scpA::Tn::Tet

This study

BDG2390

USA300 LAC aur::Tn::Spc/sspB::Tn::Erm/scpA::Tn::Tet

This study

BDG2641

USA300 LAC aur::Kan/sspB::Tn::Tet/spl::Erm

This study

BDG2644

USA300 LAC aur::Kan/scpA::Tn::Tet/spl::Erm

This study

BDG2388

USA300 LAC sspA::Tn::Spc/sspB::Tn::Tet/spl::Erm

This study

BDG2344

USA300 LAC sspA::Tn::Spc/scpA::Tn::Tet/spl::Erm

This study

BDG2749

USA300 LAC sspA::Tn::Spc/sspB::Tn::Tet/scpA::Tn::CM

This study

BDG2747

USA300 LAC sspB::kan/scpA::Tn::Tet/spl::Erm

This study

BDG2650

USA300 LAC aur::Tn::Erm/scpA::Tn::Tet

This study

BDG2653

USA300 LAC aur::Tn::CM/scpA::Tn::Tet

This study

BDG2758

USA300 LAC aur::Kan/scpA::Tn::Tet

This study

BDG2638

USA300 LAC aur::Kan/sspA::Tn::Spc

This study

BDG2757

USA300 LAC aur::Kan/sspB::Tn:Tet

This study

BDG2389

USA300 LAC aur::Tn::Spc/sspB::Tn::Kan

This study

BDG2489

USA300 LAC aur::Tn::Spc/spl::Erm

This study

BDG2645

USA300 LAC sspA::Tn::Spc/sspB::Tn::Tet

This study
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Table 1 (Continued)
DM2292

USA300 LAC sspA::Tn::Erm/scpA::Tn::Tet

This study

BDG2346

USA300 LAC sspA::Tn::Spc/spl::Erm

This study

BDG2746

USA300 LAC sspB::Kan/scpA::Tn::Tet

This study

DM2291

USA300 LAC sspB::Tn::Tet/spl::Erm

This study

DM2289

USA300 LAC scpA::Tn::Tet/spl::Erm

This study

NE1300

USA300 JE2 lukA::Tn::Erm

(153)

BG2744

USA300 LAC aur::Tn::CM/scpA::Tn::Tet/lukA::Tn::Erm

This study

Plasmid to create mutants in S. aureus

(154)

Plasmids
pJB68
pBB01

R

R

Plasmid construct for aur mutation, Amp CM
R

This study
R

pBDG03

Plasmid construct for sspB mutation, Amp CM

This study

pBDG04

Plasmid for chloramphenicol cassette switch (pCM)

This study

pKan

Plasmid for kanamycin cassette switch

(154)

pTet

Plasmid for tetracycline cassette switch

(154)

pSpc

Plasmid for spectinomycin cassette switch

(154)

a

The following abbreviations specify resistance cassettes to: Erm – erythromycin, Tet –
tetracycline, Kan – kanamycin, CM – chloramphenicol, Spc – Spectinomycin, Amp –
ampicillin
Mutant strain construction
Transposon mutants in S. aureus USA300 JE2 for aur, sspA, sspB, and scpA were
obtained from the Nebraska Transposon Mutant Library (NTML). The spl operon mutant
in S. aureus RN6390 was previously constructed by Reed et al (105). Each mutant was
transduced into the USA300 LAC wild-type strain using phi11, as described by us
previously (93), and confirmed by PCR using gene specific primers (aur –
OL535/OL3402, sspA – OL3528/OL3529, sspB – OL147/OL148, scpA – OL15/OL16, spl
– OL1979/OL3872). All primers used in this study are listed in Table 2. In order to
construct the protease mutant combinatorial library, several of the protease mutants
needed to be constructed containing different antibiotic resistance cassettes to facilitate
simultaneously selection for multiple chromosomal mutations.
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Table 2: Primers used in this study.
Sequencea

Descriptionb

OL4212

ATGgaattcGTAACTAACTTGAGTACACGTG

aur KO A frag

OL4213

ATGacgcgtGTATGAAGCATGGAATGAAGTAG

aur KO A frag

OL4214

ATGacgcgtTGCCATACTTGTAAATGCATATC

aur KO B frag

OL4215

ATGggtaccGATTGGAGTAACAGTTGTTGAA

aur KO B frag

OL4220

ATGacgcgtGATAAACCCAGCGAACCATTTG

Kanamycin cassette

OL4221

ATGacgcgtATCGATACAAATTCCTCGTAGGC

Kanamycin cassette

OL4216

ATGggtaccTTTAGAGAAAGTTGAAGATGAAACTGTG

sspB KO A frag

OL4217

ATGagatctGCCTATTACATTTATCATTCAATCG

sspB KO A frag

OL4218

ATGagatctGCATTGAAACCATTATGATGCT

sspB KO B frag

OL4219

ATGggtaccTATTCGTTGCAACTTTGACAAC

sspB KO B frag

OL4473

ATGgagctcCTAGCTTAGCCTGCCATGATG

pKan inverse

OL4474

ATGgagctcGGTCAATCGAGAATATCGTCAACTG

pKan inverse

OL4563

ATGgagctcCCAGTCATACCAATAACTTAAGGG

Chloramphenicol cassette

OL4564

ATGgagctcCTTATCAATTTGTTGCAACGAACAG

CM cassette

OL4618

AGGAGCGATTTACATATGAGTTATG

pCM screening

OL4619

GAGATACCCAGATCATATGAAACAG

pCM screening

OL535

ATGATGgcatgcGGTGTGTAGACATCTTCACCC

aur screening

OL3402

TCAAGATTACGCTGTTACTGATGT

aur screening

OL15

ATCccgcggGTGTTACCCCTATTGCAAACGC

scpA screening

OL16

GCTggatccCATCGTATAGCCTGCACACCAACC

scpA screening

OL3496

CGGTAATAGAGGGAAACGATGAC

Tn::Tet screening

OL3528

TTCCGGTGTAGTTGTAGGTAAAG

sspA screening

OL3529

TGGTTCATCTGGGTTGTTAGG

sspA screening

OL147

GCCAAAGCCGATTCACACTC

sspB screening

OL148

CCTGCACACCATGAGTTATCG

sspB screening

OL1979

ATGATGggatccGTTGGATGTGAAAGATTG

spl screening

OL3872

TCTTCATCTGCCCATGCTTC

spl screening

OL5135

CAAATGAAGTAGCTGGTAATAC

lukA screening

OL5136

ATTCACATGTCGATACATATCAAC

lukA screening

Primer

a

Restriction sites are underlined lowercase letters
To create such mutants (aur::Tn::cm, aur::Tn::spc, sspA::Tn::spc, sspB::Tn::kan,

sspB::Tn::tet, scpA::Tn::tet, scpA::Tn::cm), allelic exchange plasmids were used to
replace the transposon with alternative antibiotic resistance cassettes. The previously
described allelic exchange plasmids pTet and pSpc were used to replace the transposon
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in mutants with a tetracycline or spectinomycin resistance cassette, respectively (154).
An additional allelic exchange plasmid pCM was constructed in this study (pBG04), in
order replace the transposon with a chloramphenicol resistance cassette. To construct
pBG04, an inverse PCR was performed on pTET using OL4473 and OL4474 to amplify
the entire plasmid excluding its tetracycline resistance cassette. A chloramphenicol
resistance cassette was amplified from pKOR1 using OL4563 and OL4564. Next, these
fragments were ligated together using SacI sites. This was then transformed into
chemically competent E. coli, with clones confirmed by PCR using gene specific and
plasmid specific primers OL4618 and OL4619. The correct plasmids were then
electroporated into RN4220 and again confirmed by PCR.

All resistance cassette switches were transduced into a clean USA300 LAC wildtype background and confirmed by PCR using the same gene specific primers noted
above (excluding sspB::Tn::tet and scpA::Tn::tet). Gene specific and tetracycline cassette
specific primers were used to confirm sspB::Tn::tet (OL148/OL3496) and scpA::Tn::tet
(OL15/OL3496) because of the similarity in size for the erythromycin and tetracycline
resistance cassettes.

Despite these alterations, we still found it necessary to create a de novo deletion
mutant for the aur gene. A kanamycin marked deletion was thus generated using plasmid
pJB38, as described by Bose et al. (154). Using primers OL4212/OL4213 and
OL4214/OL4215, two fragments containing the regions up and downstream of aur, along
with small portions of the 5’ and 3’ ends of the gene, were amplified by PCR. A kanamycin
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resistance cassette was amplified using OL4220 and OL4221 from a 8325-4 sarA::kan
mutant (54). The kanamycin cassette was ligated between the two previously generated
fragments using a MluI site and then the ligated fragment was cloned into pJB38 using
EcoRI and KpnI sites. Deletion of the majority of the aur gene was then performed using
an established protocol of allelic replacement (154). To confirm correct construction, the
region where the deletion occurred was amplified by PCR using OL4212 and OL4215
and subjected to sequencing. Similarly, a new kanamycin marked sspB deletion was also
constructed herein, using the method described above. The flanking fragments were
generated using OL4216/OL4217 and OL4218/OL4219. The kanamycin cassette was
ligated in between the two fragments using a BglII site. This fragment was then cloned
into pJB38 using XhoI and KpnI sites. The sspB deletion was confirmed using primers
OL4216 and OL4219.

To construct the aur/scpA/lukA mutant, a lukA transposon mutant was obtained
from

the

NTML

library.

The

lukA

mutant

was

transduced

into

the

aur::Tn::CM/scpA::Tn::Tet mutant, using phi11 as described above, and was confirmed
by PCR using primers OL5135/OL5136.

Murine model of bacterial sepsis
These experiments were carried out as previously described (136). To prepare
cultures for infection, aliquots of overnight cultures were washed twice and diluted to 1 x
109 CFU/mL in PBS. Next, six-week old CD-1 female mice purchased from Charles River
Laboratories were separately inoculated by tail vein injection with 100 μl of culture (final
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inocula is 1 x 108 CFU/mL). The infection was then allowed to progress for 6 days, or until
mice reached a premoribund state (used as a measure of mortality), at which point they
were euthanized. Percent survival of mice infected with our various strains was
determined and compared using a Logrank test to determine statistical significance.

Proteomic analysis of secretomes
Secreted proteins were isolated from stationary phase (15 h) cultures of the wildtype, protease null mutant, and the aur/scpA mutant. To isolate secretomes, cultures were
centrifuged and the supernatants were placed in a fresh tube, before the addition of 10%
trichloroacetic acid for protein precipitation. Samples were incubated overnight at 4°C,
and then centrifuged the following morning, to pellet precipitated protein. These were
washed with 100% ethanol three times and resuspended in PBS, before undergoing
quantification with a commercially available kit (Pierce 660 nm, ThermoFisher Scientific).
For size selection, 25 µg of each protein sample was denatured at 95 °C for 5 minutes in
Laemmli buffer and underwent electrophoresis on a 12 % SDS-PAGE gel, and visualized
using Instant BlueTM. Following this, each sample lane of the gel was cut into 10 pieces
with specific mass ranges determined using the protein ladder (depicted in Figure 1).
Each gel piece was then placed into individual microcentrifuge tubes. To remove SDS
and Instant BlueTM stain, gel pieces were washed twice by adding 200 μl of 50:50
acetonitrile (ACN)-Ammonium bicarbonate (ABC) to the sample tubes, followed by
vortexing for 15 minutes and then removal of the wash. To dehydrate gel pieces, ACN
was added to samples and allowed to incubate for 5-10 minutes, or until the gel pieces
turned white. Next, gel pieces were resuspended in 20-50 μl (determined by the size of
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the gel piece) of 100 mM ABC was added to samples and incubated for 5 minutes to
rehydrate gel pieces. To achieve a 1:1 ratio of ACN:100 mM ABC, an equal volume of
ACN was added, and then the samples were vortexed for 15 minutes. Following this,
excess wash was removed and samples were placed in a SpeedVac for 5 minutes to dry.
For gel digestion, 100 μl of 50 mM dithiothreitol (DTT) was added to samples for
rehydration of gel pieces. Samples were then incubated at 55°C for 30 minutes, before
cooling to room temperature. DTT was then removed via pipetting, 100 μl of 100 mM
iodoacetamide (IAA) was added, and samples were then incubated in the dark for 30 min.
Next, the buffer was removed by pipetting, and fragments were washed and vortexed for
15 min in 100 μl of 50:50 ACN/100 mM ABC. To dry samples, buffer was removed, and
samples were placed in a SpeedVac for 5 min. Samples were then placed on ice for 5
minutes before the addition of cold trypsin and incubation for 30 minutes. Following this,
samples were placed at 37°C and incubated overnight. The next day, supernatants
containing the peptides were transferred to fresh microcentrifuge tubes. To further extract
peptides from gel pieces, samples were washed twice by adding 200 μl of 50:50
ACN/water in 0.1% formic acid (FA) and vortexing for 15 minutes. Each time the wash
was added to the tube containing the supernatant. Samples were then placed in a
SpeedVac until completely dry, before being resuspened in 20 µl of 0.1% FA, and then
placed into an ultrasonic water bath for 10 minutes. Following this, samples were
centrifuged at 15,000 x g for 10 minutes with the supernatant subsequently transferred
into autosampler vials. Aliquots (5 µl) were separated on a 50 cm Acclaim™ PepMap™
100 C18 reversed-phase high-pressure liquid chromatography (HPLC) column (Thermo
Fisher Scientific) using an Ultimate3000 UHPLC (Thermo Fisher Scientific), with a 120
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min gradient (2 to 32 % acetonitrile with 0.1 % formic acid). Peptides were analyzed on a
hybrid Quadrupole-Orbitrap instrument (Q Exactive Plus; Thermo Fisher Scientific) using
data-dependent acquisition in which the top 10 most abundant ions were selected for
MS/MS analysis. Each sample was analyzed as separate fractions to identify intact
proteins (i.e. of their predicted mass), proteins were included for further analysis only if
their predicted molecular weight (kDa) fell within that of their mass fraction (as observed
on the SDS-PAGE gel, and proteins with a predicted mass within +/- 20 % of the upper
size threshold of the fraction were considered “intact” and included for analysis). LFQ
intensity was used to establish fold change in intact proteins between WT and mutants.

Figure 1: Depiction of how SDS-PAGE gel was sectioned by mass fraction for
proteomic analysis.
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Results

Generating a combinatorial library of protease mutant strains in S. aureus.
We have previously demonstrated that, upon deletion of all ten extracellular
proteases of S. aureus, a hypervirulent phenotype is observed in a murine model of sepsis
(136) (Figure 2). This finding is explained by a profound increase in virulence factor
abundance in the complete protease-null strain (136). Thus, it would appear that the S.
aureus secreted protease exist to modulate the stability of secreted virulence factors, so
as to regulate infection severity. To explore these findings more fully, we first wanted to
establish whether it is necessary to delete all secreted proteases to produce this
phenomenon, or if the ablation only a select few elicited the same outcome. Accordingly,
to understand the mechanism behind this important observation, we first generated a
library of protease mutant strains, encompassing every possible combination of disruption
(Table 1). It is worth noting that, in these studies, SplABCDEF were considered as a
single unit, rather than as individual enzymes. This was firstly a result of simplicity, to
reduce the number of strains generated, but also because the Spl enzymes have a very
narrow substrate specificities (118-120), and likely have only a limited number of
individual proteolytic targets.
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Figure 2: The absence of all 10 secreted proteases results in a hypervirulent
phenotype in a murine model of sepsis. The wild-type (WT) and protease-null mutant
were separately inoculated via tail vein injections into groups of 10 CD-1 mice, at 1 x 108
cells. Infections were allowed to progress for 6 days or until mice reached premoribund
state (a measure of mortality). Statistical significance was determined used a Logrank
test.
Restoring activity of single enzymes to the protease-null strain does not limit
hypervirulence.
Using the murine model of sepsis, we begin our analyses by infecting mice with
strains lacking all but one of the secreted proteases (with the Spl caveat noted above),
alongside the wild-type and protease null strains. The infections were allowed to progress
for 6 days or until mice reached premoribund state (as a measure of mortality). When
reviewing this data, we observed that each of the “quadruple” mutants screened displayed
enhanced virulence, as compared to the wild-type. When comparing these strains to the
protease-null mutant, we noted that the spl/aur/sspB/scpA mutant mirrored the proteasenull mutant in its lethality, whilst the spl/sspA/aur/sspB, sspA/aur/sspB/scpA and
spl/sspA/aur/scpA mutants exhibited an even more pronounced hypervirulent phenotype
(Figure 3). The finding with these latter strains is most intriguing, and emphasizes the
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individual roles of the proteases present in each strain for disease progression. Indeed,
while there is still clearly an increase in abundance of virulence factors with these mutants
(due to the enhanced pathogenic potential), the presence of individual proteases appears
to aid in the infectious process, resulting in an even more severe infection.

Figure 3: Quadruple protease mutants exhibit a hypervirulent phenotype during a
murine model of sepsis. The wild-type (WT), protease-null mutant, and quadruple
protease mutants were separately inoculated via tail vein injections into groups of 10 CD1 mice, at 1 x 108 cells. Infections were allowed to progress for 6 days or until mice
reached premoribund state (measure of mortality). Statistical significance was
determined used a Logrank test (*, P < 0.033; **, P < 0.002).
The restoration of two enzymes to the protease-null strain has a variable impact on
hypervirulence.
Given that each of our quadruple combinations of protease deletions proved to be
at least as virulence as the null mutant, we next assessed the impact of adding back two
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proteolytic enzymes to the null strain. Accordingly, eight of the different combinations of
triple protease deletion mutants were tested, alongside the wild-type and null strain, in
the murine model of sepsis. Interestingly, with these mutants we observed a mixture of
wild-type and hypervirulent phenotypes. For five of the combinatorial protease mutants
(aur/sspB/spl, aur/sspA/spl, aur/sspA/sspB, sspA/scpA/spl, and sspA/sspB/spl), they
demonstrated virulence that followed that of the wild-type strain (Figure 4), indicating that
they had lost the hypervirulence phenotype of the complete null mutant. In contrast, we
found that the aur/scpA/sspA, aur/scpA/sspB, and aur/scpA/spl mutants displayed
enhanced virulence, and in some cases (the latter two strains) proved more lethal than
the protease-null mutant (Figure 5).

Figure 4: Select triple protease mutants did not exhibit a hypervirulent phenotype
during a murine model of sepsis. The wild-type (WT), protease-null mutant, and triple
protease mutants were separately inoculated via tail vein injections into groups of 10 CD1 mice, at 1 x 108 cells. Infections were allowed to progress for 6 days or until mice
reached premoribund state (measure of mortality). Statistical significance was
determined used a Logrank test.
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Figure 5: Select triple protease mutants do exhibit a hypervirulent phenotype
during a murine model of sepsis. The wild-type (WT), protease-null mutant, and triple
protease mutants were separately inoculated via tail vein injections into groups of 10 CD1 mice, at 1 x 108 cells. Infections were allowed to progress for 6 days or until mice
reached premoribund state (measure of mortality). Statistical significance was
determined used a Logrank test (*, P < 0.033).
The combined loss of aureolysin and staphopain A activity is necessary, and
sufficient, for hypervirulence in S. aureus.
When analyzing our triple mutant data more closely, it became apparent that the
common thread for the hypervirulent phenotype was that all strains displaying this trait
were lacking both Aureolysin (aur) and Staphopain A (scpA), and that the other enzyme
missing alongside these two did not seem to matter. To determine if in fact the combined
loss of aur and scpA alone was sufficient to generate a hypervirulent phenotype, we next
assessed the pathogenic potential of an aur/scpA mutant, alongside our wild-type and
protease-null mutant strains. In so doing, we determined that the aur/scpA mutant proved
to not only be more virulent than the wild-type strain, but also caused more rapid death
(although to the same final extent) than the protease-null mutant (Figure 6). Thus, it is
clear that these two combined mutations together are the minimum requirement for
generating a hypervirulent phenotype in S. aureus. As such, this suggests that together
Aureolysin and Staphopain A must modulate the stability of virulence factors with
profound impacts on disease progression.
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Figure 6: The loss of Aureolysin and Staphopain A is necessary and sufficient to
generate hypervirulent S. aureus in a murine model of sepsis. The wild-type (WT),
protease-null mutant, and aur/scpA mutant were separately inoculated via tail vein
injections into groups of 10 CD-1 mice, at 1 x 108 cells. Infections were allowed to
progress for 6 days or until mice reached premoribund state (measure of mortality).
Statistical significance was determined used a Logrank test.
Identification of virulence factors contributing to the hypervirulent phenotypes of
the protease null and aur/scpA mutant strains
As proposed previously, in the absence of secreted proteases, virulence factors
exist unchecked, leading to their enhanced accumulation, and ultimately a hypervirulent
phenotype. Thus, having identified the loss of Aureolysin and Staphopain A activity as
being necessary and sufficient for hypervirulence, we next wanted to narrow in on those
virulence factors modulated by these two enzymes, and thus potentially proving causative
for this phenotype. To do this we sought to identify those secreted factors that have
increased abundance across both the protease-null and aur/scpA mutant, but that display
more limited accumulation in the wild-type. As such, we isolated secreted proteins from
our wild-type, protease-null, and aur/scpA mutant after 15h growth, and separated them
using SDS-PAGE. Following this, each sample lane of the gel was sectioned into 10
fragments that were subjected to analysis using proteomic approaches. This data was
41

then processed as fold change from the wild-type across each mass fraction (Table 3).
When setting the threshold for significance to a fold change of 1.5 fold or greater, we
identified 15 secreted proteins that were increased in abundance across the aur/scpA
and protease null mutants, in comparison to the wild-type strain (Figure 7). Of these
changes, the greatest differences was for SAUSA300_0964, which is designated as being
a chitinase related protein. Specifically, it demonstrated a 53.3 fold-change in abundance
for the aur/scpA mutant and a 66.4 fold-change for the protease-null strain. With regards
to more commonly known virulence factors, we observed an increase in abundance for
immunoglobulin binding protein Sbi (aur/scpA – 14.5-fold, protease null – 15.5-fold), the
LukA leukotoxin (aur/scpA – 11.9-fold, protease null – 4.1-fold), phenol-soluble modulin
alpha 4 (aur/scpA – 3.6-fold, protease null – 2.3-fold), delta hemolysin (aur/scpA – 2.7fold, protease null – 2.6-fold), LukB leukotoxin (aur/scpA – 3.4-fold, protease null – 2.4fold), enterotoxin K (aur/scpA – 2.1-fold, protease null – 2.5-fold), and the major autolysin
(aur/scpA – 2-fold, protease null – 2.5-fold). Given that, beyond SAUSA300_0964, each
of these are well known virulence factors, known to play key roles in the infectious
process, they represent an excellent list of candidates for mediating the hypervirulent
phenotypes observed for our protease mutant strains.
Table 3: Proteins increased in abundance in both the aur/scpA mutant and
protease-null mutant in comparison to the wild-type.
Accession
Number

Gene

Description

Fold
Change
aur/scpA
vs WT
53.3

Fold
Change
ESPN vs
WT
66.4

SAUSA300_0964

Chitinase-related protein

SAUSA300_0277

Staphyloxanthin biosynthesis protein

30.9

47.2

SAUSA300_0409

Hypothetical protein

30.0

38.1

SAUSA300_1052

ecb

Complement inhibitory protein

25.2

24.5

SAUSA300_2364

sbi

Immunoglobulin-binding protein

14.5

15.5
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Table 3 (Continued)
SAUSA300_0146

Hypothetical protein

14.3

15.4

11.9

4.1

SAUSA300_1975

lukA

Leukotoxin

SAUSA300_2561

phoB

Alkaline phosphatase

5.1

6.3

SAUSA300_2579

lytZ

Putative peptidoglycan hydrolase

1.7

6.0

SAUSA300_0424.1

psmα4

Phenol-soluble modulin alpha 4

3.6

2.3

SAUSA300_1988

hld

Delta-hemolysin

2.7

2.6

SAUSA300_1974

lukB

Leukotoxin

3.4

2.4

SAUSA300_0800

sek

Enterotoxin K

2.1

2.5

Hypothetical protein

1.9

2.9

Autolysin

2.0

2.5

SAUSA300_0602
SAUSA300_0955

atl

Fold Change from WT

80

aur/scpA

60

Protease-null
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Figure 7: Secreted proteins increased in abundance in both the aur/scpA and
protease-null mutant. Secretomes were isolated from 15 h cultures of the wild-type,
aur/scpA, and protease-null mutant. Isolated proteins were separated using an SDSPAGE gel. Full length proteins were identified at each mass fraction and fold change in
LFQ intensity was determined for aur/scpA and protease-null mutant in comparison to
wild-type.
Abrogating LukAB activity in an aur/scpA mutant delays the development of
hypervirulence
To assess the importance of the virulence factors identified above as being
increased in abundance in the aur/scpA and protease-null mutant, we next set out to
assess their impact during infection. We began with LukA, a pore forming leukotoxin,
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which has been previously shown to contribute to increased virulence in USA300 (155).
To assess its importance in our study, mice were separately infected with the wild-type,
protease-null mutant, aur/scpA mutant and aur/scpA/lukA mutant strains. Upon analysis,
and as expected, we observed a hypervirulent phenotype for the protease-null and
aur/scpA mutant strains (Figure 8). When assessing the aur/scpA/lukA strain, we noted
that, although we also observed the hypervirulent phenotype in terms of overall mortality,
the phenotype took considerably longer to manifest in comparison to the aur/scpA mutant.
Specifically, with aur/scpA/lukA, the percent survival dropped to 90% at day 4 and
remained the same until day 6, at which point it drastically declined to 50%. In contrast,
with the aur/scpA mutant, the percent survival dropped to 90% on day 1, 80% on day 2,
70% on day 3, and then to 50% on day 4, where it remained. Further, with protease-null
mutant, the percent survival dropped to 80% on day 2, then to 50% on day 5, and
ultimately to 40% on day 6. Indeed, the aur/scpA/lukA mutant actually displayed more
limited virulence than the wild-type strain on all days other than the last one of the
infectious period. Thus, although ultimately a hypervirulent phenotype was engendered
by the aur/scpA/lukA mutant strain, the fact the progression of infection was significantly
retarded in comparison to the aur/scpA indicates that LukA clearly contributes to the
aggressive virulence phenotype observed for our protease mutant strains. Collectively,
however, our findings suggest that it is likely the increased abundance of multiple
secreted factors in our aur/scpA mutant strain that produces the hypervirulent phenotype.
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Figure 8: The disruption of lukA in the aur/scpA mutant delays the hypervirulence
phenotype during a murine model of sepsis. Wild-type (WT), protease-null mutant,
aur/scpA mutant, and aur/scpA/lukA were separately inoculated via tail vein injections
into groups of 10 CD-1 mice, at 1 x 108 cells. Infections were allowed to progress for 6
days or until mice reached premoribund state (measure of mortality). Statistical
significance was determined used a Logrank test.
Discussion

The pathogenic success of S. aureus is largely attributed to the repertoire of
virulence factors it produces in the human host. With regards to secreted proteases, their
importance for disease causation has only until recently been clarified by a study from
our group, where we reveal that these enzymes modulate the severity of infection by
controlling virulence factor abundance (136). This is evidenced by our finding that a
protease-null strain has a substantially increased infectious capacity in a murine model
of sepsis; resulting from the unchecked accumulation of virulence determinants. A
limitation to our previous study, however, is that we only assessed the pathogenic
potential of a strain genetically lacking all 10 secreted proteases. As such, in this study
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we followed up on these earlier findings, and assessed the individual importance of these
proteases by constructing and assessing a combinatorial protease mutant library using
the same murine model. Herein, we found that when only adding a single protease back
to the null-strain (quadruple mutants), all strains still displayed enhanced virulence akin
to that previously demonstrated with the protease-null mutant. Moreover, strains that
lacked all protease but either SspB, ScpA, or the Spls, resulted in even more severe
infections than the null-strain, likely as a result of the influence of these proteases
themselves on disease progression. Indeed, Staphopain A (ScpA) has been shown to
contribute to immune evasion by blocking neutrophil recruitment via its cleavage of the
CXC chemokine receptor (CXCR2) (124). Similarly, Staphopain B (SspB) blocks
phagocytosis by neutrophils and monocytes via cleavage of CD31 (125). Additionally,
SplA has been shown to contribute to bacterial invasion and dissemination in a rabbit
model of pneumonia through its cleavage of mucin 16 (126). As such, this data
emphasizes that the targeting of host proteins by secreted proteases plays a significant
role in the infection process.

When adding back two proteolytic enzymes (triple mutants), there was a variable
impact on hypervirulence, as strains exhibited a mixture of virulent and hypervirulent
phenotypes. However, we noted that each of the strains demonstrating a hypervirulent
phenotype lacked both Aureolysin and Staphopain A. Indeed, when assessed together,
we determined that these mutations alone were sufficient to generate the hypervirulent
phenotype, suggesting that they modulate the stability of factors that have profound
impacts on disease progression. Of note, previous studies have shown that Aureolysin
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can specifically cleave alpha hemolysin (Hla) (128) and the phenol-soluble modulins
(PSMs) (127), whereas Staphopain A has been shown to control the abundance of biofilm
components (130). When we assessed alterations in secreted factor abundance in our
various strains, we observed increased abundance in the aur/scpA mutant and the
protease-null mutant for PSMa4, suggesting its cleavage or lack thereof by Aureolysin
could influence disease progression. In addition to this, we found several other commonly
known factors such as Ecb, LukAB, and Sek that were increased in abundance.
Importantly, these factors are known to play key roles in the infectious process. While
LukAB have been shown to specifically target human neutrophils (156), it was also shown
that a strain lacking lukAB was significantly decreased in viability during a murine renal
abscess model (155). With regards to staphylococcal enterotoxin K (Sek), it has been
shown that mortality was decreased during a murine model of sepsis model when mice
were immunized with SEK-specific mAbs (157). Lastly, Ecb has been shown to contribute
to immune evasion by preventing the recognition of opsonized bacteria by neutrophils
(158). As such, an increase in the abundance of these factors could contribute the more
severe infections observed herein.

The most substantial increase in abundance in the protease-null and aur/scpA
mutants was observed for a chitinase-related protein (SAUSA300_0964). Chitinases are
enzymes that breaks down chitin by hydrolyzing glycosidic bonds, and are found in all
kingdoms of life (159). With regards to bacteria, while chitinases are important for nutrient
acquisition in marine and soil-dwelling bacteria, their role in non-chitinous hosts is not
completely understood (160). However, when assessed in pathogens such as Listeria
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monocytogenes and Legionella pneumophila, chitinases have been found to be important
for virulence using murine models of infection (160-162). Interestingly, while no studies in
S. aureus have specifically focused on the importance of this chitinase-related protein, its
abundance was found to be altered in various strains, including an spl (126), saeR (163),
and an xdrA mutant (our unpublished data). Although the importance of the chitinaserelated protein was not determined in this study, as a result of no mutant being currently
available, we suggest this protein could play an important, and as yet overlooked, role in
S. aureus virulence.

With regards to LukA, its individual impact to the hypervirulence phenotype was
explored herein using an aur/scpA/lukA mutant strain. While its absence still ultimately
resulted in a hypervirulent phenotype, it took substantially longer for the infection to
become severe, in comparison to the aur/scpA mutant. Thus, it is clear that the absence
of lukA in our aur/scpA mutant slows disease progression, given the retarded mortality of
the triple mutant. However, as hypervirulence was still observed with aur/scpA/lukA, we
believe that this phenotype results from an increase in multiple secreted factors. Given
that the success of S. aureus as a pathogen is the result of coordinated production of a
variety of virulence factors, the involvement of multiple factors in the production of the
hypervirulence phenotype is not entirely surprising.

Collectively, when considering our infection data, we note that there is some
variability with regards to the severity of infections, in that the difference between our
virulent and hypervirulent strains, at times ranges from profound to more modest
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differences. In our studies, CD-1 mice were used, which is an outbred strain. We chose
this mouse lineage because its genetic diversity is more representative of what might be
expected in a human population than more common inbred strains (164). However, with
this diversity, there also comes greater phenotypic variation (164, 165). As such, we
suggest that, despite the experimental variance observed, the reproducibility of our
virulence trends is clear, reproducible and undeniable.

In summary, this study solidifies the importance of secreted proteases for S.
aureus virulence and more specifically, demonstrates the significant importance of
Aureolysin and Staphopain A. Our findings support the role of the secreted proteases as
mediators of virulence factor abundance and further shows that these factors do
contribute to disease progression, albeit in a combined manner. Collectively, our novel
findings shed light on the influence of extracellular proteases, and the manner in which
the infectious process is regulated in S. aureus.
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Chapter 3: Mapping the Global Network of Extracellular Protease
Regulation in Staphylococcus aureus

Note to the Reader

This chapter has been previously published (166) and has been attached
(Appendix A). Permission from the publisher is not required as we retain the copyright for
the manuscript.
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Chapter 4: XdrA Ablation Engenders Diminished Cytolytic Potential
but Enhanced Pathogenesis in Staphylococcus aureus

Abstract

The success of Staphylococcus aureus as a pathogen results from the production
of a wealth of virulence determinants that aid in immune evasion, host cell invasion and
dissemination of infection. Given the niche specific roles of these factors in infection, their
production is controlled by a complex network of regulatory factors. In a continued effort
to understand this network, the present study is aimed at characterizing the role of the
transcriptional regulator XdrA and its effects on S. aureus gene expression. Using an
unbiased global analysis, we find that XdrA has a broad impact on gene expression,
influencing the transcription of several important virulence determinants, and factors
involved in gene regulation. When assessing the role of XdrA in virulence, we find that an
xdrA mutant has an increased ability to survive in whole human blood, mediated in part
by an increased in survival within neutrophils, and an upregulation in expression of
several factors involved in immune evasion, including sbi, fnbpA and efb. Furthermore,
the increased survival within neutrophils appears to result from an upregulation in
expression of sodM, recA, and sae, all of which assist bacterial cells in combating the
effects of oxidative stress. In addition to these changes, we find that the xdrA mutant has
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a decreased abundance of cytolytic toxins, likely resulting from changes in agr and sae
activity. We suggest that the broad impact of XdrA on the expression of genes involved
in immune evasion, DNA damage, and oxidative stress tolerance, collectively result in a
survival advantage allowing for the increased ability to causes disease in vivo, when xdrA
is disrupted. In sum, our findings shed new light on the role of XdrA and its seemingly
novel influence on S. aureus survival during infection.

Introduction

Staphylococcus aureus is a highly adaptive Gram-positive pathogen capable of
causing a multitude of diseases, ranging from superficial skin infections to invasive and
life-threatening (5, 15, 16). This ability can be attributed, at least in part, to the wealth of
virulence factors produced by S. aureus in the human host, that aid in immune evasion,
tissue invasion, nutrient acquisition, and dissemination (121-123). The production of
these factors is coordinately regulated by a complex network of factors, including
transcriptional regulators, two-component systems, sigma factors, and regulatory RNAs
(42).

In S. aureus, the two most important global regulators of virulence factor
production are, arguably, the agr (accessory gene regulator) (44) two-component,
quorum sensing system and sarA (staphylococcal accessory regulator) (167). The
function of the agr system is growth phase dependent and allows for S. aureus to
transition from adherent to invasive phenotypes by its repression of cell surface adhesins
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and promotion of secreted factors in post-exponential phase (45). In contrast, SarA
promotes the production of cell-wall-associated proteins through direct action as well as
by its influence on the agr system (45). In addition to these regulators there are several
others, such as Rot, MgrA, CodY, SaeR, and SarS, that have been shown to play an
important role in virulence factor regulation through direct action, as well as by their
interactions with other regulators (57, 62, 143, 144, 148, 168-170).

In recent work by our group exploring the proteinaceous regulome of S. aureus for
factors influencing secreted protease activity, we identified the transcriptional regulator
XdrA as strongly repressing protease transcription (166). XdrA belongs to the Xre
(xenobiotic response element) family of transcription factors and was first characterized
for its ability to affect b-lactam resistance and bind the mecA promoter in the CHE482
strain (171). However, its effect on beta lactam resistance was shown to be independent
of this binding, as XdrA does not influence the expression of mecA. A subsequent study,
also in CHE482, found that XdrA promotes the production of protein A (spa), potentially
in a direct manner, as no interactions were identified between XdrA and known spa
regulators (34). Following this, it was found that XdrA influenced the production of biofilms
in strain HG003 through its effect on eDNA release (172). Most recently, it was discovered
that XdrA represses capsule production in Newman via direct binding of the capsule
operon promoter (173).

In this study our goal was to further explore the role of XdrA in controlling protease
activity, and uncover novel regulatory roles for XdrA in S. aureus virulence factor
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production through the use of unbiased global analyses. Herein, we present a novel study
of XdrA, for the first time in USA300, finding that, in addition to its regulation of secreted
proteases and protein A (spa), XdrA also influences the production of multiple cytolytic
toxins, resulting in the reduced ability of an xdrA mutant to lyse human erythrocytes. In
contrast, we demonstrate that not only is the mutant better able to resist oxidative stress,
but that it is also better able to survive when challenged by components of the human
innate immune system. Lastly, when using a murine model for skin abscess formation,
we observed increased bacterial burden within abscesses, and increased abscesses
size, for mice infected with the xdrA mutant in comparison to the wild-type strain.
Collectively, our study presents unique insight into the role of XdrA, identifying it’s novel
contribution to virulence factor regulation and S. aureus pathogenesis.

Materials and Methods

Media and growth conditions
Liquid cultures were prepared in 5mL of either tryptic soy broth (TSB) or lysogeny
broth (LB) and grown overnight with shaking at 250 rpm and 37°C. If antibiotics were
required, they were added using the following concentrations: E. coli –100 μg ml-1
ampicillin; S. aureus - 5 μg ml-1 erythromycin, 25 μg ml-1 lincomycin, 10 μg ml-1
chloramphenicol, 5 μg ml-1 tetracycline. Overnight cultures were diluted 1:100 into 5mL
of fresh TSB and grown for 3h. Following incubation, cultures were standardized in 100
mL of fresh TSB, to an optical density (OD600) of 0.05 to obtain synchronous cultures. For
induction of the complementation plasmid, 0.4µM cadmium chloride was used.
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Bacterial strains
All strains and plasmids used are listed in Table 4. The xdrA mutant was obtained
from the Nebraska Transposon Mutant Library (NTML). The mutation was transduced
into USA300 Houston, as described by us previously (93), using Φ11, and confirmed by
PCR using gene-specific primers (OL3788/OL3789). All primers used are listed in Table
5. To switch the antibiotic resistance cassette of the xdrA mutant from erythromycin to
tetracycline, an established protocol using allelic replacement was used (154). Following
confirmation of the cassette exchange, the xdrA mutant was transduced into a clean HOU
wild-type background, and confirmed as detailed above.
Table 4: Strains and plasmids used in this study.
Strain or plasmid

Descriptiona

Reference
or source

Cloning strain

(150)

Restriction-deficient strain

Lab stock

E. coli
DH5α
S. aureus
RN4220

USA300 HOU USA300 HOU MRSA Isolate
BDG2332

(174)
-

USA300 HOU xdrA::Tn::erm xdrA
-

(166)

BDG2751

USA300 HOU xdrA::Tn::tet xdrA

This study

BDG2756

USA300 HOU pJB67, HOU WT empty vector

This study

BDG2752

USA300 HOU xdrA::Tn::tet/pJB67::xdrA, xdrA mutant empty vector This study

BDG2755

USA300 HOU xdrA::Tn::tet/pJB67, xdrA+

This study

Plasmids
pJB67

pCN51 with optimized RBS and Cd-inducible promoter, Ampr Ermr (175)

pBDG02

pJB67::xdrA

This study

a

The following abbreviations specify resistance cassettes to: Erm – erythromycin, , Tet –
tetracycline, Amp – ampicillin.
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Table 5: Primers used in this study.
Sequencea

Descriptionb

OL3788

TATTGCAATTTCTTGTGTCCGG

F xdrA confirmation

OL3789

GACTCCTTTGTGACAACATAGT

R xdrA confirmation

OL5171

ATGcccgggATGGATAGACAGAGTTTTACAGAT

F xdrA for pJB67

OL5172

ATGgaattcCTAGATATGTACTAATTCTTCTTTAG

R xdrA for pJB67

OL4093

GGCAGATAATGATGATCGC

F pJB67 screening

OL4094

CATGTCAACGATAATACAAAATATAATAC

R pJB67 screening

Primer

a

Restriction sites are underlined lowercase letters
b
F – forward, R – reverse
Complementing the xdrA mutation
The xdrA gene was PCR amplified using primers OL5171/OL5172, which begins
at the xdrA start codon and ends at its stop codon. The fragment was then ligated into
pJB67, which bears a CdCl2-inducible promoter and S. aureus ribosome binding site
(175), using XmaI and EcoRI sites. Following this, ligations were transformed into
chemically competent E. coli DH5α with clones confirmed using plasmid specific primers
(OL4093/OL4094), and subsequent validation for correct construction via Sanger
sequencing (Eurofins genomics) using the same plasmid specific primers. The newly
generated construct, pBDG02, was transformed into S. aureus RN4220 by
electroporation, before being transduced into the xdrA mutant, as described by us
previously (93), using Φ11. Strains were again confirmed by PCR using plasmid specific
primers. The pJB67 empty vector was also transduced into HOU wild-type and the xdrA
mutant to serve as controls.

Zymography and western blot analysis
Strains were grown in biological triplicate as described above, and samples were
taken at the desired time points. To assess proteolytic activity, zymograms were
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performed using concentrated supernatants as described by us previously (91). To
observe secreted protein abundance, western blot analysis was performed as described
by us previously (91). Immunoblotting was performed using rabbit polyclonal anti-Hla
(IBT), anti-HlgC (IBT), or anti-LukS (IBT) antibodies at a 1:10,000 dilution. The secondary
antibody used was a horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Cell
Signaling Technologies).

RNA sequencing and bioinformatic analysis
RNA isolation for RNA-seq experiments were performed as described previously
(176). Briefly, the S. aureus wild-type and xdrA mutant strains were grown in triplicate as
described above. Cells were harvested at 5h, added to an equal volume of ice-cold PBS,
and pelleted by centrifugation at 4°C. Total RNA was isolated using a RNeasy Kit
(Qiagen) and DNA was removed using a TURBO DNA-free kit (Invitrogen). Sample
quality was assessed using an Agilent 2100 Bioanalyzer system and RNA 6000 Nano kit
(Agilent); all had an RNA integrity of >9.8. Prior to mRNA enrichment, biological triplicates
were pooled at equal concentrations followed by rRNA removal using a Ribo-Zero Kit for
Gram Positive Bacteria (Illumina) and MICROBExpress Bacterial mRNA enrichment kit
(Invitrogen). Removal efficiency of rRNA was confirmed using an Agilent 2100
Bioanalyzer system and an RNA 6000 Nano kit (Agilent). Library preparation was
performed using the TruSeq Stranded mRNA Kit (Illumina) omitting mRNA enrichment
steps. Quality, concentration, and average fragment size of each sample was assessed
with an Agilent TapeStation and High Sensitivity DNA ScreenTape kit. Library
concentration for pooling of barcoded samples was assessed by qPCR with a KAPA
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Library Quantification kit (KAPA Biosystems), as recommended for high sensitivity.
Samples were run on an Illumina NextSeq with a corresponding 150-cycle NextSeq Mid
Output Kit v2.5. Upon completion, data was exported from BaseSpace (Illumina) in fastq
format and analyzed using CLC Genomics Workbench 11 (Qiagen Bioinformatics). Data
was aligned to the S. aureus reference genome (NC_007793), and experimental
comparisons were carried out after quantile normalization (177) using the CLC
Workbench expression browser.

Hemolysis assay
As described above, strains were grown in biological triplicate to stationary phase
(6h). Next, culture supernatants were obtained by centrifugation and mixed 1:1 with
hemolysin buffer (0.145M sodium chloride and 20mM calcium chloride). For each sample,
25 µl of pooled, whole human blood (BioIVT) was added and then incubated for 50 min
in a rotator at 37oC. Following this, samples were centrifuged at 5.5 x g for 1 min. Using
a Synergy 2 plate reader (Bio-Tek), the OD543 was measured to determine erythrocyte
lysis.

Oxidative stress assay
Strains were grown in biological triplicate as described above. Following
synchronization, cultures were standardized to an OD600 of 0.1. Next, cultures were
treated with 20mM hydrogen peroxide and incubated for 30 min at 37oC with shaking.
Following incubation, the reaction was stopped using 10 µg/ml of catalase. In order to
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quantify percent recovery, CFU/ml before and after treatment with hydrogen peroxide was
determined.

HL-60 Neutrophil infection assay
Human promyelocytic leukemia cells HL-60 (ATCC) were grown at 37oC with 5%
CO2, in RPMI-1640 media containing L-glutamine supplemented with 10% heat
inactivated FBS and penicillin/streptomycin antibiotics. Once the desired density was
reached, cells were differentiated by the addition of 1.25% DMSO and incubated for four
days. Differentiated cells were then seeded into 24-well non-treated cell culture plates at
a density of 2 x 106 per well, in RPMI 1640 supplemented with 10% FBS. Cells were then
infected with the respective strains at a multiplicity of infection (MOI) of 30 and incubated
for 1 h at 37oC with 5% CO2. Following incubation, cells were washed twice with warm
PBS and resuspended in RPMI 1440 supplemented with 10% FBS and 30µg/ml
gentamycin. Cells were returned to the 24 well plate and incubated for 24 h at 37oC with
5% CO2. To determine the number of surviving bacteria within neutrophils, cells were
washed twice with warm PBS and resuspended in 0.5% Triton X-100 for neutrophil lysis.
Lysates were serially diluted and plated for bacterial quantification.

Survival in whole human blood
Synchronized cultures of the wild-type, xdrA mutant, and xdrA complement strains
were grown to exponential phase, washed two times in PBS and standardized to an OD600
of 0.1 in 1 mL of pooled, whole human blood (BioIVT). Samples were taken following
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standardization, as well as after incubation at 37oC on a rotator for 4 h. Before and after
incubation, samples were serially diluted and plated to determine percent recovery.

Murine model of abscess formation
A murine model of subcutaneous abscess formation was performed as described
previously (178). The wild-type and xdrA mutant strains were grown for 2.5h in TSB until
an OD600 of approximately 0.75 was reached. To prepare an inocula of 1 x 107 CFU/50µl,
bacterial cells were pelleted using centrifugation and then resuspended in sterile PBS.
The inocula was confirmed by serial dilution, plating and enumeration. For infection, sixweek-old BALB/c female mice had their right flank shaved, before being treated with Nair,
to ensure complete hair removal. Subsequently, exposed flanks were injected with 50µl
of either the wild-type or xdrA mutant, and the mice were monitored for 7 days. Following
the infection period, mice were euthanized, and abscesses excised and weighed. To
determine the abscess area (in square millimeters), the length and width of the abscess
was measured. Lastly, to determine bacterial burden, abscesses were homogenized in
sterile PBS, and serially diluted and plated onto TSA.

Results

XdrA impacts protease production in S. aureus
During a recent study by our group analyzing the impact of transcriptional
regulators on extracellular protease production in S. aureus, we identified XdrA as a novel
and potent repressor of the aur and scp operons, and an activator of the spls (166). To
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further explore the impact of XdrA on protease activity, we first set out to confirm its role
in protease regulation via in trans complementation. Accordingly, we measured the
proteolytic capabilities of our strains using gelatin zymography with supernatants obtained
from 15h cultures. As we had previously reported, our xdrA mutant displayed a substantial
increase in proteolysis, that was returned to wild-type levels upon complementation
(Figure 9). As such, these results confirm that the XdrA is indeed a novel repressor of
extracellular protease activity.

Figure 9. XdrA represses the production of secreted proteases in S. aureus. To
visualize proteolytic activity, zymography was performed using 15h culture supernatants
harvested from the wild-type, xdrA mutant (xdrA-), and xdrA-complemented strain (xdrA+).
Prior to concentrating culture supernatants, strains were adjusted to equal optical density.
EV – empty vector.
Exploring the role of XdrA on the S. aureus transcriptome
Considering that the role of XdrA in S. aureus gene regulation is relatively
understudied, and to try and shed further light on how it controls secreted protease
production (and potentially other virulence factors), we next wanted to explore its
influence on the transcriptome using RNA sequencing. For this, RNA samples from the
wild-type and xdrA mutant were isolated after 5h of growth, which is a peak window for
protease expression (104), and processed as described above. To display the array of
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changes between the two transcriptomes, a genomic plot was constructed displaying a
heat map of fold changes in expression (Figure 10). Upon analysis, 444 genes in the
xdrA mutant were found to be changed in expression in comparison to the wild-type strain
using a ³3-fold cut off (Appendix B). Of these genes, 167 were upregulated whilst the
remaining 277 were downregulated (Figure 11A). In agreement with our previously
published study (166), an increase in transcription was observed for aur (+2.0), and scpA
(+2.5), in addition to decreases for the spl operon (splA,-3.2; splB, -3.0; splC, -3.8; splD,
-4; splE, -4.3; splF, -5.2). Interestingly, we also observed changes in sspA (+2.3) and
sspB (+2.1) expression that were in excess of our previous observations (166), where
only a modest increase in ssp transcription was observed upon xdrA inactivation.
Importantly, we also noted a 5.2-fold decrease in hla expression in comparison to the
wild-type strain, whilst hlgA (+3.2), hlgB (+5.1) and hlgC (+8.5) displayed increases in
transcript abundance. This indicates that the influence of XdrA is not limited to inhibiting
extracellular protease production, but also extends to other key virulence factors (beyond
that previously noted for Spa, which we confirm in our data set) (34).

Following the sorting of data into ontological groups (Figure 11B), we noted that
there were a number of other key virulence factors with altered expression in the xdrA
mutant. Of the 26 virulence factors identified, we found that, in addition to the toxins and
proteases previously noted, there were also factors involved immune evasion (isaB, -3.4;
ecb, +7; scinA +9), attachment (fnbpA, +4), and biofilm formation (atl, +3), that had
changes in transcription in the mutant strain. Another major group of genes changed in
expression were those involved in transcriptional regulation, where we identified 29 such
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factors as having altered transcript abundance in the mutant. In line with our previously
published study (166), we observed changes in transcript levels for the sae (saeP, +6.2;
saeQ, +3.5; saeR, +3.4; saeS, +3.2) and agr operons (agrA, -3.2; agrB, -3.4; agrC, -3.5;
agrD, -4.7) in the xdrA mutant strain. In addition, we identified 67 genes with differential
expression in the mutant involved in protein synthesis and degradation, including those
with roles in transcription, translation, and amino acid metabolism. We further found
alterations in transcription for genes involved in transport (67 genes), including those with
roles in sugar uptake, oligopeptide transport, and protein secretion. Lastly, genes involved
in DNA metabolism and repair (20 genes), and in nucleic acid biosynthesis (15 genes)
were found to have significantly different expression. Of note, within each of these groups,
the majority of genes were decreased in expression in the mutant strain. Collectively
these findings suggest that XdrA has a broad and substantial impact on S. aureus gene
expression, influencing not only virulence related processes, but also those involved in
nutrition, stress response and general cellular housekeeping.

XdrA influences the interaction of S. aureus with the human innate immune system
Given the changes in transcription for a variety of virulence factors in the xdrA
mutant, we next wanted to assess the important of XdrA for survival during engagement
with the human innate immune system. To do this, we measured the survival of our wildtype, xdrA mutant, and complemented strains, in the presence of whole human blood.
Upon analysis we found that, following incubation for 4h, 6.2% of the wild-type and 7.2%
of the complement were recovered (Figure 12A). In contrast, for the xdrA mutant, 9.5%
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of cells were recovered; resulting in a significant 1.5-fold increase in recovery in
comparison to the wild-type strain.
To further explore the increase in blood survival noted, we next determined the
requirement of a functional XdrA during phagocytosis by human neutrophils. To do this,
neutrophils were infected with our wild-type and xdrA mutant strain for 24 h, before
intracellular bacterial loads were quantified. Upon analysis we noted that the xdrA mutant
had significantly increased survival (5-fold) within neutrophils compared to the wild-type
(Figure 12B). Collectively, these findings confirm that, upon xdrA deletion, S. aureus is
presented a survival advantage during confrontation by components of the human innate
immune system. This is potentially mediated in part by the upregulation of a collection of
immune modulators, several of which have been identified as complement inhibitors,
including the secreted proteases (aureolysin (2-fold) (179); V8 (2.1-fold) (179);
Staphopain B (2.1-fold) (179); Staphopain A (2.5-fold) (179)), extracellular fibrinogen
binding protein, efb (3.8) (180), and staphylococcal complement inhibitor A, scinA (9-fold)
(181). In addition, factors that have been shown to interfere with phagocytosis were also
upregulated, including the IgG binding protein, sbi (3.5-fold) (182), and fibronectin binding
protein A (4-fold) (35, 183). As such, we suggest the upregulation of a multitude of factors
involved in immune evasion facilitate survival of the xdrA mutant when challenged with
components of the innate immune system.
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Figure 10. Assessing transcriptomic alterations in the xdrA mutant. RNAseq was
performed with RNA isolated at 5h from the wild-type and xdrA mutant strain. Genomic
map showing transcription profiles of the two strains. The middle circle depicts FPKM
values for the wild-type and the inner circle depicts FPKM values for the xdrA mutant. The
outer (spectrum) circle is a heat map showing fold changes in expression.

Figure 11. The disruption of xdrA has a global effect on the S. aureus
transcriptome. RNA sequencing was performed on replicate cultures of the wild-type
and xdrA mutant strains grown for 5h. (A) Number of genes changed in expression. (B)
Ontological grouping of genes changed in expression.
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Figure 12. xdrA inactivation increases survival during engagement with
components of the human innate immune system. (A) The wild-type, xdrA mutant
(xdrA-), and xdrA complemented strains (xdrA+) were inoculated into whole human blood
and incubated for 4h. Statistical significance was assessed using a one-way ANOVA and
Tukey’s multiple comparisons test (*, P < 0.05 **; P < 0.01; ns, not significant). Error bars
are shown ± SEM. EV – empty vector. (B) Human neutrophil-like cells (nHL-60) were
infected with the wild-type and xdrA mutant. Following infection for 24h, intracellular
bacterial loads were quantified. Statistical significance was determined using a Student’s
t test (**, P < 0.01). Error bars are shown ± SEM.
xdrA disruption leads to an increase in tolerance to oxidative stress
Given that tolerance to oxidative stress is important for survival following
phagocytosis (184), we next wanted to determine if the xdrA mutant had an altered
tolerance for this type of stress. To explore this, we exposed our wild-type, mutant and
complemented strains to 20mM hydrogen peroxide for 30 minutes. In order to quantify
percent survival, we determined the CFU/mL before and after treatment. Following
analysis, we found that, whilst our wild-type and complement stains demonstrated a
percent survival of 27%, we observed 42% percent survival for the xdrA mutant (Figure
13). As such, it appears that deletion of xdrA results in enhanced survival of S. aureus
during ROS stress, resulting in increased survival when challenged with components of
66

the innate immune system. This is potentially mediated by the upregulation of recA (10fold) leading to an enhanced DNA repair response, given that the expression of the typical
detoxification enzyme, katA, is not changed in the xdrA mutant.
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Figure 13. Ablated XdrA activity leads to an increase in tolerance to oxidative
stress. Percent recovery for the wild-type, xdrA mutant (xdrA-), and xdrA complemented
strains (xdrA+) was determined following exposure to 20mM hydrogen peroxide for 30min.
Statistical significance was assessed using a one-way ANOVA and Tukey’s multiple
comparisons test (**, P < 0.01; ns, not significant). Error bars are shown ± SEM. EV –
empty vector.
XdrA influences the abundance and activity of key cytolytic virulence factors in S.
aureus
The xdrA mutant is better able to survive in the presence of whole human blood,
likely aided by its increased tolerance to oxidative stress and increased expression of
factors contributing to immune evasion. As the lysis of erythrocytes could contribute to
nutritional survival during growth in blood, we next wanted to determine if hemolytic
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capacity of the xdrA mutant was altered; given it’s contrasting changes in cytolytic toxin
transcripts (hlgC, +8.5; hla, -5.2). To do this, we assessed the lysis of erythrocytes in
whole human blood following its incubation with supernatants obtained from our various
strains. Following analysis, we observed that the xdrA mutant had a significant decrease
(11-fold) in hemolytic activity in comparison to the wild-type, which was restored upon
complementation (Figure 14).
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Figure 14. XdrA is required for the full cytolytic capacity of S. aureus. Lysis of human
erythrocytes was measured from 6h culture supernatants of the wild-type, xdrA mutant
(xdrA-), and xdrA complemented strains (xdrA+). Samples were incubated with whole
human blood for 30 min. Statistical significance was assessed using a one-way ANOVA
and Tukey’s multiple comparisons test (**, P < 0.01; ns, not significant). Error bars are
shown ± SEM. EV – empty vector.
To confirm which cytolytic toxins were contributing to this decreased ability to lyse
erythrocytes, we determined toxin abundance using western blot analysis at 6h. We
began with alpha hemolysin (Hla), where we noted that, as our previous studies had
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suggested, a substantial decrease in the abundance of a-toxin was observed in the xdrA
mutant, which was restored to wild-type levels upon complementation in trans (Figure
15A). We next set out to determine the abundance of gamma hemolysin component C
(HlgC). Interestingly, upon analysis we found that as with Hla, in the absence of xdrA,
there was a decrease in HlgC protein levels, in comparison to the wild-type and
complemented strains (Figure 15B). This decrease in protein abundance conflicts,
however, with our transcriptome analysis, where enhanced expression from the hlg
operon was noted. To determine if there was variance for other key cytolytic factor, we
next probed for Panton-Valentine leukocidin (LukS) abundance, even though its
transcription was unaltered in the xdrA mutant. Here we found again that, for the xdrA
mutant, we observed a decrease in LukS protein levels, which was restored to wild-type
levels upon complementation (Figure 15C).

Collectively, these findings support the notion that XdrA regulates the production
and activity of multiple S. aureus virulence factors. Regarding the conflict observed
between transcript and protein abundance, this would seem to suggest XdrA influences
posttranscriptional control of LukS and HlgC. Importantly, this level of control over toxin
production has also been suggested in an rsp mutant for Hla, LukB, and HlgB (185).
Lastly, whilst the impairment in toxin production would reduce cytotoxicity, it might actually
explain increased survival of the xdrA mutant during engagement with components of the
innate immune system. The rationale for this is that previous work has shown impaired
cytotoxicity actually promotes intracellular survival, whilst maintaining blood survival and
effective dissemination during infection (185).
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Figure 15. XdrA enhances production of key cytolytic virulence factors in S. aureus.
To visualize the abundance of important secreted factors, western blots for alphahemolysin (Hla, A), gamma hemolysin component C (HlgC, B) and Panton-Valentine
leukocidin (PVL, C), were performed for the the wild-type, xdrA mutant (xdrA-), and xdrA
complemented strains (xdrA+). Supernatants were collected from 6h cultures that were
adjusted to equal optical density. EV – empty vector.
An xdrA mutant of S. aureus is more virulent in a murine model of skin abscess
formation
As we have already demonstrated the ability of xdrA mutants to survive better in
comparison to the wild-type during ex vivo models of infection, we next wanted to assess
whether these findings would be mirrored in vivo. To do this, we tested our strains using
a murine model of skin abscess formation. Following separate sub-cutaneous inoculation
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of either our wild-type or xdrA mutant strains, mice were monitored for the progression of
infection for seven days. Following this, abscesses were harvested and measured for size
and bacterial burden. With regards to abscess area, the xdrA mutant displayed a modest
1.3-fold increase in comparison to the wild-type strain (Figure 16A). When we considered
bacterial burden, however, there was a significant 3.2-fold increase in the number of xdrA
mutant cells recovered from abscesses, in comparison to the wild-type (Figure 16B).
These findings not only support our observed ex vivo phenotypes, but also demonstrate
that in a model of localized skin infection, the disruption of xdrA results in a hypervirulent
phenotype.

Figure 16. An xdrA mutant has enhanced virulence in a murine model of skin
abscess formation. Groups of 10, 6-week-old BALB/c mice, were injected
subcutaneously with 1 x 107 CFU of either the wild-type or xdrA mutant strain. Infections
were allowed to progress for 7 days before mice were euthanized for abscess excision.
Abscess area (mm2) (A) and CFU/g (B) were determined. Statistical significance was
assessed using a Student’s t test (*, P < 0.05). Error bars are shown ± SEM.
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Discussion

Virulence factor production in S. aureus is controlled by a complex network of
regulatory factors. A recent study by our group that focused on expanding upon this
network, led to the identification of a novel regulator of protease expression, XdrA (166).
Herein, we confirmed the role of XdrA in protease regulation, in addition to its previously
established role in regulating protein A production, and further show it to have a broad
and unique impact on gene expression and virulence in S. aureus.

One of the primary factors with altered expression was alpha hemolysin (hla),
which was found to be substantially decreased in the xdrA mutant. Of the transcriptional
regulators that have been attributed a role for influencing hla transcription, the agr operon
demonstrated a significant decrease in expression upon xdrA inactivation. Given that Agr
activates hla transcription (186), it would follow that this change could result in the
decrease in hla transcript levels and abundance observed. Further to this, an increase in
transcription of arlR, a known repressor of agr (145), was also observed in the mutant
strain, suggesting it could be the cause of decreased agr transcription. As no other
transcriptional regulator with altered expression in our study can account for the increase
in arlR expression observed, it is possible that XdrA directly influences transcription of the
two-component system. As such, we suggest that XdrA could be regulating hla
transcription through an ArlR-Agr mediated pathway (Figure 17).

Beyond hla, XdrA was found to repress the transcription of hlgC. It has been
reported previously that hlgC is activated by the Sae system (187). Indeed, a notable
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increase in expression was observed for this system, suggesting that it could be
responsible for the changes in hlgC transcript levels. Further to this, as Agr indirectly
represses sae via Rot (58), it is possible that the decrease in agr expression for the xdrA
mutant result in increased transcription of the sae system (Figure 17). While we did not
observe a change in rot transcription, the regulation of rot by Agr occurs posttranscriptionally (188); thus, such a change is not necessarily expected.

Interestingly, with regards to the abundance of HlgC, it was found to be decreased
when assessed via western blot analysis, rather than increased, as our RNAseq would
suggest. Similarly, with LukS, a decrease in protein abundance was observed, even
though no change in transcript levels were identified in the transcriptome analyses. We
initially hypothesized that this conflict between transcript and protein abundance could be
the result of some form of post-transcriptional regulation occurring in the xdrA mutant
strain. The most obvious form of such regulation could perhaps proceed via the action of
secreted proteases, given their role in modulating virulence factor abundance (136), and
their enhanced activity in the mutant strain. Our initial exploration of this postulation,
however, proved negative: when we assessed the abundance of HlgC and LukS in an
aur/xdrA double mutant (data not shown), the abundance of these proteins were not
altered in comparison to the xdrA mutant. It is possible that some of the other proteases
with enhanced expression in the mutant strain could be mediating this phenotype,
however, at least for V8 and Staphopain B, their substrate specificity is known to be quite
restricted (112, 113, 189); thus Staphopain A, and its wider proteolytic capacity (114),
may hold the answer.
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Support for this idea is presented by the study of an rsp mutant, where differences
between transcription and translation were also observed for the production of HlgB,
LukB, and Hla (185). With each toxin, transcript levels were increased while each was
found to have a decrease in protein abundance. Interestingly, similar to our study, an
increase in the secreted proteases, Aureolysin, V8, and Staphopain B, were also
observed in conjunction with the diminshed toxin abundance. As such, as we suggested
above, this conflict between transcript and protein abundance may indeed be the result
of increased production of secrete proteases.

With our virulence assays, we found that the xdrA mutant had increased survival
in whole human blood that likely results from a decrease in susceptibility to neutrophil
killing. This latter point likely results from an increase in expression of several immune
modulators within the mutant, including efb, sbi, and scinA (180-182). Further to this, we
show that the xdrA mutant has increased tolerance to oxidative stress, which results in
increased survival within neutrophils. However, as mentioned previously, the expression
of the detoxifying enzyme KatA, which converts H2O2 to O2 and H2O (190), was not found
to be changed in the RNA-seq analysis. An increase in sodM expression was observed,
which would support neutrophil survival, but would not explain the increase in tolerance
to hydrogen peroxide, given that SodM catalyzes the dismutation of superoxide anions
(O2-) to H2O and H2O2 (190). An alternate explanation could be the finding that DNA
damage repair proteins have been suggested as being central to counteracting the effects
of oxidative stress (191), and that recA transcription was strongly increased (10-fold) for
the mutant strain. This could thus lead to a more robust DNA repair response in the

74

mutant, resulting in increased survival. In addition to this, the sae system, which was
found to be increased in expression for the xdrA mutant, has been previously shown to
play an important role in neutrophil survival by decreasing neutrophil hydrogen peroxide
activity, independent of catalase and superoxide dismutase (192). Therefore, it appears
that XdrA governs a unique pathway for survival during combat with the innate immune
system that is perhaps mediated by SodM, RecA and/or Sae activity.

A more unusual factor contributing to survival of the xdrA mutant during immune
system engagement could be the observed decrease in cytolytic toxin abundance and
activity. It has previously been demonstrated that the decrease in toxin production
observed for an rsp mutant of S. aureus was found to promote intracellular survival within
host cells, and effective dissemination during infection (185). Indeed, naturally occurring
rsp mutations have been found in patients with chronic, long-term S. aureus nasal
colonization that resulted in decreased cytolysis, but aggressive systemic infection that
ultimately resulted in patient death (185). Such an idea is not entirely novel, as the
downregulation of agr and Agr-regulated toxins has been shown to facilitate bacterial
survival and persistence during chronic infections (193). While most studies focus on the
persistence of S. aureus within non-professional phagocytes, it has been shown that
survival of this organism within neutrophils also contributes to the progression and
severity of infection (194). Accordingly, we suggest that for the xdrA mutant, its decrease
in toxin abundance in combination with increased ROS tolerance collectively allows for
enhanced bacterial survival within host cells.
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Although S. aureus can cause a variety of diseases, ranging in severity, skin and
soft tissue infections are the most common community associated afflictions caused by
this organism (183). With our xdrA mutant, we noted an increase in bacterial burden within
skin abscess using a murine infection model, and that the abscesses produced were
significantly larger in size. Given the importance of neutrophils in the formation and
resolution of abscesses (183), the increase in survival of the xdrA mutant following
phagocytosis could lead to enhanced virulence with this type of model. In addition, several
factors involved in immune evasion that were found to be increased in expression in the
xdrA mutant, including fnbpA and ecb, could also support survival during infection.
Specifically, it has been shown for Ecb that its binding to C3 and fibrinogen leads to
decreased phagocytosis by human neutrophils (195). Additionally, FnbpA decreases
phagocytosis by professional phagocytes by promoting uptake by non-professional
phagocytes (35). Thus, the ability of the xdrA mutant to evade phagocytosis as well as
survive better within phagocytes, could result in an increased ability to cause infection in
vivo.

In summary, our study further characterizes the role of XdrA, finding that it has a
broad impact on S. aureus gene regulation and, more specifically, defines it as a key
regulator of virulence factor production. In addition, we find its impact on the expression
of genes involved in immune evasion, DNA damage, and oxidative stress resistance
(Figure 17), results in a survival advantage during infection when xdrA is disrupted. Our
findings further lend support to the idea that a decrease in cytolytic toxins can promote
bacterial survival, whilst still allowing for successful infection. Collectively, our findings
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shed new light on the role of XdrA and its seemingly novel influence on S. aureus survival
during infection.

Aur
SspA
SspB
ScpA

XdrA

RecA
SodM

Spl
ArlR

Hla

Agr

Rot

FnbpA

Sae

ScinA
Ecb
Efb
Sbi
HlgC

Figure 17. Predicted XdrA regulatory network. Shown are the predicted regulatory
pathways of XdrA. Arrows indicate activation, and bars indicate repression.
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Chapter 5: Final Discussion and Future Directions

Final Discussion

The success of Staphylococcus aureus results from the coordinated production of
its arsenal of virulence factors (26-28). Of note, 10 extracellular proteases are produced
alongside these virulence factors and have multifaceted roles in infection (103, 104). In
general, these proteases are thought to have a biphasic function in disease causation:
The first being through their cleavage of host proteins for immune evasion, host tissue
invasion, and for survival (121-123); whilst the second is mediated by the cleavage of
self-derived virulence determinants to influence disease progression and severity (136).
Given these complex regulatory roles, it follows that production of these enzymes is tightly
controlled by a collection of regulatory factors, which is evidenced by the number of
elements that have been identified as influencing protease production, including RNAIII,
SaeRS, ArlRS, CodY, MgrA, Rot, SarA, SarA, SarS, SarZ, SarX, and SarV (60, 138-149).

This dissertation focused on a continued investigation of these secreted proteases
given that much still remained unknown regarding their specific roles in virulence, and
how their production is controlled by regulatory factors. In chapter 2, we began by
following up on a previous study by our group that found that secreted proteases influence
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disease progression via the modulation of virulence factor stability (136). Given that our
initial study was performed using a complete protease-null strain, we aimed to
characterize the individual roles of these secreted proteases in modulating virulence
factor stability to temper infection severity. In chapter 3, we focused on determining how
the protease promoters are controlled by S. aureus transcriptional regulators. In the past,
these proteases were often thought of as a single entity, instead of 10 individual proteases
produced from four separate loci, and as such the effects of a majority of the primary
protease regulators had not been determined for each loci. With our investigation into
protease regulators, we identified a novel and profound repressor of protease expression,
XdrA, which led us to chapter 4, where we continued to characterize the importance of
this factor for S. aureus virulence.

Chapter 2
As noted above, S. aureus controls the progression of infection through the
coordinated production of extracellular proteases (26-28). This is evidenced by our
previous finding that a protease-null strain has a substantially increased infectious
capacity in a murine model of sepsis; resulting from the unchecked accumulation of
virulence factors (136). To characterize the individual contributions of these secreted
protases, we constructed and assessed of a combinatorial protease mutant library. We
revealed that the enhanced killing observed for the complete protease-null strain during
sepsis appears to be driven by the absence of only Aureolysin and Staphopain A. This
finding suggested that these proteases are modulating the stability of factors with
profound impacts on disease causation. Of note, previous studies have shown that
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Aureolysin can specifically cleave alpha hemolysin (Hla) (128) and the phenol-soluble
modulins (PSMs) (127), whereas Staphopain A has been shown to control the abundance
of biofilm components (130).

To narrow in on those virulence factors modulated by Aureolysin and Staphopain
A, and thus potentially proving causative for this phenotype, we used a proteomics
approach where we identified a number of secreted factors increased in abundance
across both the aur/scpA and protease-null mutant, but not in the parent, including LukA,
Ecb, and PSMa4. Finding that PSMa4 was increased in these strains suggests that its
cleavage or lack thereof by Aureolysin could influence disease progression. In addition to
PSMa4, as LukA and Ecb have demonstrated roles in virulence, an increase in the
abundance of these factors could contribute the more severe infections observed herein.

Lastly, we began to assess the importance of the virulence factors identified as
being increased in abundance in the aur/scpA and protease-null mutant. With LukA, when
assessing the virulence of an aur/scpA/lukA mutant, the progression of infection was
substantially delayed, however hypervirulence was ultimately still observed; suggesting
the hypervirulent phenotype is engendered by multiple secreted factors. Given that the
success of S. aureus as a pathogen is the result of coordinated production of a variety of
virulence factors, the involvement of multiple factors in the production of the
hypervirulence phenotype is not entirely surprising.
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With this study we solidified the importance of secreted proteases for S. aureus
virulence and more specifically, demonstrated the significant importance of Aureolysin
and Staphopain A. These findings support the role of the secreted proteases as mediators
of virulence factor abundance and further shows that these factors do contribute to
disease progression, albeit in a combined manner.

Chapter 3
As we established in chapter 2, secreted proteases are able to control disease
progression by selectively modulating virulence factor stability. Therefore, it follows that
there would be a complex regulatory network to tightly control protease abundance, to
promote the accumulation, or degradation, of specific virulence factors. The complexity
of protease regulation is emphasized by the number of factors that have been found to
influence protease expression. Of the identified protease regulators, seven have been
found to be major effectors of protease expression, including MgrA, Rot, SarA, SarR,
SarS, SaeR, and CodY, given that they directly bind to and influence the transcription
from specific protease promoters (60, 138-143). However, as noted above, the effects of
these factors on each of the four protease promoters had not been established, given that
they were often thought of as a single entity.

With this study we characterized the loci specific effects of each of the major
regulators using qRT-PCR. In doing so we were able to confirm 14 established regulatory
pathways, as well as identify eight new circuits for controlling protease expression. Of the
new pathways, the majority involved the regulation of Staphopain A and the Spls. With
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regards to scpA, we found that it was regulated by SarS, CodY, SaeR, and SarR, in
addition to the established regulators, Rot and SarA. Most of the primary regulators were
shown to have moderate effects on scpA transcription, apart from SarA and SarR. Both
of these elements were shown to strongly influence scpA transcription, with SarA
repressing and SarR activating transcription. We suggest having two opposing regulators
influencing expression would allow for tight control of scpA transcription, which could be
beneficial for rapid adaptation to different niches. For example, either SarR could promote
the production of ScpA or SarA could represses the production of ScpA, to influence the
abundance of either host of self-derived proteins. Given the broad enzymatic specificity
of ScpA (114), tight control over its production is obviously required. With regards to spl
expression, we found that they are subject to profound upregulation by MgrA, SarR, and
SaeR. As the substrate specify of these enzymes is narrow (118-120), similar to that of
the exfoliative toxins (40), we suggest that the expression of these proteases would only
need to be upregulated when encountering an environment in which they were required
to influence infection.

When exploring the expression of aur, we found that in contrast to spl regulation,
the majority of regulation that aur undergoes is repression, with SarA and CodY having
the most profound influence. As Aureolysin sits atop the protease activation cascade
(110, 121, 196, 197), this repression would keep the production of the majority of the
proteases inhibited until required, just by controlling the production of Aureolysin.
Considering that Aureolysin has a broad substrate specificity (107), and controls the
production of the most of the other proteases, it is logical that the expression of aur would
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be heavily repressed. Lastly, while no new regulation was identified for ssp, we found that
its regulation is very similar to that aur. Given that ssp is also a part of the protease
activation cascade, this similarity in regulation is not entirely a surprise.

As these proteases are tightly controlled by a collection of regulatory factors, we
set out to uncover additional factors influencing protease transcription, in order to
generate a more compressive protease regulation map. To do this, over 100 regulator
mutants from the NTML were screened using zymography to observe changes in
proteolytic activity. In addition to observing the expected changes with the major protease
regulators, we found 45 mutants in the screen with changes in protease activity. The most
intriguing of the novel protease regulators were chosen for additional studies, where
changes in protease transcription was validated using qRT-PCR. In doing so, we
confirmed SarU, Rbf, ArgR2, MntR, Rex, AtlR to be activators of protease transcription,
whereas XdrA is a strong repressor of protease expression. To determine how these new
effectors were influencing protease transcription, we looked for changes in transcript
levels for the major protease regulators, with each of the novel regulator mutants. From
this data we found that, apart from ArgR2, these novel regulators appeared to be
controlling protease transcription by influencing the expression of the major protease
regulators.

By incorporating the data from this study with what is currently known about
protease regulation, we were able to generate a comprehensive map of protease
regulation. This map made it possible to visualize the complex interactions between these
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regulators which allowed for the identification of more specific regulatory pathways
between the novel and major protease regulators. When considering the complexity of
this map, we suggest it highlights the importance of secreted proteases, given that their
level of regulation rivals that of some of the most important S. aureus virulence factors.
We further believe that this type of network would support the intricate regulation required
for proteases to selectively titrate toxin abundance and to facilitate the niche specific
behaviors of S. aureus.

Chapter 4
The next step in understanding the regulatory networks identified in chapter 3, was
to begin characterizing the novel elements identified. Of those uncovered in the previous
chapter (166), we focused our additional studies on XdrA, given its strong impact on
protease expression, and its previous established role in regulating protein A (spa). After
confirming that XdrA is indeed a potent repressor of protease expression, we moved
forward in characterizing the role of xdrA in influencing S. aureus gene expression by
using an unbiased global analysis. With this data we found that over 400 genes were
altered in expression, and following their sorting into ontological groups, we concluded
that XdrA had a global impact on gene expression.

Of the genes that were altered in expression for the xdrA mutant, we were most
interested in those with roles in virulence and gene regulation. With the identified genes
changes we were able to predict that XdrA activates hla transcription through an ArlRAgr mediated pathway (145, 186). In addition, we found that XdrA could be repressing
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the transcription of hlgC, through an Agr-Rot-Sae mediated pathway (58, 187). When
investigating these changes in lytic toxins, we found that in addition to observing a
decrease in the abundance of Hla, there was also a decrease in the abundance of HlgC,
regardless of hlgC transcript levels being increased. We found that this conflict between
transcript and protein abundance was not just specific to HlgC, as we also observed a
decrease in protein abundance for LukS even though transcript levels were found to be
unchanged in the xdrA mutant. Regarding the conflict observed between transcript and
protein abundance, this would seem to suggest XdrA influences posttranscriptional
control of LukS and HlgC. Importantly, this level of control over toxin production has also
been suggested in an rsp mutant for Hla, LukB, and HlgB (185, 198). We believe that the
decreases in HlgC and LukS could be a result of the increased expression of secreted
proteases, given their established role in modulating virulence factor stability (136). While
we currently know that it does not appear to be a result of an increase in Aureolysin, we
still need to investigate, Staphopain A, Staphopain B, and V8 in this regard.

Given the array of genes changed in the xdrA mutant, we sought to explore the
importance of XdrA in virulence. We found that the xdrA mutant had an increased ability
to survive in whole human blood, mediated in part by increased survival within
neutrophils, and an upregulation in expression of several factors involved in immune
evasion, including sbi, fnbpA and efb (35, 180, 182, 183). Furthermore, the increased
survival within neutrophils appears to result from an upregulation of sodM, recA, and sae,
all of which assist bacterial cells in combating the effects of oxidative stress (190-192).
We suggest that in addition to the already noted survival advantages, the xdrA mutant
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could also be benefitting from decreased cytolytic toxin abundance when challenged with
components of the innate immune system, given that previous work has shown impaired
cytotoxicity actually promotes intracellular survival, whilst maintaining blood survival and
effective dissemination during infection (185). When assessing the importance of xdrA in
vivo using a murine model of sepsis, we observed that as with our other virulence assays,
the xdrA mutant exhibited enhanced survival and virulence. Given the importance of
neutrophils in the formation and resolution of abscesses (183), the increase in survival of
the xdrA mutant following phagocytosis could lead to enhanced virulence in this type of
model. In addition, several factors involved in immune evasion were found to be increased
in expression in the xdrA mutant, including fnbpA and ecb, which could also support
survival during infection (35, 195). Thus, the ability of the xdrA mutant to evade
phagocytosis as well as survive better within phagocytes, could result in an increased
ability to cause infection in vivo.

In sum, we were able to further characterize the role of XdrA, finding that it has a
broad impact on S. aureus gene regulation, and, more specifically, defining it as a key
regulator of virulence factor production. In addition, we find its impact on the expression
of genes involved in immune evasion, DNA damage, and oxidative stress resistance,
results in a survival advantage during infection when xdrA is disrupted.
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Future Directions

Chapter 2
To solidify that the minimum requirement for the hypervirulent phenotype of the
protease-null mutant is the loss of Aureolysin and Staphopain A, we have to complete our
screening of the combinatorial protease mutant collection. The remaining strains to be
screened are sspA/sspB/scpA/spl, sspA/sspB/scpA, and sspB/scpA/spl. We expect that
as with our other quadruple mutants, sspA/sspB/scpA/spl will display hypervirulence.
Further, with sspA/sspB/scpA and sspB/scpA/spl, we expect that they will display
virulence similar to that of the wild-type strain, as neither mutant contains mutations for
both aureolysin and staphopain A.

LukA was found to be increased in abundance for both the aur/scpA and proteasenull mutant. Further, in the context of the hypervirulent phenotype, we were able to show
that LukA does appear to contribute to this phenotype, given that disruption of lukA in the
aur/scpA mutant slowed disease progression in comparison to the aur/scpA mutant. To
further solidify that LukA is aiding the hypervirulence, we need to confirm its increase in
the aur/scpA and protease-null mutant. To do this, we will immunoblot for LukA in our
wild-type, aur/scpA, and protease-null mutant.
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Given that we observed the most substantial increase in abundance for the
chitinase-related protein in both the aur/scpA and protease-null mutant, and that we
believe it could be contributing to the hypervirulence of our strains, we need to
characterize its role in this phenotype. However, as already mentioned there is not a
transposon mutant available in the NTML. Therefore, to move forward in characterizing
this protein, we must generate a kanamycin marked mutant using pJB38, as described
by Bose et al. (154). Following this, as was done with lukA, the mutation will be transduced
into the aur/scpA and the resulting triple mutant will be screened using our murine model
of sepsis, alongside our wild-type, protease-null mutant, and aur/scpA mutant.

As it appears that the hypervirulent phenotype is the result of an increase in
multiple virulence factors, we will continue to assess the importance of other factors found
to exhibit increased stability in the aur/scpA and protease-null mutant. If we observe that
in the absence of other factors, the severity of the hypervirulence phenotype is delayed
as with the LukA, we will generate aur/scpA mutants with multiple virulence factor
mutations. These strains will be screened as all others, with the expectation that in the
absence of multiple virulence factors, the hypervirulent phenotype of the aur/scpA mutant
will revert back to that of the wild-type.

For factors found to be increased in abundance in the aur/scpA and protease-null
mutant, the next step is to confirm that they are being proteolytically cleaved by either
Aureolysin or Staphopain A. To do this we would need to purify Aureolysin and
Staphopain A and separately treat supernatants obtained from the aur/scpA with either
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purified enzyme. Supernatants will then be analyzed for changes in our proteins of
interest using mass spectrometry (as detailed in chapter 2).

Chapter 3
In completely characterizing the effects of the major regulators on secreted
protease production, we identified eight new nodes of expression. However, whether this
regulation is occurring through interaction of the major regulators with other transcription
factors, or through direct binding of protease promoters, has not been established. To
complete the characterization of these regulators on protease expression, this needs to
be determined. To do this, the major regulators need to be purified so that EMSAs can
be performed. If it is found that protease regulation is not occurring via direct binding of
promoters, their action on other regulators will be explored using epistasis experiments.
With regards to the novel regulators, their protease specific effects need to be explored
further as detailed with the major regulators.

The complex network of secreted protease regulation is believed to facilitate niche
specific pathogenic behavior, through their ability to selectively influence the abundance
of individual virulence factors. Given that different S. aureus clonal complexes are
typically more prone to specific disease outcomes, to understand how secreted proteases
influence this, we need to understand their regulation in these different strains. To do this,
mutations for the major regulators should be transduced into different clonal complexes
and then the transcript abundance for the secreted proteases should be assessed using
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qRT-PCR. A network for protease regulation can then be constructed and compared
across strains looking for trends in how the proteases are regulated.

Chapter 4
In the xdrA mutant, we observed a decrease in hla expression, likely as a result of
a decrease in agr transcription. Further, the decrease in agr expression is likely a result
of an increase in the expression of arlR, a transcriptional repressor of agr. In order to
understand how XdrA is influencing the expression of hla, it needs to be determined if it
is occurring via an ArlR-Agr mediated route. To do this, we could quantify agr transcript
abundance in an xdrA/arlR mutant. If there is an increase in agr transcripts, it is possible
the predict route is correct, which could then be further investigated.

In addition to the decrease in Hla abundance, we also observed decreases for
LukS and HlgC. These decreases in protein abundance, however, did not correlate with
their observed transcript abundance. We suggested that this disconnect could be the
result of the increase in secreted proteases in the xdrA mutant, as the proteases have an
established role in modulating toxin stability. We have already investigated aureolysin as
being the protease responsible for toxin decrease, however toxin abundance was not
altered when disrupting aur in the xdrA mutant. Therefore, our next step is to generate
additional xdrA mutants with the remaining proteases disrupted. With these strains we
will again immunoblot for HlgC and LukS.
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As the production of virulence factors in typically influenced by environmental cues,
we wanted to determine if xdrA expression is influenced by external stressors. Using an
xdrA-lacZ transcriptional fusion, we found that xdrA transcription was increased when the
cells were subjected to oxidative stress by hydrogen peroxide. As this was observed using
a plate-based assay, we need to specifically quantify the change in transcription either
using Beta-galactosidase assays or qRT-PCR. Confirming that xdrA transcription is
influenced by oxidative stress would further strengthen the role of XdrA in influencing
survival within host cells.

We suggest that the decrease in cytolytic toxin abundance in the xdrA mutant could
promote survival within host cells, which in combination with the other survival
advantages of the xdrA mutant, results in enhanced virulence during infection. Given that
enhanced intracellular survival can result in effective dissemination, we want to determine
if the xdrA mutant has enhanced pathogenesis with a murine model of sepsis.

To confirm that the xdrA mutant promotes survival within host cells by decreasing
cytolytic toxin production, we should confirm that there is a decrease in cytotoxicity with
professional and non-professional phagocytes. As such we would infect both cells types
with either the wild-type or xdrA mutant, and measure death of the phagocytes. Lastly, to
confirm that there is an increase in survival of the xdrA mutant within host cells and not
an increase in internalization, we need to measure the uptake of our wild-type and xdrA
mutant.
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ABSTRACT A primary function of the extracellular proteases of Staphylococcus aureus is to control the progression of infection by selectively modulating the stability
of virulence factors. Consequently, a regulatory network exists to titrate protease
abundance/activity to influence the accumulation, or lack thereof, of individual virulence factors. Herein, we comprehensively map this system, exploring the regulation
of the four protease loci by known and novel factors. In so doing, we determined
that seven major elements (SarS, SarR, Rot, MgrA, CodY, SaeR, and SarA) form the
primary network of control, with the latter three being the most powerful. We note
that expression of aureolysin is largely repressed by these factors, while the spl operon
is subject to the strongest upregulation of any protease loci, particularly by SarR and
SaeR. Furthermore, when exploring scpA expression, we find it to be profoundly influenced in opposing fashions by SarA (repressor) and SarR (activator). We also present the screening of !100 regulator mutants of S. aureus, identifying 7 additional
factors (ArgR2, AtlR, MntR, Rex, XdrA, Rbf, and SarU) that form a secondary circuit of
protease control. Primarily, these elements serve as activators, although we reveal
XdrA as a new repressor of protease expression. With the exception or ArgR2, each
of the new effectors appears to work through the primary network of regulation to
influence protease production. Collectively, we present a comprehensive regulatory
circuit that emphasizes the complexity of protease regulation and suggest that its
existence speaks to the importance of these enzymes to S. aureus physiology and
pathogenic potential.
IMPORTANCE The complex regulatory role of the proteases necessitates very tight

coordination and control of their expression. While this process has been well studied, a major oversight has been the consideration of proteases as a single entity
rather than as 10 enzymes produced from four different promoters. As such, in this
study, we comprehensively characterized the regulation of each protease promoter,
discovering vast differences in the way each protease operon is controlled. Additionally, we broaden the picture of protease regulation using a global screen to identify
novel loci controlling protease activity, uncovering a cadre of new effectors of protease expression. The impact of these elements on the activity of proteases and known
regulators was characterized by producing a comprehensive regulatory circuit that
emphasizes the complexity of protease regulation in Staphylococcus aureus.
KEYWORDS Staphylococcus aureus, gene regulation, proteases, transcriptional
regulation, virulence factors

S

taphylococcus aureus is an opportunistic human pathogen known for causing both
hospital- and community-acquired infections. It is capable of causing a plethora of
diseases that range from minor skin and soft tissue infections, such as boils and
carbuncles, to septicemia, endocarditis, osteomyelitis, and toxic shock syndrome (1–3).
This broad disease potential can be attributed to the coordinated production of a
wealth of virulence factors by S. aureus within the human host. Collectively, these
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FIG 1 Genetic organization of the S. aureus secreted protease loci. The colors of arrows are representative of catalytic activity classification: metalloprotease in pink; serine proteases in green; cysteine
proteases in purple; and the inhibitors of the staphopains (the staphostatins) in blue.

elements allow the pathogen to evade phagocytosis, promote abscess formation, travel
from initial sites of infection to invade new tissues, and induce a variety of syndromes
(4). These virulence-causing entities can be divided into two broad groups: adherence
factors and exoproteins. Adherence factors are responsible for the attachment of S.
aureus to host tissues so that colonization may occur (5) and can also interfere with the
host immune system to facilitate immune evasion (6). Conversely, exoproteins are
secreted by S. aureus and function to acquire nutrients by breaking down host tissues and,
more importantly, target the immune system, engendering immune subversion (7).
Parts of this cadre of secreted factors are 10 extracellular proteases, which are
produced by almost every S. aureus strain (Fig. 1) (8, 9). These include the following: a
metalloprotease, aureolysin (aur); a serine protease, V8 (sspA); two cysteine proteases,
staphopain B (sspB) and staphopain A (scpA); and six serine protease-like enzymes
(splABCDEF) (9, 10). The functions of these enzymes have been studied by ourselves and
others and include their ability to hydrolyze a variety of host proteins as well as
self-derived toxins. With regard to host factors, the secreted proteases have been
demonstrated to proteolyze proteins such as fibrinogen, elastin, and the heavy chains
of immunoglobulins to promote tissue invasion, immune system evasion, and the
dissemination of infection (11–13). In the context of the self-degradome, these enzymes
can cleave multiple virulence determinants to promote bacterial invasion, immune
evasion, and survival. For example, aureolysin was shown to control the stability of both
phenol-soluble modulins and alpha-toxin (14, 15) as well as the adhesin clumping factor B
(ClfB) (16), while SspA is able to cleave surface protein A (SpA) and the fibrinogen-binding
proteins (FnBPs) (17, 18).
Recently, our group assessed the importance of secreted proteases in S. aureus
pathogenesis using a strain where all 10 enzymes were deleted (19). Here, we demonstrated that secreted proteases are required for growth in whole human blood,
serum, peptide-rich medium, and in the presence of antimicrobial peptides. Additionally, these enzymes are also necessary for S. aureus to resist phagocytosis by human
granulocytes and monocytes. Most striking, however, were the in vivo phenotypes of
this mutant, where a decrease in dissemination and abscess formation were observed
in infected mice compared to in the wild type. Conversely, when assessing mortality,
the complete protease-null strain demonstrated pronounced hypervirulence. These
contrasting phenotypes were explained using proteomics, where an increase in the
stability of secreted and surface-associated virulence factors was demonstrated en
masse in the mutant, thus facilitating more aggressive and deadly infections.
Importantly, many of these findings were also demonstrated in a companion study
by Zielinska et al. (20). As such, it would appear that secreted proteases have a biphasic
role in infection, serving on the one hand to modulate the stability of self-derived
pathogenic determinants, so as to control disease severity and progression, while at the
same time playing their own direct role by cleaving host proteins to promote invasion,
immune evasion, and survival.
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Given the complex regulatory role of S. aureus proteases during infection, it follows
that there must be, and indeed is, tight control of their expression mediated by a
collection of different factors. This is evidenced by the number of elements that have
been identified thus far as influencing protease production, including RNAIII SarS, SarR,
SarA, SarV, SarX, SarZ, ArlRS, CodY, Rot, MgrA, and SaeRS (21–33). Of these factors, SarS,
SarR, CodY, Rot, MgrA, SaeR, and SarA are considered the primary regulators, with each
being shown to directly influence protease transcription (21–27). A major oversight
when studying the control of protease production in S. aureus, however, has been the
consideration of these factors as a single entity rather than as 10 enzymes produced
from four different promoters. Of the seven major regulators, only SarA and Rot have
been explored in the context of all four protease promoters (9, 10), with SarA shown to
specifically repress the transcription of aur, scpA, and ssp but not spl (9, 10), while Rot
has been described as a direct negative regulator of all secreted protease operons (23).
For the other primary regulators, CodY has been shown to directly repress ssp transcription (22), while SarS and SarR have been explored only in the context of aur and
ssp promoter binding (21). Finally, MgrA has been shown to activate aur, ssp, and spl
transcription (25, 34), while SaeR has been described as an activator for spl but a
repressor for aur (24).
Consequently, the overarching goal of this study was to explore and further our
understanding of the regulation of secreted proteases by known regulatory factors in
S. aureus while concurrently uncovering new effectors of protease transcription. Accordingly, we present a comprehensive mapping of protease regulation by all known
S. aureus transcription factors in community-acquired methicillin-resistant S. aureus
(CA-MRSA) strain USA300.
RESULTS AND DISCUSSION
Exploring the differential regulation of protease expression by primary regulators. To date, seven different transcriptional regulators (Rot, CodY, SarA, SarS, MgrA,
SarR, and SaeR) (21–27) have been identified as being the primary modulators of
secreted protease expression. An oversight, however, is the consideration of S. aureus
proteases as a single entity rather than as 10 enzymes produced from four distinct loci
(Fig. 1). Thus, although these elements do indeed have the capacity to regulate the
expression of one or more proteases, only a few have been explored in the context of
all four operons. Therefore, our initial goal was to fill in missing gaps using quantitative
real-time PCR (qRT-PCR). To assess this, wild-type and regulator mutant strains were
grown to postexponential phase (5 h), which is a known window of peak protease
expression (9), and assessed for the expression of each protease operon.
We began with the best-studied regulator, SarA, whose ability to repress the
transcription of aur, scpA, and ssp but not spl has been well established (9, 10). Here, our
analysis provided the expected results: in the absence of SarA, there was a 275-fold
increase in aur, 10.9-fold increase in sspA, and a 23.7-fold increase in scpA transcript
levels, with no changes in spl expression (Fig. 2A).
Next, we investigated CodY, whose ability to influence protease expression was
identified by microarray analysis in UAMS-1 (22). There, Majerczyk et al. (22) found that
in the absence of CodY, sspA had increased transcript levels. Additionally, in the same
study, CodY was shown to bind the spl, sspA, and aur promoters; however, the binding
to aur and spl was deemed biologically irrelevant, as changes in their expression were
not observed upon codY deletion. As such, the ability of CodY to modulate expression
of aur, scpA, and spl has not been previously described. Herein, in the absence of CodY,
we observed a significant 324-fold increase in aur, 12.8-fold increase in sspA, 3.3-fold
increase in scpA, and 6.2-fold increase in spl transcript levels (Fig. 2B). Collectively, these
data suggest that CodY is a negative regulator of secreted protease expression that
rivals SarA in its potency.
We next considered Rot, which was first shown to negatively regulate sspA and spl
transcription in a RN6390 microarray (35). In another study assessing aur and sspA
regulation in strain 8325-4, Rot functioned as a direct repressor of both loci (25). In
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support of these studies, others have demonstrated that Rot represses aur and sspA
while also directly repressing spl through promoter binding in strain LAC (23). Additionally, in the same study, Rot was shown for the first time to directly repress scpA
transcription. In our study, upon rot inactivation, there were significant increases of
6.2-fold for aur and 4.5-fold for sspA transcript levels, which is in line with previous
research (23). Additionally, a significant 2.1-fold decrease in scpA expression along with
no change for spl was observed, contradicting previous studies, where increased
transcription for both was observed upon rot deletion (Fig. 2C). We note, however, that
previous studies regarding Rot regulation differ from ours through the use of medium
supplemented with different nutrients. Specifically, in work by Mootz et al. (23), growth
medium was supplemented with glucose, which has been documented as repressing
the agr quorum sensing system via the decreased pH produced from carbon metabolism (23, 36, 37). As such, this decrease in agr activity could alter the expression of
downstream factors also capable of regulating the secreted proteases. Similarly, SaidSalim et al. (35) used Casamino Acids-yeast extract-glycerol phosphate broth for their
September/October 2019 Volume 4 Issue 5 e00676-19

msphere.asm.org 4

111

Downloaded from http://msphere.asm.org/ on October 23, 2019 at Univ of South Florida

FIG 2 Individual protease loci are differentially controlled by major regulators of S. aureus. qRT-PCR was used to determine transcript levels for aur, scp, ssp,
and spl in regulator mutants after 5 h of growth. The strains used were wild type (WT) USA300 Houston (HOU) and mutants for sarA (A), codY (B), rot (C), sarS
(D), saeR (E), mgrA (F), and sarR (G). RNA was isolated from three independent cultures. The 16S rRNA gene was used as an internal control. Fold change from
WT was determined using the 2!∆∆CT method. Student’s t tests were used to determine statistical significance. *, P " 0.05; **, P " 0.01; ***, P " 0.001; ****,
P " 0.0001 relative to the wild-type strain. Error bars show the standard deviations (SDs).
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studies. Here, the addition of glycerol, as well as the use of an entirely different complex
medium, altered the activity of other transcriptional regulators such as CodY, CcpE,
CcpA, and RpiRC, which are known to sense the carbon status of the cell (38). Therefore,
while Rot has the potential to regulate all four protease loci, our data suggest that Rot
primarily controls expression of aur and sspAB, likely in an agr-dependent manner.
SarS was formerly shown to have no significant effect on aur and ssp transcription
during investigation in strain 8325-4 (27). Oscarsson et al., however, established that
when sarS is overexpressed in 8325-4, aur and sspA transcription is suppressed (25). In
support of a role in sspA regulation, another study showed that SarS could bind the
sspA promoter (27). To date, the effects of SarS on scpA and spl transcription have not
yet been investigated. Our analysis of protease transcription in the absence of SarS
revealed significant increases for aur (6.9-fold), sspA (2.9-fold), and spl (1.6-fold) but a
1.7-fold decrease in scpA transcript levels (Fig. 2D). These data thus support a role for
SarS as a repressor of aur and sspA expression and identify the spl operon as a new
target of negative regulation by this factor. Conversely, we reveal scpA as a being
activated by SarS, demonstrating, as with our data for Rot, that each of the four proteases
are often subject to differential and opposing regulation by the same element.
The ability of SaeR to influence protease expression was previously described by
microarray analysis, where, in the absence of SaeR/S in strain LAC, there was a decrease
in spl transcription (24). Furthermore, in that same study, it was observed that this effect
was direct, as SaeR was shown to bind to the spl promoter. Additionally, in the same
background, Cassat et al. showed a decrease in SplA-F protein levels following sae
inactivation (39). In support of this, we observed a striking 671-fold decrease in spl
transcript levels upon saeR deletion, which is the most pronounced alteration in
expression for any protease observed in this study (Fig. 2E). With regard to aur, the
previously referenced studies revealed an increase in aur transcription (24) as well as an
increase in Aur protein levels (39) in the absence of saeRS. In our study, however, no
change in transcription was observed, which is in line with Oscarsson et al., who derived
similar findings in strain RN6390 (25). Of note, the changes observed during microarray
and proteomic analyses were during stationary phase rather than postexponential
phase. Therefore, the disagreement regarding aur regulation could be a product of
different time points used for assessment. This is supported by our observation that,
when analyzed throughout growth, SaeRS is the only major regulator in S. aureus to
demonstrate a rebound in transcriptional activity during stationary phase (our unpublished observation). This suggests that SaeRS may have various or biphasic functions
with regard to virulence factor regulation during S. aureus growth. Regarding scpA, the
effect of SaeR on transcription has not until now been investigated. Herein, we
observed a 2.5-fold decrease in scpA transcription in the absence of SaeR, indicating
that, similarly to the spls, it is activated by this factor. Lastly, no change in sspA
transcription was observed, which, while in line with Oscarsson et al. (25), contradicts
Cassat et al. (39), who observed an increase in SspA and SspB protein levels during
stationary phase. As previously suggested, this conflict is likely explained by the varying
impact of SaeRS during different growth phases. As such, our data support a role for
SaeR during postexponential growth in the activation of spl and identify scpA as a new
target for SaeR upregulation.
We next investigated MgrA, which was previously shown to activate aur and sspA
transcription in 8325-4 (25). Using RNA sequencing in LAC, others have shown that the
absence of MgrA decreased aur and spl transcript levels (34). Herein, in agreement with
previous studies, we observed a significant 7.6-fold decrease in aur, 3.2-fold decrease in
sspA, and 26.7-fold decrease in spl transcript levels (Fig. 2F). Lastly, until now, the effect
of MgrA on scpA had not been investigated. In our study, no changes in scpA transcript
levels were identified, which again demonstrates differential regulation of the various
protease loci. This is particularly interesting, as it is an additional example of the two
staphopain enzymes (SspB and ScpA), which share strong homology (40–42) although
quite different substrate specificities (42), as being regulated in opposing fashions.
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FIG 3 Primary network of control for individual protease loci. Shown are transcriptional regulation
events for the seven primary protease regulators of S. aureus on the four individual protease loci. Bars
indicate repression, and arrows represent activation. New regulatory pathways identified herein between
the primary regulators and the protease loci are shown in green.

Finally, we investigated SarR, which was formerly shown to positively affect aur and
sspA transcript levels in 8325-4 (21). In contrast, in another study, it was shown to
negatively affect aur when overexpressed in an 8325-4 agr sarA double mutant (25).
Interestingly, however, in our study, no change in aur transcript levels was detected in
the absence of sarR. When considering ssp expression, we observed a significant
1.6-fold decrease in transcript levels (Fig. 2G) in the sarR mutant, which is in agreement
with Gustafsson et al. (21). With regard to scpA and spl, SarR was not previously
investigated as controlling their transcription. Herein, we observed a significant 29.1fold decrease in scpA and 48.8-fold decrease in spl transcript levels. Our data therefore
support a role for SarR in upregulating the ssp operon to a minor extent while serving
as one of the strongest activators of scpA and spl expression identified thus far.
Defining the pathway of control for secreted protease expression by known
major regulators. Collectively, our findings confirm 14 regulatory pathways for secreted protease transcription while identifying eight new nodes of expression (Fig. 3).
For aur, we found it was regulated by CodY in addition to SarA, Rot, SarS, and MgrA.
Interestingly, with the exception of MgrA, each of these factors engenders repression
of aur expression, with some (SarA and CodY) exerting profound influence. This is
perhaps explained by the observation that aureolysin sits atop the protease activation
cascade, which flows from Aur to V8 and then staphopain B (11, 43–45). As such,
repressing aureolysin would allow the S. aureus cell to keep the majority of proteases’
activity restrained by the single act of limiting expression from Paur. This would be to
the cells advantage as, although proteases are undoubtedly valuable enzymes with
important roles, they are also destructive in nature. Thus, limiting their activity until it
is absolutely required is a major goal of living cells from all kingdoms (46, 47). This
would be particularly true of aureolysin, given that it has among the broadest substrate
specificities of any S. aureus protease (48). In the context of enzymes from the ssp
operon, we did not identify new regulatory nodes but confirmed their broad regulation,
albeit at modest levels, in a fashion that closely resembles that of aur control. This
finding is again logical, given that the enzymes produced from these loci are part of the
protease activation cascade referenced above.
Interestingly, much of the new knowledge generated herein involves the regulation
of the more underappreciated proteases, staphopain A and the Spls. While the importance of scpA in virulence has been shown through in vivo studies, as well as by its
ability to cleave specific host proteins (13, 49, 50), its transcriptional regulation has been
underexplored. While it has been shown previously that scpA is regulated by Rot and
SarA, we identified herein that SarS, CodY, SaeR, and SarR also control its expression.
While much of this regulation is at modest levels, scpA expression is profoundly
influenced in opposing fashions by SarA (repressor) and SarR (activator). This presents
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a scenario whereby the presence of this enzyme during infection could be discretely
titrated, with high SarA activity resulting in decreased staphopain A, while elevated
SarR levels would engender significant production of this enzyme. This could then
provide rapid niche-specific control of the pathogenic process through staphopain A
activity (or lack thereof) toward self- and host-derived proteins. The need for such a
network of opposing and stringent control is supported by the observation that staphopain
A is one of only two S. aureus secreted proteases with a broad and promiscuous substrate
specificity (aureolysin being the other) (51); thus, tightly modulating its influence is a
necessity for a coordinated and controlled infectious process.
When exploring control of spl expression, we note that this operon is subject to
some of the strongest regulation observed for any protease loci in this study. Specifically, MgrA, SarR, and SaeR each bring about profound upregulation of the spl operon,
to levels that rival and, in the case of SaeR, exceed, that of SarA and CodY for protease
control. This is of interest because the Spls are well known for their narrow substrate
specificity (52–54). Indeed, these enzymes share strong homology and many enzymatic
characteristics with the exfoliative toxins of S. aureus. In the case of these latter
proteases, they have only a single known target, desmoglein-1 in the skin of humans,
the cleavage of which results in scalded skin syndrome (55). The Spl enzymes are
projected to have a similarly narrow range of substrates (56); thus, it is logical that the
cell would limit the production of these enzymes until it finds itself in an environment
where their activity would prove beneficial. As such, it is logical that the presence and
activity of the Spl enzymes can be selectively and rapidly stimulated by these regulatory
factors in response to environmental cues within the host to facilitate infection.
Identification of a cadre of new effectors of protease activity. Given the complex
regulatory function of S. aureus secreted proteases, tight modulation of their expression
is required. As such, we set out to more deeply characterize their network of control by
uncovering novel effectors of their activity. This was achieved by screening all 108
available transcriptional regulator mutants within the Nebraska Transposon Mutant
Library (NTML) (57) for alterations in proteolytic capacity. Culture supernatants from all
strains grown for 15 h (a window of peak accumulation for secreted proteases) were
prepared and subjected to zymography using gelatin as a substrate, as described by us
previously (9). Of the 108 mutants screened, five of the seven primary regulators (sarS,
saeR, rot, sarA, and codY mutants) were included as controls (sarR and mgrA mutants are
not present in the NTML), along with two other major regulators of protease production: agrA and sigB. As expected, an increase in proteolytic activity was observed with
sarS, rot, sarA, codY, and sigB mutants, while a decrease was observed for saeR and agrA
mutants, in comparison to that in the wild type (Fig. 4). For all strains, the intensities of
proteolytic banding resulting from gelatin degradation were assessed visually and by
densitometry using ImageJ software (Fig. 5).
Excluding the known major regulators, a total of 45 mutants were identified as
having notable alterations in proteolytic activity from our screen, with 26 found to have
decreased proteolysis (see Table S1 in the supplemental material), while 19 had an
increase (Table S2). When assessing mutants that showed increased proteolysis, we
identified SarX and NsaR, which were both previously identified as regulating proteases.
SarX has been shown to repress sspA transcription in strain RN6390 (31), while NsaR
was shown to be a repressor of scpA, sspA, and splA-F in strain SH1000 (58). When
considering mutants that had decreased proteolysis, we noted SarV and CcpE, both of
which have been implicated in modulating protease activity. Specifically, sarV disruption in RN6390 led to a decrease in transcription for aur, scpA, and splA (32), while loss
of ccpE in strain Newman results in impaired expression of all protease loci (59).
Beyond these known factors, we identified a number of intriguing regulators which
have yet to be implicated in protease regulation. Of these, several displayed a prominent decrease in protease activity, including SarU. This regulator is an understudied
transcription factor belonging to the Sar family, with many of its counterparts already
known to have a role in regulating protease production (60). In addition, a notable
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FIG 4 Impact of primary regulator mutation on protease activity. Gelatin zymography was performed to
visualize protease activity on 15-h culture supernatants obtained from USA300 JE2 and mutants of sarS,
saeR, codY, sigB, agrA, rot, and sarA. All strains were adjusted to equal optical densities prior to analysis.

decrease in protease activity was also observed for mutants of rbf and atlR, which
encode regulators known to control biofilm formation (61–63). Further, Rex and MntR,
both of which regulate different aspects of cellular metabolism, also caused pronounced decreases in protease activity upon ablation. We also observed a decrease in
protease activity upon disruption of argR2, which is located within the arginine catabolism
metabolic element (ACME) found in USA300 strains (64). Finally, XdrA/xdrA, which has
a role in immune evasion via its involvement in the production of protein A (65), was
found to produce a notable increase in protease activity upon disruption.
Exploring protease control via a secondary network of regulation. To more
deeply explore the new protease regulatory factors identified herein, the seven referenced above were chosen for more detailed study. First, each mutation was transduced
into a clean USA300 HOU background, and protease activity was continuously monitored throughout growth (see Fig. S1). In agreement with results from our zymography
screen, a decrease in protease activity was observed at all time points for mutants of
argR2, mntR, atlR, rbf, sarU, and rex, while the xdrA mutant demonstrated a minor
decrease in protease activity at early times points, but produced the expected increase
in proteolysis thereafter. To ensure that the changes observed were not the result of a
simple growth defect, growth curves were performed for all strains, revealing no
notable alterations compared to the growth of the wild type (see Fig. S2).
Our next step was to determine if the changes observed in the novel regulatory
mutants were driven by changes at the level of transcription. Thus, qRT-PCR analysis for
each protease loci was performed for the wild-type and regulator mutant strains during
postexponential phase, with the exception of the argR2 mutant, which appears to most
notably alter proteolysis at 3 h of growth; thus, this time point was used for this strain.
When studying changes in the argR2 mutant, a 1.6-fold decrease in aur, 1.8-fold increase in
sspA, and 1.7-fold increase in spl transcripts were observed (Fig. 6A), along with no
change in scpA transcription. Next, with the mutant of atlR, we observed a significant
2-fold decrease in aur and a 2.2-fold decrease in spl transcripts (Fig. 6B), whereas with
scpA and sspA, no changes in transcript levels were noted. For the mntR mutant, we
observed a significant 2.5-fold decrease in sspA and 1.7-fold decrease in spl transcript
levels (Fig. 6C), with no changes detected for aur and scpA. In the context of rex, a
significant 3.3-fold decrease was seen with sspA transcript levels, while there were no
changes in transcription for the other protease loci in this mutant (Fig. 6D). Following
this, we investigated the xdrA mutant, in which we observed a significant 1.9-fold
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increase for aur and 4.2-fold increase in scpA transcript levels (Fig. 6E); however, with
spl, we observed a significant 2.4-fold decrease in expression. When studying the rbf
mutant, there was a significant 1.7-fold decrease for aur, 2-fold decrease for sspA, and
1.8-fold decrease for spl transcript levels (Fig. 6F), along with no changes for scpA
transcription. Lastly, for the sarU mutant, we observed a significant 2.3-fold decrease for
sspA and 1.7-fold decrease for aur transcript levels (Fig. 6G), while no changes were
noted for scpA and spl transcription. Collectively, almost all of the regulators solely
activate protease transcription, with the exception of XdrA, which differentially regulates protease loci in opposing fashions, akin to that observed with Rot and SarS.
Determining the pathway of control for the novel protease regulators. In the
work described above, we identified 14 new regulatory pathways for secreted protease
transcription. These data allow us to construct a map of protease regulation for these
factors, detailing specific effects on individual protease loci (Fig. 7). To delineate the
pathway by which these regulators exert their effects, we next assessed their impact on
the primary regulators of protease expression considered previously. As such, qRT-PCR
analysis was performed on the seven novel protease regulator mutants for sarA, codY,
rot, sarS, saeR, mgrA, and sarR at the respective time points in which their protease
transcripts were previously assessed. SarA, SarR, MgrA, and CodY are able to regulate
protease production by direct action, but can also act via control of the Agr quorum
sensing system (26, 66–72). Agr in turn activates secreted protease production during
September/October 2019 Volume 4 Issue 5 e00676-19
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FIG 5 Quantitative profiling of protease activity for all available regulator mutants of S. aureus. Zymogram band intensities from all 108 regulator mutants
contained within the NTML were measured using densitometry (ImageJ). Depicted is fold change of band intensity relative to that of the USA300 JE2 wild-type
strain.

Gimza et al.

Downloaded from http://msphere.asm.org/ on October 23, 2019 at Univ of South Florida

FIG 6 Differential control of individual protease loci by a secondary network of regulatory factors.
qRT-qPCR was performed to determine transcript levels for aur, ssp, scp, and spl in the regulator mutants.
The strains used were WT USA300 HOU and mutants of argR2 (A), atlR (B), mntR (C), rex (D), xdrA (E), rbf
(F), and sarU (G). RNA was isolated from three independent cultures. The 16S rRNA gene was used as an
internal control. Fold change from WT was determined using the 2!∆∆CT method. Student’s t tests were
used to determine statistical significance. *, P " 0.05; **, P " 0.01; ***, P " 0.001 relative to the wild-type
strain. Error bars are SDs.

postexponential phase by inhibiting translation of the negative regulator Rot (73–75).
As such, for completeness, we also included analysis of the agr operon in these studies.
When data for the argR2 mutant were analyzed, we found no significant changes in
expression for any of the primary protease regulators (Fig. 8A). As such, the changes in
ssp transcript levels in the argR2 mutant are either the result of direct action by ArgR2

FIG 7 Novel regulatory network controlling expression of extracellular proteases. Shown are transcriptional regulation events for the seven novel protease regulators on the four individual protease loci. Bars
indicate repression, and arrows indicate activation.
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or are mediated by an as yet unknown circuit. When assessing the atlR mutant, a
significant 1.4-fold decrease in saeR and a 1.5-fold increase in sarS transcripts were
observed (Fig. 8B). The decrease in saeR could explain the observed decrease in spl
expression, as SaeR was shown by ourselves and others to activate spl transcription (24,
39). In addition, the increase in sarS expression could explain the decrease in both aur
and spl transcripts, as SarS was shown in this study to repress transcription of spl and
was shown here and elsewhere to repress aur expression (25).
Next, with the mntR mutant, we observed a significant 1.4-fold decrease in mgrA,
1.5-fold decrease in codY, 1.5-fold decrease in saeR, and 1.8-fold decrease in sarR
transcript levels (Fig. 8C). With regard to the decrease in ssp and spl transcripts, these
changes cannot be explained by the decrease in transcription for codY, as we show that
CodY represses both of these loci. The decrease in the saeR transcript, however, could
result in a decrease in spl transcription, as it has been shown by ourselves and others
to be an activator of this operon (24, 39). Furthermore, the decrease in mgrA and sarR
transcripts could lead to a decrease in ssp and spl expression, as we confirm the work
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FIG 8 Determining the pathway of control for the novel protease regulators. qRT-PCR was performed to determine transcript levels for agrB, sarA, mgrA, rot,
codY, saeR, sarR, and sarS in the regulator mutants. The strains used were WT USA300 HOU and mutants of argR2 (A), atlR (B), mntR (C), rex (D), xdrA (E), rbf
(F), and sarU (G). RNA was isolated from three independent cultures. The 16S rRNA gene was used as an internal control. Fold change from the WT was
determined using the 2!∆∆CT method. Student’s t tests were used to determine statistical significance. *, P " 0.05; **, P " 0.01; ***, P " 0.001 relative to the
wild-type strain. Error bars are SDs.
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of others demonstrating that MgrA activates expression for both proteases (25, 34)
while newly identifying SarR as acting in a similar fashion.
When exploring the influence of Rex, we observed a significant 1.4-fold decrease in
agrB, 1.3-fold decrease in sarA, 1.3-fold decrease in mgrA, 1.5-fold decrease in saeR,
2-fold decrease in sarR, and 1.5-fold decrease in sarS transcript levels (Fig. 8D). The
changes in sarA, saeR, and sarS cannot explain the decrease we observed for the ssp
transcript, because as shown by ourselves and others, both are repressors of ssp (9, 10,
25). However, as we and others have shown that MgrA, SarR, and Agr are activators of
ssp transcription (9, 21, 25), decreases in their expression could explain our data. When
assessing the xdrA mutant, a significant 2.1-fold decrease in agrB and 1.5-fold decrease
in codY transcript levels were observed (Fig. 8E). Additionally, a significant 1.8-fold
increase in mgrA, 4-fold increase in saeR, 1.7-fold increase in sarR, and 3-fold increase
in sarS transcripts were observed. The increase in mgrA transcript could explain the
increase in aur expression as MgrA has been shown here and by others to activate its
transcription (25, 34). Next, as we showed SaeR, SarR, and SarS are activators of scp
expression, increases in the transcription of each could result in enhanced scp transcript
abundance. Additionally, the decrease in codY expression could explain the increase
in transcript for aur and scp, as we showed CodY is a repressor of both. Lastly, the
decrease in spl transcript levels in the xdrA mutant could be explained by either the
increase in sarS or by the decrease in agrB expression, as we show that SarS is a
repressor of this locus, while it is well known that Agr is an activator of spl transcription
(10). Next, with the rbf mutant, we observed a significant 1.3-fold increase in rot
transcription as well as a 2.1-fold increase for sarS (Fig. 8F). The decrease in aur and ssp
transcript levels observed in the rbf mutant could be explained by the increase in sarS
expression, as it was shown by ourselves and others to be a repressor for both loci (25).
Furthermore, we show SarS is a repressor of spl, and as such, the increase in sarS could
have resulted in the decrease in the spl transcript. In addition, Rot was shown herein,
and by others, to be a repressor for aur and ssp; therefore, the increase in rot
transcription could result in the decrease of aur and ssp expression (23). Lastly, with the
sarU mutant, we observed a significant 1.6-fold increase in rot transcription (Fig. 8G). In
the sarU mutant, the decrease in aur and ssp transcription could be explained by the
increase in rot transcription, as it has been shown by ourselves and others to be a
repressor of both (23).
Integrating the novel secondary protease regulators into the global picture of
protease control. Using the findings from this study, along with existing knowledge,
we put forward a comprehensive map of secreted protease regulation (Fig. 9). With this
knowledge, we are able to identify specific regulatory pathways connecting our novel
protease effectors with the major protease regulators. Specifically, with regard to Rbf,
it is possible that its repressive effect on sarS transcription is through Rot, as it was
previously shown to activate sarS transcription (35, 71) and rot transcription is increased
in the rbf mutant. Next, with MntR, its positive effect on sarR transcription is likely
occurring through MgrA, as it was previously shown that MgrA activates sarR transcription (34) and mgrA expression is decreased in the mntR mutant. As for Rex, its activation
of sarR transcription could be occurring through MgrA, as it has been shown that MgrA
activates sarR (35, 71) and mgrA transcription is decreased in the absence of rex. Lastly,
with XrdA, it is possible that its represses saeR via CodY, as it has been shown that CodY
represses saeR transcription (76, 77) and codY transcription is decreased in the xdrA
mutant. Additionally, the negative effect of XdrA on sarR and sarS transcription could
be occurring via MgrA, as it was previously shown that MgrA activates sarR and sarS
transcription (34, 71) and mgrA transcription is increased in the xdrA mutant. Finally, the
activation of agr by XdrA could by occurring via the MgrA-SarR pathway, as SarR has
been shown to repress agr transcription (68) and, as already noted, sarR transcription
is increased in the xdrA mutant.
Concluding remarks. In this study, we set out to completely characterize the
locus-specific effects of regulatory factors on secreted protease expression. In so doing,
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we have identified an abundance of novel regulatory nodes controlling their production and present a comprehensive regulatory circuit that emphasizes the complexity of
protease regulation (Fig. 9). When one compares this regulatory overview with the
literature on virulence factor control in S. aureus, it becomes clear that the expansive
and complex regulatory circuits that exist to oversee secreted protease expression rivals
that of alpha-toxin and protein A, which are arguably some of the most important
virulence-affecting entities produced by this organism (35, 65, 78–85). Indeed, we
suggest that the existence of such a broad network of control speaks to the importance
of the secreted proteases to S. aureus physiology and pathogenic potential. We also
contend that there is a clear and obvious need for such a network, so as to limit or
enhance the abundance (and thus activity) of these enzymes. The rationale for this is
that a primary function of these enzymes is to control the progression of infection by
selectively modulating the stability of individual virulence factors produced by the cell
(19). Thus, in this context, it makes sense that a network of control exists to selectively
titrate in or out a given protease (and thus its activity), so as to specifically influence the
abundance (or lack thereof) of an individual virulence factor(s). This would then
facilitate the selective and niche-specific pathogenic behaviors of S. aureus and provide
a basis for control of the broad and varied infection types that is the hallmark of this
organism’s disease-causing nature. In addition to this, there is abundant evidence in the
literature implicating the secreted proteases as facilitating the infectious process by
attacking the host and cleaving host proteins. It is thus in line with the above hypothesis
that tightly controlling protease activity, by selectively limiting or enhancing their
September/October 2019 Volume 4 Issue 5 e00676-19
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FIG 9 Mapping the global network of extracellular protease regulation in Staphylococcus aureus. The seven primary regulators of protease expression are shown
in blue, while factors known to, in turn, regulate their expression are shown in dark green (activators) or dark red (repressors). The novel regulators identified
in this study are shown in light green (activators) or light red (repressors). New regulatory pathways identified herein between the primary regulators and the
protease loci are shown in green. New regulatory pathways identified herein between the primary regulators and the novel regulators are shown in blue.
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TABLE 1 Strains and plasmids used in this study

Plasmids
pJB38
pBDG01
aErm,

Descriptiona

Reference or source

Cloning strain

92

Restriction-deficient strain
USA300 HOU MRSA isolate
USA300 HOU codY::Tn::erm ∆codY
USA300 HOU sarS::Tn::erm ∆sarS
USA300 HOU sarA::Tn::erm ∆sarA
USA300 HOU rot::Tn::erm ∆rot
USA300 HOU saeR::Tn::erm ∆saeR
Becker mgrA::cm ∆mgrA
USA300 HOU mgrA::cm ∆mgrA
USA300 HOU sarR::tet ∆sarR
USA300 HOU sarU::Tn::erm ∆sarU
USA300 HOU rex::Tn::erm ∆rex
USA300 HOU rbf::Tn::erm ∆rbf
USA300 HOU argR2::Tn::erm ∆argR2
USA300 HOU atlR::Tn::erm ∆atlR
USA300 HOU mntR::Tn::erm ∆mntR
USA300 HOU xdrA::Tn::erm ∆xdrA
SH1000 sigS::tet ∆sigS

Lab stock
58
This study
This study
This study
This study
This study
87
This study
This study
This study
This study
This study
This study
This study
This study
This study
89

Plasmid to create mutants in S. aureus
pJB38 construct for sarR mutation, Ampr CMr

88
This study
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Strain or plasmid
Strains
E. coli
DH5#
S. aureus
RN4220
USA300 HOU
BDG2625
BDG2623
BDG2621
BDG2624
BDG2622
CYL1040
BDG2626
BDG2479
BDG2331
BDG2333
BDG2329
BDG2334
BDG2336
BDG2328
BDG2332
LES55

erythromycin; CM, chloramphenicol; Tet, tetracycline; Amp, ampicillin.

activity in specific niches, is to the advantage of S. aureus and its highly effective and
efficient infectious process.
MATERIALS AND METHODS
Media and growth conditions. All cultures were grown overnight at 37°C with shaking at 250 rpm
in 5 ml of either tryptic soy broth (TSB) or lysogeny broth (LB). When required, antibiotics were added at
the following concentrations: for Escherichia coli, 100 !g ml!1 ampicillin, 12.5 !g ml!1 tetracycline; for S.
aureus, 5 !g ml!1 tetracycline, 5 !g ml!1 erythromycin, 25 !g ml!1 lincomycin, and 2.5 !g ml!1
chloramphenicol. To obtain synchronous cultures, overnight S. aureus cultures were diluted 1:100 into
5 ml of fresh medium and grown for 3 h before being standardized to an optical density at 600 nm
(OD600) of 0.05 in 100 ml of fresh TSB. When assessing growth, OD600 was measured hourly using a
Synergy 2 plate reader (Bio-Tek).
Bacterial strains. All bacterial strains and plasmids used in this study are listed in Table 1.
Transposon mutants for all available transcriptional regulators in S. aureus USA300 JE2 were obtained
from the Nebraska Transposon Mutant Library (NTML). Those subjected to further study were transduced
into USA300 Houston, as described by us previously (86), using "11. The construction of an mgrA mutant
in S. aureus Becker was previously described (87). This mutation was transduced into USA300 Houston
using "85.
Construction of a sarR mutant strain. A tetracycline-marked disruption of sarR was generated using
pJB38, as described by Bose et al. (88). Regions up- and downstream of sarR, including portions of the 5=
and 3= ends of the coding gene, were amplified via PCR using primers OL4208/OL4209 and OL4210/
OL4211. A tetracycline resistance cassette was amplified using OL4299/OL4300 from a SH1000 sigS::tet
mutant (89). Using MluI sites, the tetracycline cassette was ligated between the upstream and downstream fragments of sarR and ligated directly into pJB38 using EcoRI and KpnI sites. Using the established
protocol, the majority of sarR was deleted in USA300 Houston using allelic replacement (88). Strains were
confirmed by PCR and sequencing (Eurofins Genomics) using primers OL4577/OL4578, which amplify
across the deleted region where the tetracycline cassette was inserted.
Quantitative real-time PCR analysis. To quantify expression changes for target genes (primers are
listed in Table S3 in the supplemental material), quantitative real-time PCR (qRT-PCR) was performed, as
described by us previously (90). All targets were normalized using 16S rRNA expression, and fold change
from the wild-type was determined using the threshold cycle (2!∆∆CT) method (91). All graphical
representations of fold changes are relative to the wild-type, "1.
Zymography. Strains grown for 15 h overnight were adjusted to equal optical densities and pelleted.
When assessing proteolytic activity over time, synchronized cultures were grown to exponential phase
and standardized to an OD600 of 0.05 in 100 ml of TSB. At the desired time points, cells were pelleted.
Thereafter, for all samples, 2 ml of supernatant was processed through an Amicon Ultra 3K centrifugal
filter for 60 min at 4,000 # g. Concentrated supernatants were recovered by removing filtrate collection
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Supplemental Table 1. Primers used in this study.
Primer
Sequence*
OL2123
GAGTTGTTATCAATGGTCAC
OL2124
ACTGCTTTAACAACTTGTGG
OL2536
AGTTTGCCACGTATCTT
OL2537
TTAGCTAAGACCTGCATC
OL3747
CGTAGATGCAAATTATTACG
OL3748
CGTTAATGAAACAATTGGAC
OL3749
GTAGTTGTAGGTAAAGATACTC
OL3750
CCATTTGGATAATTGTCTTG
OL3751
GAACACTGAAGGTAATATCG
OL3752
GGAGAAACATTGATTGTGTA
OL2491
GGATTTGTAGTTGGAAAGA
OL2492
CTATTTGGATGTGCAGTAA
OL4047
GCTCAAAGACAAGTTAATCGCTAC
OL4048
CGTTTACAGGAGATTCATCCCA
OL4034
CAGCGAGATTGAAAGCGAATAC
OL4035
CTGTCCATTTCTTTAAGCGTCATAG
OL4011
CTAGGTGAATATGCTGCTACAG
OL4012
CCATTGTAATAGCAGCTTTATCG
OL3116
ACCACAATAACTCAAATTCCTTAATACG
OL3117
GTTGAACAACTGTCGTTTGATGA
OL4445
AACTGTTCTTTCGTCTTGTAAACT
OL4446
TGCTCAGAGTTCAAACCTTACT
OL2495
AACAATCGGATTTAGTACAG
OL2496
GTAAGTATTACGCTCATCAA
OL1184
AGCCGACCTGAGAGGGTGA
OL1185
TCTGGACCGTGTCTCAGTTCC
OL4208
ATGGAATTCCTAAATCAATCTACCATTCCTACAT
OL4209
ATGACGCGTCAGTTATTGTTTATGTTACAGATACAC
OL4210
ATGACGCGTGAAATGTTGCGTTGACTAAATC
OL4211
ATGGGTACCGTCACTATGCTTATTCAAGCAT
OL4299
ATGACGCGTGAGTAATGCTAACATAGC
OL4300
ATGACGCGTCCCAAAGTTGATCCCTTAACG
OL4577
GACTAGTGTACCTTGTTTCAAGC
OL4578
TTGCTACAACAAGATGTGCATC
*Restriction sites present in primers are denoted by underlining.
** KO – Knockout
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Description**
sarA qPCR
sarA qPCR
agrB qPCR
agrB qPCR
aur qPCR
aur qPCR
sspA qPCR
sspA qPCR
scpA qPCR
scpA qPCR
splB qPCR
splB qPCR
mgrA qPCR
mgrA qPCR
rot qPCR
rot qPCR
codY qPCR
codY qPCR
saeR qPCR
saeR qPCR
sarR qPCR
sarR qPCR
sarS qPCR
sarS qPCR
16s qPCR
16s qPCR
sarR KO A fragment
sarR KO A fragment
sarR KO B fragment
sarR KO B fragment
Tetracycline cassette
Tetracycline cassette
sarR KO screening
sarR KO screening

Supplemental Table 2. Transcriptional regulators identified as producing a
decrease in protease activity upon transposon disruption.
Gene ID
NE#
Name
Family
SAUSA300_0066

1233

ArgR2

ArgR

SAUSA300_0093

505

N/A

LyTR

SAUSA300_0217

49

N/A

TCS-RR

SAUSA300_0621

431

MntR

FeoA

SAUSA300_0653

872

Rbf

AraC/XylS

SAUSA300_0658

1557

CcpE

LysR

SAUSA300_0691

1622

SaeR

TCS-RR

SAUSA300_0954

1543

AtlR

MarR/SlyA

SAUSA300_1019

456

N/A

Xre

SAUSA300_1455

1566

N/A

AraC/XylS

SAUSA300_1969

523

N/A

Xre

SAUSA300_1992

1391

AgrA

TCS-RR

SAUSA300_1999

1158

Rex

Rex

SAUSA300_2050

1971

N/A

TenA

SAUSA300_2106

837

MtlR

BglG

SAUSA300_2156

436

LacR

GntR

SAUSA300_2218

1941

SarV

Sar

SAUSA300_2248

1532

N/A

AraC/XylS

SAUSA300_2279

1511

HutR

LysR

SAUSA300_2310

671

N/A

LyTR

SAUSA300_2437

514

SarT

Sar

SAUSA300_2438

1471

SarU

Sar

SAUSA300_2445

1534

N/A

MerR

SAUSA300_2459

1560

N/A

MarR/SlyA

SAUSA300_2509

1295

N/A

TetR

SAUSA300_2547
1201
N/A
N/A
Strains chosen for further study are highlighted in grey.
NE# - NTML strain number.
Transcriptional regulator family assignment is from [93].
N/A – gene name has not yet been assigned.
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Supplemental Table 3. Transcriptional regulators identified as producing an
increase in protease activity upon transposon disruption.
Gene ID
NE#
Name
Family
SAUSA300_0104

78

N/A

AraC/XylS

SAUSA300_0114

165

SarS

Sar

SAUSA300_0195

1659

RpiRB

RpiR

SAUSA300_0373

1226

N/A

Xre

SAUSA300_0605

1193

SarA

Sar

SAUSA300_0645

481

GraR

TCS-RR

SAUSA300_0654

296

SarX

Sar

SAUSA300_0804

1950

N/A

Xre

SAUSA300_0998

1362

N/A

Xre

SAUSA300_1148

1555

CodY

CodY

SAUSA300_1469

1895

ArgR3

ArgR

SAUSA300_1708

386

Rot

Sar

SAUSA300_1797

1389

XdrA

Xre

SAUSA300_1888

1955

HisR

SAUSA300_2022

1109

SigB

Trp
Sigma
Factor

SAUSA300_2247

210

SarY

Sar

SAUSA300_2322

1064

N/A

TetR

SAUSA300_2331

567

SarZ

Sar

SAUSA300_2559
1643
NsaR
TCS-RR
Strains chosen for further study are highlighted in grey.
NE# - NTML strain number.
Transcriptional regulator family assignment is from [93].
N/A – gene name has not yet been assigned.
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A

argR2

WT

WT

H1

WT

H2

argR2

WT

argR2

argR2

WT

H3

argR2

WT

H5

argR2

H4

WT

argR2
H24

H6

B

mntR

WT

mntR

WT

H1

H2

mntR

WT
H5

mntR

WT
H3

mntR

WT
H6
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mntR

WT
H4

WT

mntR
H24

C

atlR

WT

atlR

WT

H1

H2

atlR

WT

H3

atlR

WT

atlR

WT

H5

H4

atlR

WT

WT

H6

atlR
H24

D

rbf

WT
H1

rbf

WT
H4

rbf

WT

H3

H2

rbf

WT

rbf

WT

H5

H6

129

rbf

WT

WT

rbf
H24

E

sarU

WT
H1

sarU

WT

H3

sarU

WT

H5

H4

sarU

WT

H2

sarU

WT

sarU

WT

WT

H6

sarU
H24

F

rex

WT
H1

rex

WT
H4

rex

WT
H2

rex

WT

H3

rex

WT

H5

H6

130

rex

WT

WT

rex
H24

G

xdrA

WT
H1

xdrA

WT
H4

xdrA

WT
H2

xdrA

WT

xdrA

WT
H3

xdrA

WT

H5

H6

WT

xdrA
H24

Supplemental Figure 2. Zymography of Novel Regulators Over Time. Gelatin
zymography was performed on USA300 HOU WT and mutant strain culture supernatants
obtained over time to visualize protease activity. Culture supernatants were concentrated
and ran on a SDS-PAGE gel containing 0.1% gelatin. Strains used are indicated on each
gel.
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1.0

0

2

0.0
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8
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WT
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10
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WT
rex

1.5
1.0
0.5
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6
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4
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0.5

4

10

2.0

0.5

2

8

1.5

OD600

OD600

1.5

0

6

Hour

OD600

D

atlR
OD600

OD600

OD600
0.0

WT

1.0

1.0

0.5

C 1.5

mntR

8

10

0.0

0

2

4

6

8

10

Hour

xdrA

G

1.5

WT
xdrA

OD600

1.0

0.5

0.0

0

5

10

Hour

Supplemental Figure 2. Growth Analysis of Novel Protease Regulators. USA300
HOU WT and regulator mutants of: argR2, mntR, atlR, rbf, sarU, xdrA, and rex were
grown under standard conditions in TSB. Data is from three biological replicates with error
bars shown ±SD.
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Appendix II

Table A1: Genes changed ( > 3 fold) in abundance in the xdrA mutant in
comparison to the wild-type.
Accession
Number

Gene

Description

Fold
Change
(M/WT)

Acetyltransferase
SAUSA300_0956

acetyltransferase, GNAT family

20.4

SAUSA300_0343

acetyltransferase, GNAT family

4.9

SAUSA300_2253

ssaA_2

SsaA-like protein with C-terminal CHAP,
amidase domain

8.0

SAUSA300_0158

cap5G

capsular polysaccharide biosynthesis protein
Cap5G

-3.0

SAUSA300_0159

cap5H

capsular polysaccharide biosynthesis protein
Cap5H

-3.2

Predicted permeases

-3.3

SAUSA300_0827
SAUSA300_0136

sasD

LPXTG cell wall surface protein

-3.4

SAUSA300_0160

cap5I

capsular polysaccharide biosynthesis protein
Cap5I

-3.7

SAUSA300_1334

piuB

TMHMM, PepSY domain, M4 domains

-7.4

single-stranded DNA-binding protein

405.8

SAUSA300_0734

Superfamily II DNA/RNA helicase required for
DNA uptake

69.9

SAUSA300_0735

Predicted amidophosphoribosyltransferase;
Competence protein ComFC

31.3

SAUSA300_1609

Type III/IV leader peptidase family

19.8

SAUSA300_1608

JAB superfamily of metalloproteins

14.5

DNA Metabolism/Repair
SAUSA300_2052

ssb

SAUSA300_1178

recA

recombinase A protein

10.5

SAUSA300_1549

comEA

Competence Protein

9.3

SAUSA300_0992

Putative cell-wall binding lipoprotein

4.6

SAUSA300_1238

conserved hypothetical protein - DUF896
superfamily

4.6
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Table A1 (Continued)
SAUSA300_1612

tag

DNA-3-methyladenine glycosidase

4.2

SAUSA300_1955

putative endodeoxyribonuclease RusA

4.2

SAUSA300_1958

single-strand binding protein

3.8

SAUSA300_1548

comEB

Competence Protein

3.2

SAUSA300_1043

mutS2

DNA mismatch repair MutS2 protein

-3.0

SAUSA300_1346

dinG/dnaQ

DnaQ family exonuclease/DinG family helicase

-3.1

SAUSA300_0367

ssb

single-strand binding protein

-3.2

DNA double-strand break repair Rad50 ATPase

-3.3

SAUSA300_1792
SAUSA300_0677

phrB

Deoxyribodipyrimidine photolyase

-3.4

SAUSA300_2499

crtM

4,4′-diapophytoene synthase (squalene
desaturase)

-3.5

NUDIX hydrolase, nucleoside triphosphatase
YtkD

-3.8

Cmp-binding-factor 1

-4.8

SAUSA300_2431

Superfamily II Helicase

-5.0

SAUSA300_2432

hydrolase, MutT/nudix family

-7.1

SAUSA300_1734
SAUSA300_1791

cbf1

Fatty Acid/Lipid Metabolism
SAUSA300_1124

fabG

3-oxoacyl-(acyl-carrier-protein) reductase

-3.6

SAUSA300_1475

accA

acetyl-CoA carboxylase biotin carboxylase
subunit

-3.7

acetyl-CoA acetyltransferase

-3.8

SAUSA300_0355
Hypothetical protein
SAUSA300_0733

21.8

SAUSA300_2132

7.8

SAUSA300_1181

6.8

SAUSA300_1903

6.0

SAUSA300_0782

5.4

SAUSA300_0409

5.2

SAUSA300_0568

4.4

SAUSA300_2282

4.3

SAUSA300_1446

4.2

SAUSA300_0780

4.1

SAUSA300_2263

4.0

SAUSA300_1942

4.0

SAUSA300_1180

4.0

SAUSA300_1899

3.9

SAUSA300_0567

3.9

SAUSA300_0661

3.9

SAUSA300_0197

3.8
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Table A1 (Continued)
SAUSA300_2080

3.8

SAUSA300_0384

3.7

SAUSA300_1481

3.6

SAUSA300_0710

3.6

SAUSA300_0361

3.6

SAUSA300_0754

3.5

SAUSA300_0779

3.5

SAUSA300_0732

3.4

SAUSA300_0553

3.4

SAUSA300_2447

3.4

SAUSA300_1963

3.4

SAUSA300_2085

3.3

SAUSA300_1011

3.3

SAUSA300_0739

3.3

SAUSA300_0198

3.3

SAUSA300_0365

3.2

SAUSA300_2321

3.2

SAUSA300_1736

3.2

SAUSA300_2356

3.1

SAUSA300_2350

3.1

SAUSA300_0378

3.1

SAUSA300_2031

3.0

SAUSA300_0608

3.0

SAUSA300_2513

-3.0

SAUSA300_2641

-3.0

SAUSA300_0422

-3.0

SAUSA300_0326

-3.0

SAUSA300_0192

-3.0

SAUSA300_0288

-3.0

SAUSA300_0098

-3.1

SAUSA300_2604

-3.2

SAUSA300_2517

-3.2

SAUSA300_2523

-3.2

SAUSA300_2632

-3.2

SAUSA300_1744

-3.3

SAUSA300_2522

-3.3

SAUSA300_2053

-3.5

SAUSA300_0660

-3.5

SAUSA300_0304

-3.5

SAUSA300_1554

-3.5

135
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SAUSA300_0584

-4.0

SAUSA300_1508

-4.1

SAUSA300_1742

-4.3

SAUSA300_1506

-4.3

SAUSA300_1507

-4.3

SAUSA300_1602

-4.3

SAUSA300_1830

-4.8

SAUSA300_0287

-5.6

SAUSA300_2041

-5.8

SAUSA300_2620

-5.8

SAUSA300_2471

-6.3

SAUSA300_2481

-7.2

SAUSA300_1743

-7.7

SAUSA300_0286

-10.5

Lipoprotein
SAUSA300_2354

dsbA

Di-sulphide bond forming protein

25.1

SAUSA300_2355

putative lipoprotein

21.9

SAUSA300_0663

putative lipoprotein

4.4

SAUSA300_1492

lipoprotein

3.1

SAUSA300_2429

staphylococcal tandem lipoprotein - DUF576

-3.0

SAUSA300_0100

staphylococcal tandem lipoprotein - DUF576

-3.1

SAUSA300_1478

putative lipoprotein. Weak CamS domain

-3.2

SAUSA300_2430

staphylococcal tandem lipoprotein - DUF576

-3.6

SAUSA300_0079

DUF 1541, potential lipoprotein

-3.9

Metabolism
SAUSA300_2051

sceD

Lytic transglyosylase

61.8

SAUSA300_2577

manA

mannose-6-phosphate isomerase

28.8

SAUSA300_2443

gntK

gluconate kinase

7.9

SAUSA300_0030

Glycerophosphodiester phosphodiesterase

5.3

SAUSA300_0839

Likely Fe-S assembly protein (NifU homolg).
Also COG 0694 Trx by CDD.

4.6

molybdenum cofactor biosynthesis protein C

4.4

aromatic amino acid aminotransferase

4.3

SAUSA300_2225

moaC

SAUSA300_0952
SAUSA300_1499

aroK

shikimate kinase

4.1

SAUSA300_1498

gcvT

glycine cleavage system
aminomethyltransferase T

3.9

Haloacid dehalogenase-like hydrolase

3.6

SAUSA300_0557
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Table A1 (Continued)
SAUSA300_0842

DUF1450 superfamily; UDP-Nacetylmuramoylalanine--D-glutamate ligase;
moderate homology

3.3

SAUSA300_1458

glyoxalase/bleomycin resistance
protein/dioxygenase superfamily protein

3.3

Glycine cleavage system protein P,
dehydrognease subunit 1

3.3

L-threonine dehydrogenase or UDP-glucose 4epimerase
putative peptidoglycan hydrolase

3.2

tRNA adenosine deaminases

3.1

SAUSA300_1497

gcvP1

SAUSA300_0538
SAUSA300_1720

lytX

SAUSA300_0543

3.2

SAUSA300_1049

murI

glutamate racemase

3.0

SAUSA300_0623

tagA

N-acetylglucosaminyldiphosphoundecaprenol Nacetyl-beta-D-mannosaminyltransferase

3.0

SAUSA300_0449

treC

alpha-phosphotrehalase

3.0

SAUSA300_0193

murQ

N-acetylmuramic acid-6-phosphate etherase

-3.0

SAUSA300_1465

2-oxoglutarate dehydrogenase subunit E1, beta
subunit

-3.0

SAUSA300_2484

3-hydroxy-3-methylglutaryl CoA synthase

-3.0

SAUSA300_1614

hemL

glutamate-1-semialdehyde aminotransferase

-3.0

SAUSA300_0836

dltB

D-alanyl-lipoteichoic acid biosynthesis protein

-3.0

Thiaminase II - has HTH domain also

-3.1

quinol oxidase, subunit II

-3.1

2-oxoglutarate dehydrogenase subunit E2,
dihydrolipoamide acetyltransferase

-3.1

SAUSA300_2050
SAUSA300_0963

qoxA

SAUSA300_1464
SAUSA300_2049

thiD

bifunctional hydroxy-methylpyrimidine kinase/
hydroxy-phosphomethylpyrimidine kinase

-3.1

SAUSA300_2238

ureA

urease, gamma subunit

-3.2

Predicted lactoylglutathione lyase or Glyoxalase

-3.2

ATP synthase F0 subunit A

-3.2

NADH dehydrogenase, FAD-containing subunit

-3.2

molybdopterin converting factor, subunit 2

-3.2

putative lysophospholipase

-3.3

SAUSA300_2512
SAUSA300_2064

atpB

SAUSA300_0844
SAUSA300_2222

moaE

SAUSA300_0070
SAUSA300_0220

pflB

formate acetyltransferase

-3.3

SAUSA300_0686

nagA

N-acetylglucosamine-6-phosphate deactylase

-3.4

SAUSA300_2061

atpH

F1-type ATP synthase, delta subunit

-3.4

SAUSA300_2165

budA

alpha-acetolactate decarboxylase

-3.4
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SAUSA300_0837

dltC

D-alanine--poly(phosphoribitol) ligase subunit 2

-3.5

SAUSA300_2060

atpA

F1-type ATP synthase, alpha subunit

-3.5

SAUSA300_0636

dhaK

dihydroxyacetone kinase subunit DhaK

-3.5

SAUSA300_0637

dhaL

dihydroxyacetone kinase subunit DhaL

-3.5
-3.6

SAUSA300_2239

ureB

putative NAD dependent epimerase /
oxidoreductase
urease, beta subunit

SAUSA300_1895

nos

Nitric oxide synthase

-3.6

SAUSA300_2084

coaA

pantothenate kinase

-3.7

SAUSA300_0221

pflA

pyruvate formate-lyase activating enzyme

-3.7

SAUSA300_0962

qoxB

quinol oxidase, subunit I

-3.7

SAUSA300_2498

crtN

4,4′-diapophytoene desaturase (squalene
synthase ) - Staphyloxanthin biosynthesis

-3.8

SAUSA300_1226

homoserine dehydrogenase

-3.8

SAUSA300_0574

Mevalonate Diphosphate Decarboxylase

-3.8

SAUSA300_1733

Peptidase S9 superfamily; DAP2 domain;
peptidase, Dipeptidyl
aminopeptidase/acylaminoacyl-peptidase

-3.9

SAUSA300_1505

Metallo-beta-lactamase superfamily

-3.9

SAUSA300_2097

-3.6

SAUSA300_2224

moeA

molybdopterin biosynthesis protein A

-4.0

SAUSA300_2477

cidC

pyruvate oxidase

-4.0

SAUSA300_0960

qoxD

quinol oxidase, subunit IV

-4.1

SAUSA300_0638
SAUSA300_2059

atpG

dihydroxyacetone kinase, PTS IIA subunit
F1-type ATP synthase, gamma subunit

-4.1
-4.1

SAUSA300_0961

qoxC

quinol oxidase, subunit III

-4.2

SAUSA300_1655

ald

Alanine dehydrogenase

-4.3

SAUSA300_2567

arcC

carbamate kindase

-4.6

SAUSA300_2048

thiM

Hydroxyethylthiazole kinase

-4.7

SAUSA300_2223

mobB

molybdopterin-guanine dinucleotide biosynthesis
protein B

-4.7

SAUSA300_0572

mvk

mevalonate kinase

-4.7

phosphoglucomutase/phosphomannomutase
family protein

-4.7

SAUSA300_2433
SAUSA300_0573

mvaD

Mevalonate Diphosphate Decarboxylase

-4.9

SAUSA300_2057

atpC

F1-type ATP synthase, epsilon subunit

-5.0

SAUSA300_2240

ureC

urease, alpha subunit

-5.0

SAUSA300_2242

ureF

urease accesory protein

-5.0

SAUSA300_2058

atpD

F1-type ATP synthase, beta subunit

-5.0

SAUSA300_2047

thiE

thiamine-phosphate pyrophosphorylase

-5.1
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SAUSA300_2243

ureG

urease accesory protein

-5.2

SAUSA300_2244

ureD

urease accesory protein

-5.4

SAUSA300_2241

ureE

urease accesory protein

-5.6

SAUSA300_2278

hutU

urocanate hydratase

-5.9

SAUSA300_2469

sdaAA

-6.2

SAUSA300_2277

hutI

L-serine dehydratase, iron-sulfur-dependent
subunit alpha
Imidazolonepropionase

SAUSA300_0235

ldh1

nitric oxide inducible L-lactate dehydrogenase

-6.6

SAUSA300_0594

adh

alcohol dehydrogenase/acetaldehyde reductase

-6.9

SAUSA300_0151

adhE

alcohol dehydrogenase, iron-containing

-7.1

SAUSA300_2104

glmS

glucosamine-fructose-6-phosphate
aminotransferase

-7.2

myosin-cross-reactive antigen like family

-7.5

SAUSA300_0108

-6.3

SAUSA300_1063

arcC

carbamate kinase

-8.5

SAUSA300_2470

sdaAB

L-serine dehydratase, iron-sulfur-dependent,
beta subunit

-8.6

SAUSA300_1331

ald

Alanine dehydrogenase

-8.7

SAUSA300_2149

lacG

6-phospho-beta-galactosidase

-12.6

SAUSA300_2154

lacB

galactose-6-phosphate isomerase

-16.0

SAUSA300_2570

arcA

arginine deiminase

-16.4

SAUSA300_2155

lacA

galactose-6-phosphate isomerase

-20.2

SAUSA300_2152

lacD

tagatose 1,6-diphosphate aldolase

-29.5

SAUSA300_2153

lacC

tagatose-6-phsophate kinase

-39.5

Nucleic Acid Biosynthesis
SAUSA300_1102

gmk

guanylate kinase

3.9

SAUSA300_2183

adk

adenylate kinase

-3.2

SAUSA300_0969

purS

phosphoribosylformylglycinamidine synthase

-3.3

SAUSA300_0968

purC

phosphoribosylaminoimidazolesuccinocarboxamide synthase

-3.4

SAUSA300_0138

deoD1

Purine nucleoside phosphorylase

-3.7

SAUSA300_0970

purQ

phosphoribosylformylglycinamidine synthase I

-4.1

pseudouridine-5'-phosphate glycosidase

-4.7

SAUSA300_0312
SAUSA300_2081

pyrG

CTP synthase

-5.0

SAUSA300_0971

purL

phosphoribosylformylglycinamidine synthase II

-5.5

SAUSA300_0973

purM

phosphoribosylformylglycinamidine cyclo-ligase

-6.2

139

Table A1 (Continued)
SAUSA300_0972

purF

amidophosphoribosyltransferase

-6.3

SAUSA300_0975

purH

bifunctional purine biosynthesis protein

-6.3

SAUSA300_0976

purD

phosphoribosylamine--glycine ligase

-6.4

SAUSA300_0974

purN

phosphoribosylglycinamide formyltransferase

-6.5

SAUSA300_0017

purA

Adenylosuccinate synthetase

-9.5

SAUSA300_1209

putative phage head morphogenesis protein

6.7

SAUSA300_1957

phiPVL ORF046-like protein

4.1

SAUSA300_1962

phiPVL ORF39-like protein

4.1

SAUSA300_1960

putative phage-related DNA recombination
protein

4.1

SAUSA300_1966

phi77 ORF014-like protein, phage anti-repressor
protein

4.0

SAUSA300_1056

Scin-b/Scin-C fibrinogen-binding protein
precursor-related protein

3.8

SAUSA300_1964

conserved hypothetical phage protein

3.8

SAUSA300_1947

phi77 ORF031-like protein

3.7

SAUSA300_1946

phiPVL ORF057-like protein,
transcriptionalactivator RinB

3.5

SAUSA300_1951

phiPVL ORF052-like protein

3.5

SAUSA300_1961

phiPVL ORF41-like protein

3.5

SAUSA300_1944

phi77 ORF026-like protein, phage transcriptional
activator

3.3

SAUSA300_1945

phi77 ORF071-like protein

3.3

SAUSA300_0349

DUF1398 superfamily; phage envelope protein

3.2

SAUSA300_1959

phiPVL ORF044-like protein

3.2

SAUSA300_1943

phi77 ORF040-like protein

3.0

SAUSA300_1941

phi77 ORF003-like protein, phage terminase,
large subunit

3.0

SAUSA300_1968

putative phage transcriptional regulator

3.0

SAUSA300_1432

phiSLT ORF78-like protein

-3.4

SAUSA300_0207

glycyl-glycine endopeptidase

4.2

SAUSA300_1286

aspartate kinase

3.9

SAUSA300_0534

putative amidohydrolases

3.9

SAUSA300_2316

acetyltransferase, GNAT family

3.8

SAUSA300_0373

XRE-family DNA Binding Protein

3.7

Cysteine synthase/cystathionine beta-synthase

3.7

Phage protein

Protein synthesis/Degradation

SAUSA300_0433

cysM
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SAUSA300_1256

msrA2

Peptide methionine sulfoxide reductase MsrA

3.6

SAUSA300_1103

rpoZ

RNAP omega subunit

3.2

SAUSA300_1053

flr/fll

formyl peptide receptor-like 1 inhibitory protein

3.2

SAUSA300_1589

dtd

D-Tyrosyl-tRNAtyr deacylase

3.0

SAUSA300_1287

asd

Aspartate-semialdehyde dehydrogenase

3.0

SAUSA300_2203

rplD

50S ribosomal protein L4

-3.0

SAUSA300_2009

ilvC

ketol-acid reductoisomerase

-3.0

SAUSA300_1509

yqgP

rhomboid membrane protease

-3.0

SAUSA300_2010

leuA

2-isopropylmalate synthase

-3.1

nucleoside hydrolases

-3.1

SAUSA300_0237
SAUSA300_2182

infA

Translation Initiation factor IF-1

-3.2

SAUSA300_1149

rpsB

30S ribosomal protein S2

-3.2

SAUSA300_2178

rpoA

RNAP alpha-subunit

-3.2

SAUSA300_2201

rplB

50S ribosomal protein L2

-3.2

acetyltransferase, GNAT family

-3.2

SAUSA300_1980
SAUSA300_2185

rplO

50S ribosomal protein L15

-3.2

SAUSA300_2204

rplC

50S ribosomal protein L3

-3.2

SAUSA300_2181

rpmJ

50S ribosomal protein L36

-3.3

Ribosomal L7Ae superfamily; ribosomal protein
L7Ae

-3.3

ribosomal protein S18

-3.3

30S ribosomal protein S7

-3.3

SAUSA300_0529
SAUSA300_0368

rpsR

SAUSA300_0531
SAUSA300_0366

rpsD

ribosomal protein S6

-3.3

SAUSA300_0533

tuf

translation elongation factor Tu

-3.3

SAUSA300_1603

rplU

50S ribosomal protein L21

-3.4

SAUSA300_2202

rplW

50S ribosomal protein L23

-3.5

SAUSA300_1190

glpP

glycerol uptake operon antiterminator regulatory
protein

-3.6

SAUSA300_2011

leuB

3-isopropylmalate dehydrogenase

-3.6

SAUSA300_1601

rpmA

50S ribosomal protein L27

-3.6

SAUSA300_2199

rplV

50S ribosomal protein L22

-3.6

SAUSA300_1896

pheA

pdt - bifunctional chorismate mutase-prephenate
dehydratase (CM-PDT)

-3.7

SAUSA300_0532

fusA

translation elongation factor G

-3.7

SAUSA300_2594

msrA3

Peptide methionine sulfoxide reductase MsrA

-3.7

putative amidohydrolases

-3.8

threonine synthase

-3.8

SAUSA300_0105
SAUSA300_1227

thrC
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SAUSA300_1666

rpsD

30S ribosomal protein S4

-3.8

SAUSA300_2008

ilvN

acetolactate synthase, small subunit

-3.8

SAUSA300_1228

thrB

homoserine kinase

-3.9

SAUSA300_2200

rpsS

30S ribosomal protein S19

-3.9

Dual specificity inositol
monophosphatase/NADP(H) phosphatase

-4.0

SAUSA300_2260
SAUSA300_2198

rpsC

30S ribosomal protein S3

-4.1

SAUSA300_2191

rpsN

30S ribosomal protein S14

-4.1

SAUSA300_2187

rpsE

30S ribosomal protein S5

-4.3

SAUSA300_2012

leuC

3-isopropylmalate dehydratase, large subunit

-4.3

SAUSA300_2188

rplR

50S ribosomal protein L18

-4.3

SAUSA300_2189

rplF

50S ribosomal protein L6

-4.5

SAUSA300_2194

rplN

50S ribosomal protein L14

-4.5

SAUSA300_2197

rplP

50S ribosomal protein L16

-4.6

SAUSA300_2196

rpmC

50S ribosomal protein L29

-4.6

SAUSA300_2192

rplE

50S ribosomal protein L5

-4.7

SAUSA300_2013

leuD

3-isopropylmalate dehydratase, small subunit

-4.7

SAUSA300_2186

rpmD

50S ribosomal protein L30

-4.8

SAUSA300_2193

rplX

50S ribosomal protein L24

-5.2

SAUSA300_2014

ilvA

threonine dehydratase

-5.3

SAUSA300_2190

rpsH

30S ribosomal protein S8

-5.3

SAUSA300_2195

rpsQ

30S ribosomal protein S17

-5.8

SAUSA300_0524

rplJ

50S ribosomal protein L10

-7.2

SAUSA300_0525

rplL

50S ribosomal protein L7/L12

-7.9

SAUSA300_0009

serS

seryl-tRNA synthetase

-8.3

SAUSA300_0026

rimH

rRNA large subunit methyltransferase

-8.8

SAUSA300_1062

argF

ornithine carbamoyltransferase

-10.2

SAUSA300_2569

arcB

ornithine carbomyltransferase

-11.7

SAUSA300_1330

ilvA_1

threonine dehydratase

-12.1

SAUSA300_2156

lacR

Lactose operon Repressor

23.0

SAUSA300_0928

comK / comK1

ComK like protein

10.9

SAUSA300_2444

gntR

gluconate operon transcriptional repressor

10.4

SAUSA300_0693

saeP

lipoprotein, putative

6.2

SAUSA300_1583

cymR

cystine metabolism regulator

5.7

SAUSA300_0644

graX

GraX

3.9

Regulation
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SAUSA300_0254

lytS

LytS Histidine Kinase

3.7

SAUSA300_1308

arlR

ArlR Response Regulator

3.7

TetR Regulator

3.6

SAUSA300_2300
SAUSA300_0692

saeQ

SAUSA300_2509

3.5
TetR Regulatory Protein

3.5

SAUSA300_0691

saeR

SaeR Response Regulator

3.4

SAUSA300_0690

saeS

SaeS Histidine Kinase

3.2

SAUSA300_2308

hssR

HssR Response Regulator

3.2

SAUSA300_1723

ecfY

Membrane Protein

3.1

SAUSA300_1799

airS

AirS Histidine Kinase

3.1

SAUSA300_1220

Uncharacterized Response Regulator

-3.0

SAUSA300_0217

Uncharacterized Response Regulator

-3.1

SAUSA300_2322

TetR Transcriptional Regulator

-3.1

accessory gene regulator protein A

-3.1

GntR family regulatory protein

-3.3

SAUSA300_1992

agrA

SAUSA300_1914
SAUSA300_2259

lcpC

LytR-CpsA-Psr family protien

-3.3

SAUSA300_2560

NsaX

NsaX

-3.4

SAUSA300_1989

agrB

accessory gene regulator protein B

-3.4

SAUSA300_1991

agrC

accessory gene regulator protein C

-3.5

SAUSA300_0195

rpiRB

sugar sensing regulator

-4.0

SAUSA300_2559

nsaR

NsaR Response Regulator

-4.0

SAUSA300_2558

nsaS

NsaS Histidine Kinase

-4.4

SAUSA300_1990

agrD

accessory gene regulator protein D

-4.7

Replication/Division
SAUSA300_1259

umuC/mucB

DNA Pol V subunit

9.9

SAUSA300_1078

divIB

Cell division septal protein

-4.3

SAUSA300_1077

murD

UDP-N-acetylmuramoyl-L-alanyl-D-glutamate
synthetase

-8.2

SAUSA300_1076

mraY

phospho-N-acetylmuramoyl-pentapeptidetransferase

-10.0

sRNA
SAUSA300s090

Teg58

6.6

SAUSA300s160

Teg20as

4.9

SAUSA300s120

ssr28

4.9

SAUSA300s012

T-box riboswitch

3.7

SAUSA300s003

T-box riboswitch

3.7

SAUSA300s186

Sau-6402

3.4

SAUSA300s020

FMN riboswitch

-3.0

SAUSA300s122

ssr39

-3.1
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SAUSA300s085

Teg32

-3.2

SAUSA300s083

Teg22

-3.3

SAUSA300s061

Sau-30

-3.7

SAUSA300s121

ssr29

-3.8

SAUSA300s130

ssr69

-4.1

SAUSA300s023

TPP riboswitch

-4.7

SAUSA300s089

Teg49

-5.0

SAUSA300s037

sprG1

-5.1

SAUSA300s054

RsaH

-5.3

SAUSA300s024

GlmS ribozyme

-5.8

SAUSA300s132

ssr87

-7.1

SAUSA300s138

ssr116

-12.2

SAUSA300s074

rsaOI

-12.7

Stress Response
SAUSA300_1244

mscL

Large-conductance mechanosensitive channel

4.3

SAUSA300_1590

rsh

(p)ppGpp synthase

3.3

peroxiredoxin/organic hydroperoxide resistance
protein-like protein

-3.1

choline dehydrogenase

-3.1

SAUSA300_0786
SAUSA300_2545

betA

Toxin/Virulence factor
SAUSA300_1919

scinA

Staph complement inhibitory protein A

9.3

SAUSA300_2366

hlgC

gamma-hemolysin component C

8.5

SAUSA300_1052

ehb/ecb

Ehb, complement inhibitory protein

7.0

SAUSA300_1918

hlb

truncated beta-hemolysin

6.4

SAUSA300_2367

hlgB

gamma-hemolysin component B

5.1

SAUSA300_2441

fnbA

fibronectin binding protein A

4.0

SAUSA300_1055

efb

Extracellular fibrinogen binding protein

3.8

Addiction System antitoxin (Txe/YoeB family)

3.6

SAUSA300_2402
SAUSA300_2364

sbi

igG Binding Protein

3.5

SAUSA300_0370

selX

staphylococcal enterotoxin-like toxin X

3.5

SAUSA300_2365

hlgA

gamma-hemolysin component A

3.2

addiction module toxin (Txe/YoeB family)

3.0

SAUSA300_2401
SAUSA300_0955

atl

Autolysin

3.0

SAUSA300_1757

splB

serine protease SplB

-3.0

SAUSA300_1758

splA

serine protease SplA

-3.2

SAUSA300_2573

isaB

Immunodominant Antigen B

-3.4

SAUSA300_1760

epiG

lantibiotic epidermin immunity protein G

-3.5

SAUSA300_2164

eapH1

MAP/EAP domain protein

-3.6
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SAUSA300_1756

splC

serine protease SplC

-3.8

SAUSA300_1755

splD

serine protease SplD

-4.0

SAUSA300_1767

epiA

lantibiotic epidermin biosynthesis protein EpiA

-4.2

SAUSA300_1754

splE

serine protease SplE

-4.3

SAUSA300_0883

eapH2

Eap/Map protein

-5.1

SAUSA300_2478

cidB

Holin-like protein cidB

-5.1

SAUSA300_1058

hla

alpha-hemolysin

-5.2

SAUSA300_1753

splF

serine protease SplF

-5.2

SAUSA300_2576

fructose-specific IIABC component

25.6

SAUSA300_0333

transcriptional antiterminator, BglG family

19.2

Transport/Binding protein

SAUSA300_1504

comGA

Competence protein

17.0

SAUSA300_1503

comGB

Competence protein

15.0

PTS IIA

14.5

Competence protein

12.3

SAUSA300_0331

PTS IIB - ascorbate, lactose or cellobiose

9.6

SAUSA300_0330

PTS IIC - ascorbate, lactose or cellobiose

7.7

Putative p-aminobenzoyl-glutamate transporter

7.0

SAUSA300_0432

sodium dependent transporter

6.2

SAUSA300_0797

ABC-type transport system, permease
component

5.1

SAUSA300_1874

nonheme-containing ferritin

4.7

SAUSA300_0798

ABC-type transport system, substrate binding
protein component

4.4

SAUSA300_2379

Major Facilitator Superfamily transporter

4.3

SAUSA300_0208

putative maltose ABC transporter, ATP-binding
protein

4.3

gluconate permease

4.0

SAUSA300_0796

ABC-type transport system, ATPase component

3.9

SAUSA300_2575

BglG-like antiterminator with characteristic PTS
IIA and IIB domains

3.8

SAUSA300_0332
SAUSA300_1502

SAUSA300_2417

SAUSA300_2442

comGC

abgT

gntP

SAUSA300_0784

lysE

putative LysE type translocator protein

3.5

SAUSA300_2476

ptsG_2

glucose transporter subunit IIABC

3.4

SAUSA300_0931

DUF2187 superfamily, small

3.2

SAUSA300_2395

amino acid permease

3.2

Preprotein translocase

3.2

putative maltose ABC transporter, maltosebinding protein

3.1

SAUSA300_0762
SAUSA300_0209

secG
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SAUSA300_2552

citrate transporter

3.0

SAUSA300_1493

Putative Membrane Protein

3.0

SAUSA300_0106

norC

Quinolone Resistance transporter

-3.0

SAUSA300_1763

epiP

Lantibiotic leader processing protease

-3.0

SAUSA300_2184

secY

protein translocase

-3.1

SAUSA300_2642

Membrane protein. No homology, DUF3147

-3.1

SAUSA300_2299

multidrug efflux protein

-3.1

SAUSA300_2133

membrane protein with weak GATE domain

-3.1

SAUSA300_1064

arcD

putative arginine/ornithine antiporter

-3.2

SAUSA300_0074

opp-B

oligopeptide ABC transporter, permease protein

-3.2

SAUSA300_0073

opp-A

oligopeptide ABC transporter, substrate-binding
protein

-3.2

SAUSA300_0078

copA

ATPase

-3.2

SAUSA300_1328

norB

Quinolone Resistance protein

-3.2

SAUSA300_0139

tet38

antibiotics MFS transporter - TET specific

-3.2

SAUSA300_1913

pmtA

PSM essential transporter

-3.2

hypothetical membrane protein

-3.3

SAUSA300_2206
SAUSA300_1910

pmtD

PSM essential transporter

-3.4

SAUSA300_0313

nupC

Nucleoside permease

-3.4

SAUSA300_1761

epiE

lantibiotic epidermin immunity protein E

-3.4

SAUSA300_0194

murP

-3.5

SAUSA300_1762

epiF

PTS system N-acetylmuramic acid transporter
subunits EIIBC
lantibiotic epidermin immunity protein F

SAUSA300_0280

essA

EssA - T7SS

-3.6

SAUSA300_1245

opuD

glycine betaine transporter

-3.6

SAUSA300_0281

esaB

EsaB - T7SS

-3.8

SAUSA300_1129

ylxM

YlxM-like protein

-3.9

SAUSA300_0076

opp-D

oligopeptide ABC transporter, ATP Binding
protein

-3.9

SAUSA300_0282

essB

EssB - T7SS

-3.9

SAUSA300_0589

lolS

oxidoreductase ion channel protein

-4.3

SAUSA300_0075

opp-3

oligopeptide ABC transporter, permease protein

-4.5

SAUSA300_1128

ftsY

SRP docking protein

-5.4

SAUSA300_2587

asp1

Secondary Sec System accessory secretory
protein

-5.5

SAUSA300_0283

essC

EssC - T7SS

-5.6
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Table A1 (Continued)
SAUSA300_1001

potC

ABC-type spermidine/putrescine transport
system, permease component

-5.7

SAUSA300_2588

secY2

Secondary Sec System

-6.2

SAUSA300_2586

asp2

Secondary Sec system accessory secretory
protein

-6.3

SAUSA300_2568

arcD

arginine/ornithine antiporter

-6.8

SAUSA300_0284

esaC

EsaC - T7SS

-6.8

SAUSA300_0285

esxB

EsxB - T7SS

-7.0

SAUSA300_2585

asp3

Secondary Sec system accessory secretory
protein

-7.6

amino acid permease

-12.6

SAUSA300_1329
SAUSA300_2150

lacE

PTS system, lactose specific IIBC component

-21.0

SAUSA300_2151

lacF

PTS system, lactose specific IIA component

-36.9
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